{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package punkt to\n",
      "[nltk_data]     C:\\Users\\cynhe\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import re\n",
    "import pandas as pd\n",
    "\n",
    "\n",
    "import nltk\n",
    "nltk.download(\"punkt\")\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.tokenize import word_tokenize\n",
    "from nltk.stem.snowball import SnowballStemmer\n",
    "\n",
    "import string\n",
    "\n",
    "from collections import Counter\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Unnamed: 0',\n",
       " '#',\n",
       " 'Title',\n",
       " 'Owner/Assignee',\n",
       " 'Patent/Pub. No.',\n",
       " 'Priority Date',\n",
       " 'Status',\n",
       " 'General Subject Matter']"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data = pd.read_csv('./Psilocybin_march08.csv')\n",
    "data.columns.to_list()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_p = data.rename(columns={'General Subject Matter':'general_subject'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Unnamed: 0',\n",
       " '#',\n",
       " 'Title',\n",
       " 'Owner/Assignee',\n",
       " 'Patent/Pub. No.',\n",
       " 'Priority Date',\n",
       " 'Status',\n",
       " 'general_subject']"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_p.columns.to_list()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'does', 'ma', 'his', 'you', 'with', \"mustn't\", 'again', 'more', 'some', 'nor', \"hadn't\", 'needn', 'd', 'was', \"doesn't\", 'shan', 'against', \"you'll\", 'now', 'that', 'wasn', 'couldn', 'there', 'below', 'than', 'its', 'won', 'for', 'it', \"don't\", 'has', 'doing', 'can', 'forms', 'combination', 'composition', 'ours', \"didn't\", \"wouldn't\", 'himself', 'me', 'i', 'when', 'didn', 'any', 'these', 'she', \"wasn't\", 'compositions', 'mightn', 'yourself', 'been', 't', 'herself', 'he', 'most', 'doesn', 'intermediates', \"should've\", 'few', 'why', 'disorder', 'where', 'mustn', 'about', 'very', 'who', 'just', 'had', 'once', \"mightn't\", 'ain', 'your', 'him', 'each', \"you're\", 'using', 'after', 'hasn', 'hers', 'same', 'treatment', \"it's\", 'shouldn', \"needn't\", 'haven', \"that'll\", 'don', 'wouldn', 'do', 'method', 'because', 'uses', 'a', 'whom', 'up', 'too', 'use', 'all', \"she's\", 'so', 'to', 'own', 'compounds', 'this', 'll', 'themselves', 'between', \"you'd\", 'were', \"couldn't\", 'production', 'agents', 'disorders', 'have', \"weren't\", 'be', 'while', 'into', 'which', 'but', 'o', 'our', 'under', 'myself', 'through', 'are', 'them', 'until', 'am', \"haven't\", 'by', 'ourselves', 'having', 'my', 'over', 'systems', 'yours', 'enhancing', 'thereof', 'we', 'from', 'both', 'weren', 'derivative', 'down', 'no', 'pharmaceutical', 'as', 'hadn', 'm', 'such', 've', 're', 'off', 'not', 'their', 'aren', 'and', \"hasn't\", \"shouldn't\", 'will', 'if', \"you've\", 'yourselves', 'preparation', 'comprising', 'formulations', 'before', 'on', 'major', 'or', 'itself', 'an', 'of', \"shan't\", 'is', 'in', 'other', 'then', 'receptor', 's', 'methods', 'being', 'what', 'those', 'further', \"isn't\", 'theirs', 'they', 'here', 'how', \"aren't\", 'out', 'delivery', 'her', 'above', 'the', 'should', \"won't\", 'at', 'isn', 'only', 'treating', 'did', 'y', 'during'}\n"
     ]
    }
   ],
   "source": [
    "stops = set(stopwords.words(\"english\"))\n",
    "black_list = [\"methods\", \"disorder\", \"major\",\"use\", \"compositions\", \"method\", \"treatment\", \"disorders\", \"derivative\",\n",
    "               \"comprising\",\"thereof\", \"treating\", \"formulations\", \"compounds\",\n",
    "               \"preparation\",\"receptor\", \"combination\", \"using\",\"systems\", \"uses\", \"production\",\n",
    "               \"agents\", \"disorder\",\"intermediates\",\"composition\",\"forms\",\"delivery\", \"enhancing\", \"pharmaceutical\"  ]\n",
    "for o in black_list:\n",
    "  stops.add(o)\n",
    "print(stops)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def tokenizer(frase):\n",
    "  final = []\n",
    "  sopa = word_tokenize(frase)\n",
    "  stemmer = SnowballStemmer(\"english\")\n",
    "  punct = string.punctuation+\"¿?¡\"\n",
    "  for palabra in sopa:\n",
    "    lowerPalabra = palabra.lower()\n",
    "    if lowerPalabra not in stops and lowerPalabra not in punct:\n",
    "      lowerPalabra = stemmer.stem(lowerPalabra)\n",
    "      final.append(lowerPalabra)\n",
    "\n",
    "  return final"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "#def tokenizer(text):\n",
    " #   stop_words = set(stopwords.words('english'))\n",
    "  #  punct = string.punctuation+\"¿?¡\"\n",
    "   # tokens = word_tokenize(text)\n",
    "#    palabraLower = \n",
    "    #filtered_tokens = [word.lower() for word in tokens if not word.lower() in stop_words and word.lower() not in punct]\n",
    "    \n",
    "    #Roberto dice que este word.lower no está my bien porque se repite mucho, es mejor hacer una variable anterior para anidarla\n",
    "    #return filtered_tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_p['tokenized_text'] = data_p['Title'].apply(tokenizer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "#data_p['tokens'] = data_p['general_subject'].apply(lambda x: nltk.word_tokenize(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>#</th>\n",
       "      <th>Title</th>\n",
       "      <th>Owner/Assignee</th>\n",
       "      <th>Patent/Pub. No.</th>\n",
       "      <th>Priority Date</th>\n",
       "      <th>Status</th>\n",
       "      <th>general_subject</th>\n",
       "      <th>tokenized_text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>Method of treatment based on reduced monoamine...</td>\n",
       "      <td>Lennham\\rPharmaceuticals</td>\n",
       "      <td>US11,344,564</td>\n",
       "      <td>20/8/2021</td>\n",
       "      <td>Granted 2022-5-31\\r(expires 2041-12-17)</td>\n",
       "      <td>The method includes determining whether a subj...</td>\n",
       "      <td>[base, reduc, monoamin, oxidas, activ]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>Methods of crossbreeding fungi organisms</td>\n",
       "      <td>Jerred Tudela</td>\n",
       "      <td>US11,419,280</td>\n",
       "      <td>23/7/2021</td>\n",
       "      <td>Published</td>\n",
       "      <td>Methods of crossbreeding fungi organisms. The\\...</td>\n",
       "      <td>[crossbreed, fungi, organ]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>Methods and compositions comprising psychoacti...</td>\n",
       "      <td>Psilo Scientific</td>\n",
       "      <td>US20220226405</td>\n",
       "      <td>14/6/2021</td>\n",
       "      <td>Published</td>\n",
       "      <td>This invention relates to the extraction of ps...</td>\n",
       "      <td>[psychoact, psychoact, organ]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>Methods and compositions relating to psychedel...</td>\n",
       "      <td>Terran Biosciences</td>\n",
       "      <td>WO2022212854</td>\n",
       "      <td>1/4/2021</td>\n",
       "      <td>Published</td>\n",
       "      <td>Provided herein are compositions relating to\\r...</td>\n",
       "      <td>[relat, psychedel, serotonin, modul]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1</td>\n",
       "      <td>5</td>\n",
       "      <td>Transdermal system, formulation, and method fo...</td>\n",
       "      <td>Mycrodose\\rtherapeutics inc.</td>\n",
       "      <td>WO2022212789</td>\n",
       "      <td>31/3/2021</td>\n",
       "      <td>Published</td>\n",
       "      <td>A drug delivery system is provided for transde...</td>\n",
       "      <td>[transderm, system, formul, therapeut, adminis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>219</th>\n",
       "      <td>1</td>\n",
       "      <td>220</td>\n",
       "      <td>Cannabinoid candy foodstuff compositions</td>\n",
       "      <td>Insectergy</td>\n",
       "      <td>US20220151980</td>\n",
       "      <td>3/7/2002</td>\n",
       "      <td>Published</td>\n",
       "      <td>Cannabinoid candy foodstuff compositions are\\r...</td>\n",
       "      <td>[cannabinoid, candi, foodstuff]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>220</th>\n",
       "      <td>2</td>\n",
       "      <td>221</td>\n",
       "      <td>Modulation of secondary metabolite production ...</td>\n",
       "      <td>Koninklijke DSM\\r(formerly Microbia\\rInc)</td>\n",
       "      <td>US7,229,784B2</td>\n",
       "      <td>19/9/2000</td>\n",
       "      <td>Granted 2007-06-12\\r(expires 2023-06-05)</td>\n",
       "      <td>Improving yield of fungal metabolites in\\rbioe...</td>\n",
       "      <td>[modul, secondari, metabolit, zinc, binuclear,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>221</th>\n",
       "      <td>3</td>\n",
       "      <td>222</td>\n",
       "      <td>Method of inducing therapeutic tranquilization...</td>\n",
       "      <td>Sandoz</td>\n",
       "      <td>US3,192,111A</td>\n",
       "      <td>16/2/1959</td>\n",
       "      <td>Granted 1965-06-29\\r(expired 1982-06-29)</td>\n",
       "      <td>Using psilocybin and psilocin to induce tranqu...</td>\n",
       "      <td>[induc, therapeut, tranquil, psilocybin, psilo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>222</th>\n",
       "      <td>4</td>\n",
       "      <td>223</td>\n",
       "      <td>Esters of indoles</td>\n",
       "      <td>Sandoz</td>\n",
       "      <td>US3,075,992A</td>\n",
       "      <td>12/9/1958</td>\n",
       "      <td>Granted 1963-01-29\\r(expired 1980-01-29)</td>\n",
       "      <td>Discloses, with coinventor Franz Troxler, the ...</td>\n",
       "      <td>[ester, indol]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>5</td>\n",
       "      <td>224</td>\n",
       "      <td>Obtaining psilocybin and psilocin from fungal ...</td>\n",
       "      <td>Sandoz</td>\n",
       "      <td>US3,183,172A</td>\n",
       "      <td>21/2/1958</td>\n",
       "      <td>Granted 1965-05-11\\r(expired 1982-05-11)</td>\n",
       "      <td>Extracting psilocybin and psilocin from fungal...</td>\n",
       "      <td>[obtain, psilocybin, psilocin, fungal, materi]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>224 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Unnamed: 0    #                                              Title  \\\n",
       "0             0    1  Method of treatment based on reduced monoamine...   \n",
       "1             1    2           Methods of crossbreeding fungi organisms   \n",
       "2             2    3  Methods and compositions comprising psychoacti...   \n",
       "3             0    4  Methods and compositions relating to psychedel...   \n",
       "4             1    5  Transdermal system, formulation, and method fo...   \n",
       "..          ...  ...                                                ...   \n",
       "219           1  220           Cannabinoid candy foodstuff compositions   \n",
       "220           2  221  Modulation of secondary metabolite production ...   \n",
       "221           3  222  Method of inducing therapeutic tranquilization...   \n",
       "222           4  223                                  Esters of indoles   \n",
       "223           5  224  Obtaining psilocybin and psilocin from fungal ...   \n",
       "\n",
       "                                Owner/Assignee Patent/Pub. No. Priority Date  \\\n",
       "0                     Lennham\\rPharmaceuticals    US11,344,564     20/8/2021   \n",
       "1                                Jerred Tudela    US11,419,280     23/7/2021   \n",
       "2                             Psilo Scientific   US20220226405     14/6/2021   \n",
       "3                           Terran Biosciences    WO2022212854      1/4/2021   \n",
       "4                 Mycrodose\\rtherapeutics inc.    WO2022212789     31/3/2021   \n",
       "..                                         ...             ...           ...   \n",
       "219                                 Insectergy   US20220151980      3/7/2002   \n",
       "220  Koninklijke DSM\\r(formerly Microbia\\rInc)   US7,229,784B2     19/9/2000   \n",
       "221                                     Sandoz    US3,192,111A     16/2/1959   \n",
       "222                                     Sandoz    US3,075,992A     12/9/1958   \n",
       "223                                     Sandoz    US3,183,172A     21/2/1958   \n",
       "\n",
       "                                       Status  \\\n",
       "0     Granted 2022-5-31\\r(expires 2041-12-17)   \n",
       "1                                   Published   \n",
       "2                                   Published   \n",
       "3                                   Published   \n",
       "4                                   Published   \n",
       "..                                        ...   \n",
       "219                                 Published   \n",
       "220  Granted 2007-06-12\\r(expires 2023-06-05)   \n",
       "221  Granted 1965-06-29\\r(expired 1982-06-29)   \n",
       "222  Granted 1963-01-29\\r(expired 1980-01-29)   \n",
       "223  Granted 1965-05-11\\r(expired 1982-05-11)   \n",
       "\n",
       "                                       general_subject  \\\n",
       "0    The method includes determining whether a subj...   \n",
       "1    Methods of crossbreeding fungi organisms. The\\...   \n",
       "2    This invention relates to the extraction of ps...   \n",
       "3    Provided herein are compositions relating to\\r...   \n",
       "4    A drug delivery system is provided for transde...   \n",
       "..                                                 ...   \n",
       "219  Cannabinoid candy foodstuff compositions are\\r...   \n",
       "220  Improving yield of fungal metabolites in\\rbioe...   \n",
       "221  Using psilocybin and psilocin to induce tranqu...   \n",
       "222  Discloses, with coinventor Franz Troxler, the ...   \n",
       "223  Extracting psilocybin and psilocin from fungal...   \n",
       "\n",
       "                                        tokenized_text  \n",
       "0               [base, reduc, monoamin, oxidas, activ]  \n",
       "1                           [crossbreed, fungi, organ]  \n",
       "2                        [psychoact, psychoact, organ]  \n",
       "3                 [relat, psychedel, serotonin, modul]  \n",
       "4    [transderm, system, formul, therapeut, adminis...  \n",
       "..                                                 ...  \n",
       "219                    [cannabinoid, candi, foodstuff]  \n",
       "220  [modul, secondari, metabolit, zinc, binuclear,...  \n",
       "221  [induc, therapeut, tranquil, psilocybin, psilo...  \n",
       "222                                     [ester, indol]  \n",
       "223     [obtain, psilocybin, psilocin, fungal, materi]  \n",
       "\n",
       "[224 rows x 9 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_p[:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Palabras:   [('psilocybin', 57), ('deriv', 24), ('psychoact', 23), ('psilocin', 21), ('psychedel', 18), ('tryptamin', 17), ('extract', 12), ('drug', 12), ('agonist', 11), ('serotonerg', 11), ('modul', 9), ('anxieti', 8), ('product', 8), ('alkaloid', 8), ('polymorph', 8), ('organ', 7), ('system', 7), ('therapeut', 7), ('cns', 7), ('cannabinoid', 7), ('therapi', 7), ('differ', 7), ('activ', 6), ('analog', 6), ('salt', 6), ('lsd', 6), ('contain', 6), ('neurit', 6), ('outgrowth', 6), ('dose', 5), ('cannabi', 5), ('produc', 5), ('manufactur', 5), ('novel', 5), ('condit', 5)]\n"
     ]
    }
   ],
   "source": [
    "palabras = [word for sentence in data_p.tokenized_text.to_list() for word in sentence]\n",
    "\n",
    "r = Counter(palabras)\n",
    "print (\"Palabras:  \", r.most_common(35))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_p['year'] = data_p['Priority Date'].str.extract(r'(\\w{4})')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>#</th>\n",
       "      <th>Title</th>\n",
       "      <th>Owner/Assignee</th>\n",
       "      <th>Patent/Pub. No.</th>\n",
       "      <th>Priority Date</th>\n",
       "      <th>Status</th>\n",
       "      <th>general_subject</th>\n",
       "      <th>tokenized_text</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>Method of treatment based on reduced monoamine...</td>\n",
       "      <td>Lennham\\rPharmaceuticals</td>\n",
       "      <td>US11,344,564</td>\n",
       "      <td>20/8/2021</td>\n",
       "      <td>Granted 2022-5-31\\r(expires 2041-12-17)</td>\n",
       "      <td>The method includes determining whether a subj...</td>\n",
       "      <td>[base, reduc, monoamin, oxidas, activ]</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>Methods of crossbreeding fungi organisms</td>\n",
       "      <td>Jerred Tudela</td>\n",
       "      <td>US11,419,280</td>\n",
       "      <td>23/7/2021</td>\n",
       "      <td>Published</td>\n",
       "      <td>Methods of crossbreeding fungi organisms. The\\...</td>\n",
       "      <td>[crossbreed, fungi, organ]</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>Methods and compositions comprising psychoacti...</td>\n",
       "      <td>Psilo Scientific</td>\n",
       "      <td>US20220226405</td>\n",
       "      <td>14/6/2021</td>\n",
       "      <td>Published</td>\n",
       "      <td>This invention relates to the extraction of ps...</td>\n",
       "      <td>[psychoact, psychoact, organ]</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0</td>\n",
       "      <td>4</td>\n",
       "      <td>Methods and compositions relating to psychedel...</td>\n",
       "      <td>Terran Biosciences</td>\n",
       "      <td>WO2022212854</td>\n",
       "      <td>1/4/2021</td>\n",
       "      <td>Published</td>\n",
       "      <td>Provided herein are compositions relating to\\r...</td>\n",
       "      <td>[relat, psychedel, serotonin, modul]</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1</td>\n",
       "      <td>5</td>\n",
       "      <td>Transdermal system, formulation, and method fo...</td>\n",
       "      <td>Mycrodose\\rtherapeutics inc.</td>\n",
       "      <td>WO2022212789</td>\n",
       "      <td>31/3/2021</td>\n",
       "      <td>Published</td>\n",
       "      <td>A drug delivery system is provided for transde...</td>\n",
       "      <td>[transderm, system, formul, therapeut, adminis...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>219</th>\n",
       "      <td>1</td>\n",
       "      <td>220</td>\n",
       "      <td>Cannabinoid candy foodstuff compositions</td>\n",
       "      <td>Insectergy</td>\n",
       "      <td>US20220151980</td>\n",
       "      <td>3/7/2002</td>\n",
       "      <td>Published</td>\n",
       "      <td>Cannabinoid candy foodstuff compositions are\\r...</td>\n",
       "      <td>[cannabinoid, candi, foodstuff]</td>\n",
       "      <td>2002</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>220</th>\n",
       "      <td>2</td>\n",
       "      <td>221</td>\n",
       "      <td>Modulation of secondary metabolite production ...</td>\n",
       "      <td>Koninklijke DSM\\r(formerly Microbia\\rInc)</td>\n",
       "      <td>US7,229,784B2</td>\n",
       "      <td>19/9/2000</td>\n",
       "      <td>Granted 2007-06-12\\r(expires 2023-06-05)</td>\n",
       "      <td>Improving yield of fungal metabolites in\\rbioe...</td>\n",
       "      <td>[modul, secondari, metabolit, zinc, binuclear,...</td>\n",
       "      <td>2000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>221</th>\n",
       "      <td>3</td>\n",
       "      <td>222</td>\n",
       "      <td>Method of inducing therapeutic tranquilization...</td>\n",
       "      <td>Sandoz</td>\n",
       "      <td>US3,192,111A</td>\n",
       "      <td>16/2/1959</td>\n",
       "      <td>Granted 1965-06-29\\r(expired 1982-06-29)</td>\n",
       "      <td>Using psilocybin and psilocin to induce tranqu...</td>\n",
       "      <td>[induc, therapeut, tranquil, psilocybin, psilo...</td>\n",
       "      <td>1959</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>222</th>\n",
       "      <td>4</td>\n",
       "      <td>223</td>\n",
       "      <td>Esters of indoles</td>\n",
       "      <td>Sandoz</td>\n",
       "      <td>US3,075,992A</td>\n",
       "      <td>12/9/1958</td>\n",
       "      <td>Granted 1963-01-29\\r(expired 1980-01-29)</td>\n",
       "      <td>Discloses, with coinventor Franz Troxler, the ...</td>\n",
       "      <td>[ester, indol]</td>\n",
       "      <td>1958</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>5</td>\n",
       "      <td>224</td>\n",
       "      <td>Obtaining psilocybin and psilocin from fungal ...</td>\n",
       "      <td>Sandoz</td>\n",
       "      <td>US3,183,172A</td>\n",
       "      <td>21/2/1958</td>\n",
       "      <td>Granted 1965-05-11\\r(expired 1982-05-11)</td>\n",
       "      <td>Extracting psilocybin and psilocin from fungal...</td>\n",
       "      <td>[obtain, psilocybin, psilocin, fungal, materi]</td>\n",
       "      <td>1958</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>224 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Unnamed: 0    #                                              Title  \\\n",
       "0             0    1  Method of treatment based on reduced monoamine...   \n",
       "1             1    2           Methods of crossbreeding fungi organisms   \n",
       "2             2    3  Methods and compositions comprising psychoacti...   \n",
       "3             0    4  Methods and compositions relating to psychedel...   \n",
       "4             1    5  Transdermal system, formulation, and method fo...   \n",
       "..          ...  ...                                                ...   \n",
       "219           1  220           Cannabinoid candy foodstuff compositions   \n",
       "220           2  221  Modulation of secondary metabolite production ...   \n",
       "221           3  222  Method of inducing therapeutic tranquilization...   \n",
       "222           4  223                                  Esters of indoles   \n",
       "223           5  224  Obtaining psilocybin and psilocin from fungal ...   \n",
       "\n",
       "                                Owner/Assignee Patent/Pub. No. Priority Date  \\\n",
       "0                     Lennham\\rPharmaceuticals    US11,344,564     20/8/2021   \n",
       "1                                Jerred Tudela    US11,419,280     23/7/2021   \n",
       "2                             Psilo Scientific   US20220226405     14/6/2021   \n",
       "3                           Terran Biosciences    WO2022212854      1/4/2021   \n",
       "4                 Mycrodose\\rtherapeutics inc.    WO2022212789     31/3/2021   \n",
       "..                                         ...             ...           ...   \n",
       "219                                 Insectergy   US20220151980      3/7/2002   \n",
       "220  Koninklijke DSM\\r(formerly Microbia\\rInc)   US7,229,784B2     19/9/2000   \n",
       "221                                     Sandoz    US3,192,111A     16/2/1959   \n",
       "222                                     Sandoz    US3,075,992A     12/9/1958   \n",
       "223                                     Sandoz    US3,183,172A     21/2/1958   \n",
       "\n",
       "                                       Status  \\\n",
       "0     Granted 2022-5-31\\r(expires 2041-12-17)   \n",
       "1                                   Published   \n",
       "2                                   Published   \n",
       "3                                   Published   \n",
       "4                                   Published   \n",
       "..                                        ...   \n",
       "219                                 Published   \n",
       "220  Granted 2007-06-12\\r(expires 2023-06-05)   \n",
       "221  Granted 1965-06-29\\r(expired 1982-06-29)   \n",
       "222  Granted 1963-01-29\\r(expired 1980-01-29)   \n",
       "223  Granted 1965-05-11\\r(expired 1982-05-11)   \n",
       "\n",
       "                                       general_subject  \\\n",
       "0    The method includes determining whether a subj...   \n",
       "1    Methods of crossbreeding fungi organisms. The\\...   \n",
       "2    This invention relates to the extraction of ps...   \n",
       "3    Provided herein are compositions relating to\\r...   \n",
       "4    A drug delivery system is provided for transde...   \n",
       "..                                                 ...   \n",
       "219  Cannabinoid candy foodstuff compositions are\\r...   \n",
       "220  Improving yield of fungal metabolites in\\rbioe...   \n",
       "221  Using psilocybin and psilocin to induce tranqu...   \n",
       "222  Discloses, with coinventor Franz Troxler, the ...   \n",
       "223  Extracting psilocybin and psilocin from fungal...   \n",
       "\n",
       "                                        tokenized_text  year  \n",
       "0               [base, reduc, monoamin, oxidas, activ]  2021  \n",
       "1                           [crossbreed, fungi, organ]  2021  \n",
       "2                        [psychoact, psychoact, organ]  2021  \n",
       "3                 [relat, psychedel, serotonin, modul]  2021  \n",
       "4    [transderm, system, formul, therapeut, adminis...  2021  \n",
       "..                                                 ...   ...  \n",
       "219                    [cannabinoid, candi, foodstuff]  2002  \n",
       "220  [modul, secondari, metabolit, zinc, binuclear,...  2000  \n",
       "221  [induc, therapeut, tranquil, psilocybin, psilo...  1959  \n",
       "222                                     [ester, indol]  1958  \n",
       "223     [obtain, psilocybin, psilocin, fungal, materi]  1958  \n",
       "\n",
       "[224 rows x 10 columns]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_p"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_columns = data_p[['Title','Owner/Assignee','year']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_columns.to_csv('./years_psilocibin.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import altair as alt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "<div id=\"altair-viz-3c5e08fd39244a72881dfcc3d0930bde\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "  var VEGA_DEBUG = (typeof VEGA_DEBUG == \"undefined\") ? {} : VEGA_DEBUG;\n",
       "  (function(spec, embedOpt){\n",
       "    let outputDiv = document.currentScript.previousElementSibling;\n",
       "    if (outputDiv.id !== \"altair-viz-3c5e08fd39244a72881dfcc3d0930bde\") {\n",
       "      outputDiv = document.getElementById(\"altair-viz-3c5e08fd39244a72881dfcc3d0930bde\");\n",
       "    }\n",
       "    const paths = {\n",
       "      \"vega\": \"https://cdn.jsdelivr.net/npm//vega@5?noext\",\n",
       "      \"vega-lib\": \"https://cdn.jsdelivr.net/npm//vega-lib?noext\",\n",
       "      \"vega-lite\": \"https://cdn.jsdelivr.net/npm//vega-lite@4.17.0?noext\",\n",
       "      \"vega-embed\": \"https://cdn.jsdelivr.net/npm//vega-embed@6?noext\",\n",
       "    };\n",
       "\n",
       "    function maybeLoadScript(lib, version) {\n",
       "      var key = `${lib.replace(\"-\", \"\")}_version`;\n",
       "      return (VEGA_DEBUG[key] == version) ?\n",
       "        Promise.resolve(paths[lib]) :\n",
       "        new Promise(function(resolve, reject) {\n",
       "          var s = document.createElement('script');\n",
       "          document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "          s.async = true;\n",
       "          s.onload = () => {\n",
       "            VEGA_DEBUG[key] = version;\n",
       "            return resolve(paths[lib]);\n",
       "          };\n",
       "          s.onerror = () => reject(`Error loading script: ${paths[lib]}`);\n",
       "          s.src = paths[lib];\n",
       "        });\n",
       "    }\n",
       "\n",
       "    function showError(err) {\n",
       "      outputDiv.innerHTML = `<div class=\"error\" style=\"color:red;\">${err}</div>`;\n",
       "      throw err;\n",
       "    }\n",
       "\n",
       "    function displayChart(vegaEmbed) {\n",
       "      vegaEmbed(outputDiv, spec, embedOpt)\n",
       "        .catch(err => showError(`Javascript Error: ${err.message}<br>This usually means there's a typo in your chart specification. See the javascript console for the full traceback.`));\n",
       "    }\n",
       "\n",
       "    if(typeof define === \"function\" && define.amd) {\n",
       "      requirejs.config({paths});\n",
       "      require([\"vega-embed\"], displayChart, err => showError(`Error loading script: ${err.message}`));\n",
       "    } else {\n",
       "      maybeLoadScript(\"vega\", \"5\")\n",
       "        .then(() => maybeLoadScript(\"vega-lite\", \"4.17.0\"))\n",
       "        .then(() => maybeLoadScript(\"vega-embed\", \"6\"))\n",
       "        .catch(showError)\n",
       "        .then(() => displayChart(vegaEmbed));\n",
       "    }\n",
       "  })({\"config\": {\"view\": {\"continuousWidth\": 400, \"continuousHeight\": 300}}, \"data\": {\"name\": \"data-7bfbe9a25eb7cceec626c8c76189173b\"}, \"mark\": \"point\", \"encoding\": {\"size\": {\"aggregate\": \"count\", \"field\": \"yield\", \"type\": \"quantitative\"}, \"tooltip\": {\"aggregate\": \"count\", \"field\": \"yield\", \"type\": \"quantitative\"}, \"x\": {\"field\": \"year\", \"type\": \"nominal\"}, \"y\": {\"aggregate\": \"count\", \"field\": \"yield\", \"type\": \"quantitative\"}}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v4.17.0.json\", \"datasets\": {\"data-7bfbe9a25eb7cceec626c8c76189173b\": [{\"Unnamed: 0\": 0, \"#\": 1, \"Title\": \"Method of treatment based on reduced monoamine\\roxidase a activity\", \"Owner/Assignee\": \"Lennham\\rPharmaceuticals\", \"Patent/Pub. No.\": \"US11,344,564\", \"Priority Date\": \"20/8/2021\", \"Status\": \"Granted 2022-5-31\\r(expires 2041-12-17)\", \"general_subject\": \"The method includes determining whether a subject\\rhas monoamine oxidase A deficiency, then\\radministering to the subject a below-normal dose of\\rpsilocin or a prodrug of psilocin, or pharmaceutically\\racceptable salt, hydrate, or solvate thereof.\", \"tokenized_text\": [\"base\", \"reduc\", \"monoamin\", \"oxidas\", \"activ\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 2, \"Title\": \"Methods of crossbreeding fungi organisms\", \"Owner/Assignee\": \"Jerred Tudela\", \"Patent/Pub. No.\": \"US11,419,280\", \"Priority Date\": \"23/7/2021\", \"Status\": \"Published\", \"general_subject\": \"Methods of crossbreeding fungi organisms. The\\rmethods include placing a first fungus organism on a\\rfirst growth medium. The first fungus organism is\\rselected from the genus Psilocybe or Panaeolus. The\\rmethods further include placing a second fungus\\rorganism on the first growth medium adjacent to the\\rfirst fungus organism. The second fungus organism is\\rselected from the genus Psilocybe or Panaeolus and is\\rdifferent than the first fungus organism. The methods\\rinclude allowing the first fungus organism to replicate\\rto form a first colony and allowing the second fungus\\rorganism to replicate to form a second colony. The\\rmethods further include allowing the first colony and\\rthe second colony to expand until they intersect along\\ra clamp line where the first colony and the second\\rcolony exchange genetic material between them to\\ryield a crossbred fungus organism.\", \"tokenized_text\": [\"crossbreed\", \"fungi\", \"organ\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 2, \"#\": 3, \"Title\": \"Methods and compositions comprising psychoactive\\rcompounds from psychoactive organisms\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"US20220226405\", \"Priority Date\": \"14/6/2021\", \"Status\": \"Published\", \"general_subject\": \"This invention relates to the extraction of psychoactive\\rcompounds from organisms for use in medicine.\\rExtraction is carried out with a strong acid or strong\\rbase to either promote or inhibit dephosphorylation.\\rThe extract in the slurry form is standardized with\\radded excipient so that when it is dried the powdered\\rcomposition has a specified total psychoactive alkaloid\\rconcentration, with a known ratio of phosphorylated\\rto dephosphorylated psychoactive alkaloids.\", \"tokenized_text\": [\"psychoact\", \"psychoact\", \"organ\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 4, \"Title\": \"Methods and compositions relating to psychedelics and\\rserotonin receptor modulators\", \"Owner/Assignee\": \"Terran Biosciences\", \"Patent/Pub. No.\": \"WO2022212854\", \"Priority Date\": \"1/4/2021\", \"Status\": \"Published\", \"general_subject\": \"Provided herein are compositions relating to\\rpsychedelics and serotonin receptor modulators.\\rFurther provided herein are methods of treating a\\rdisease or disorder (e.g., depression or diseases or\\rconditions related to depression) comprising\\radministering psychedelics and serotonin receptor\\rmodulators.\", \"tokenized_text\": [\"relat\", \"psychedel\", \"serotonin\", \"modul\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 5, \"Title\": \"Transdermal system, formulation, and method for the\\rtherapeutic administration of a psychedelic agent\", \"Owner/Assignee\": \"Mycrodose\\rtherapeutics inc.\", \"Patent/Pub. No.\": \"WO2022212789\", \"Priority Date\": \"31/3/2021\", \"Status\": \"Published\", \"general_subject\": \"A drug delivery system is provided for transdermally\\radministering a psychedelic active agent to a subject\\rto provide continuous microdose plasma levels of the\\ractive agent or a metabolite thereof during an\\rextended drug delivery time period. The transdermal\\rdrug delivery system comprises a drug reservoir that\\rhouses a formulation containing the active agent, a\\rcombination of a solubilizer-type permeation\\renhancer and a plasticizer-type permeation enhancer,\\rand a pH stabilizing agent. The pH stabilizing agent\\rbrings the pH of the formulation, at the system-skin\\rinterface, and/or within the skin as the active agent is\\rtransported across the skin from the skin surface to\\rthe bloodstream, to within 25% of the pKa of the\\ractive agent. Formulations and methods of use are\\ralso provided.\", \"tokenized_text\": [\"transderm\", \"system\", \"formul\", \"therapeut\", \"administr\", \"psychedel\", \"agent\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 2, \"#\": 6, \"Title\": \"Artificial expression constructs for modulating gene\\rexpression in claustrum neurons\", \"Owner/Assignee\": \"Allen institute\", \"Patent/Pub. No.\": \"WO2022212585\", \"Priority Date\": \"30/3/2021\", \"Status\": \"Published\", \"general_subject\": \"Artificial expression constructs for modulating gene\\rexpression in targeted central nervous system cell\\rtypes are described. The artificial expression constructs\\rcan be used to express synthetic genes or modify gene\\rexpression in claustrum neurons including L6 IT Car3\\rneurons.\", \"tokenized_text\": [\"artifici\", \"express\", \"construct\", \"modul\", \"gene\", \"express\", \"claustrum\", \"neuron\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 7, \"Title\": \"Psilocybin compositions, methods of making and\\rmethods of using the same\", \"Owner/Assignee\": \"Compass Pathfinder\\rLimited\", \"Patent/Pub. No.\": \"WO2022207746\", \"Priority Date\": \"30/3/2021\", \"Status\": \"Published\", \"general_subject\": \"The present disclosure provides pharmaceutical\\rcompositions comprising a therapeutically effective\\ramount of psilocybin and one or more\\rpharmaceutically acceptable excipients. Methods of\\rmaking such compositions and use thereof in treating\\rdepressive disorders are also disclosed.\", \"tokenized_text\": [\"psilocybin\", \"make\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 8, \"Title\": \"Use of psychedelics to treat dementia\", \"Owner/Assignee\": \"Mynd Life Sciences\", \"Patent/Pub. No.\": \"WO2022204802\", \"Priority Date\": \"30/3/2021\", \"Status\": \"Published\", \"general_subject\": \"The present invention provides use of psychedelics to\\rprevent and/or treat dementia. In certain\\rembodiments, the one or more psychedelics inhibit\\rneuroinflammation, inhibit cerebral angiogenesis,\\rpromote neuroplasticity, down regulate APP and/or\\rTau or a combination thereof and thereby treat, delay\\rand/or prevent dementia.\", \"tokenized_text\": [\"psychedel\", \"treat\", \"dementia\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 2, \"#\": 9, \"Title\": \"Treatment protocol computer systems and methods\", \"Owner/Assignee\": \"Mind Cure Health\", \"Patent/Pub. No.\": \"WO2022204805\", \"Priority Date\": \"29/3/2021\", \"Status\": \"Published\", \"general_subject\": \"Computer-implemented methods of treating at least\\rone nervous system disorder in a patient through the\\ruse of technological devices capable of monitoring a\\rpatient's physiological and psychological biometric\\rdata, as well as geographic location, to increase\\rpatient participation and safety; and systems\\rcomprising the same.\", \"tokenized_text\": [\"protocol\", \"comput\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 3, \"#\": 10, \"Title\": \"Psilocybin analogs, salts, compositions, and methods of\\ruse\", \"Owner/Assignee\": \"Cybin IRL Limited\", \"Patent/Pub. No.\": \"WO2022195011\", \"Priority Date\": \"18/3/2021\", \"Status\": \"Published\", \"general_subject\": \"The present disclosure relates to psilocin compounds\\rand pharmaceutically acceptable salts, polymorphs,\\rstereoisomers, or solvates thereof, to pharmaceutical\\rcompositions, and in some embodiments, to serotonin\\r5-HT 2 receptor agonists and uses in the treatment of\\rdiseases associated with a 5-HT 2 receiver.\", \"tokenized_text\": [\"psilocybin\", \"analog\", \"salt\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 11, \"Title\": \"Improved methods for the use of psychedelics\", \"Owner/Assignee\": \"Tryp Therapeutics\", \"Patent/Pub. No.\": \"WO2022195489\", \"Priority Date\": \"15/3/2021\", \"Status\": \"Published\", \"general_subject\": \"Provided are improved methods for treating a\\rpsychological disorder in a subject comprising\\radministering to the subject an amount of psilocybin\\ror psilocin sufficient to induce a dissociative state in\\rthe subject less than 30 minutes after the\\radministration; and thereafter maintaining the mean\\rplasma concentration of the psychedelic at a\\rpredetermined value to maintain the dissociative state\\rduring a therapeutic window\", \"tokenized_text\": [\"improv\", \"psychedel\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 12, \"Title\": \"Dosing regimens of pharmaceutical and nutraceutical\\rmushroom and cannabis compositions and their use to\\rtreat cns disorders and improve mental health\", \"Owner/Assignee\": \"Allied Corp.\", \"Patent/Pub. No.\": \"WO2022187973\", \"Priority Date\": \"12/3/2021\", \"Status\": \"Published\", \"general_subject\": \"The present invention discloses compositions from\\rmushrooms and cannabis, including with synergistic\\rand entourage enhanced combinations of psilocybin\\rand other psychoactive tryptamines, THC, CBD, and\\rother cannabinoids, and other active agents, all of\\rwhich useful in methods to treat CNS and mental\\rhealth disorders and to improve mental health, for\\rexample when administered in distinct or daily dosing\\rregimens as taught herein\", \"tokenized_text\": [\"dose\", \"regimen\", \"nutraceut\", \"mushroom\", \"cannabi\", \"treat\", \"cns\", \"improv\", \"mental\", \"health\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 2, \"#\": 13, \"Title\": \"5-HT receptor agonist titration\", \"Owner/Assignee\": \"Diamond\\rTherapeutics\", \"Patent/Pub. No.\": \"WO2022189855\", \"Priority Date\": \"8/3/2021\", \"Status\": \"Published\", \"general_subject\": \"Disclosed herein are methods of treating\\rneuropsychiatric and cognitive conditions in\\rindividuals by titrating a 5-HT receptor agonist over a\\rperiod of time to provide a therapeutic effective\\ramount of the 5-HT receptor agonist to the individual.\", \"tokenized_text\": [\"5-ht\", \"agonist\", \"titrat\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 3, \"#\": 14, \"Title\": \"Formulations of Psilocin that have enhanced stability\", \"Owner/Assignee\": \"Mind Medicine\", \"Patent/Pub. No.\": \"US20220280482\", \"Priority Date\": \"6/3/2021\", \"Status\": \"Published\", \"general_subject\": \"A composition of psilocin that is stable including at\\rleast one agent or chemical modification that provides\\renhanced stability. A method making stable psilocin,\\rby providing a formulation of psilocin including at\\rleast one agent or chemical modification that provides\\renhanced stability. A method of treatment of a disease\\ror condition, by administering a composition of\\rpsilocin that is stable to an individual, and treating the\\rdisease or condition.\", \"tokenized_text\": [\"psilocin\", \"enhanc\", \"stabil\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 15, \"Title\": \"Formulations of Psilocin that have enhanced stability\", \"Owner/Assignee\": \"Mind Medicine\", \"Patent/Pub. No.\": \"WO2022192097\", \"Priority Date\": \"6/3/2021\", \"Status\": \"Published\", \"general_subject\": \"A composition of psilocin that is stable including at\\rleast one agent or chemical modification that provides\\renhanced stability. A method making stable psilocin,\\rby providing a formulation of psilocin including at\\rleast one agent or chemical modification that provides\\renhanced stability. A method of treatment of a disease\\ror condition, by administering a composition of\\rpsilocin that is stable to an individual, and treating the\\rdisease or condition.\", \"tokenized_text\": [\"psilocin\", \"enhanc\", \"stabil\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 16, \"Title\": \"Synergistic cannabinoid esters, their salts and uses\\rthereof\", \"Owner/Assignee\": \"London\\rPharmaceuticals and\\rResearch\\rCorporation\", \"Patent/Pub. No.\": \"WO2022183292\", \"Priority Date\": \"3/3/2021\", \"Status\": \"Published\", \"general_subject\": \"Cannabinoid esters and their soluble salts with\\rsynergistic or additive therapeutic counterparts and\\rstable formulations thereof, as well as their edible,\\rbeverage and medicinal applications. The synergistic\\ror additive cannabinoid esters may be used as drugs\\ror prodrugs for treating various conditions related to\\rthe modulation or biased modulation of cannabinoid\\rreceptors, including but not limited to, pain and\\rinflammation, arthritis, cancer, glaucoma,\\rneurodegenerative disorders, multiple sclerosis, renal\\rfibrosis, fibrotic disorder, mental health disorders,\\raddiction, motor function disorders and\\rgastrointestinal and metabolic disorders.\", \"tokenized_text\": [\"synergist\", \"cannabinoid\", \"ester\", \"salt\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 17, \"Title\": \"Effects of lysergic acid diethylamide [lsd] and of lsd\\ranalogs to assist psychotherapy for generalized anxiety\\rdisorder or other anxiety not related to life-threatening\\rillness\", \"Owner/Assignee\": \"Universitatsspital\\rbasel\", \"Patent/Pub. No.\": \"WO2022175821\", \"Priority Date\": \"19/2/2021\", \"Status\": \"Published\", \"general_subject\": \"A method of treating anxiety disorders specifically not\\rassociated with causes such as a life-threatening\\rserious somatic illness, by administering a psychedelic\\rto an individual, and treating anxiety and specifically\\rcausing reductions in the rating scale score measures\\rof anxiety (STAI global or state or trait anxiety) and/or\\rmeasures of depression (HDRS or BDI scores) and/or\\rmeasures of general psychological distress (SCL-90\\rratings) in the patient for several weeks beyond\\radministration of the psychedelic. A method of\\rtreating anxiety, by administering a psychedelic\\r(preferably LSD) to an individual having anxiety not\\rassociated with causes such as a life-threatening\\rserious somatic illness, and inducing positive acute\\rdrug effects and positive long-term therapeutic effects\\rin the individual.\", \"tokenized_text\": [\"effect\", \"lyserg\", \"acid\", \"diethylamid\", \"lsd\", \"lsd\", \"analog\", \"assist\", \"psychotherapi\", \"general\", \"anxieti\", \"anxieti\", \"relat\", \"life-threaten\", \"ill\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 18, \"Title\": \"Effects of lysergic acid diethylamide (lsd) and of lsd\\ranalogs to assist psychotherapy for generalized anxiety\\rdisorder or other anxiety not related to life-threatening\\rillness\", \"Owner/Assignee\": \"Universitatsspital\\rBasel\", \"Patent/Pub. No.\": \"US20220273628\", \"Priority Date\": \"19/2/2021\", \"Status\": \"Published\", \"general_subject\": \"A method of treating anxiety disorders specifically not\\rassociated with causes such as a life-threatening\\rserious somatic illness, by administering a psychedelic\\rto an individual, and treating anxiety and specifically\\rcausing reductions in the rating scale score measures\\rof anxiety (STAI global or state or trait anxiety) and/or\\rmeasures of depression (HDRS or BDI scores) and/or\\rmeasures of general psychological distress (SCL-90\\rratings) in the patient for several weeks beyond\\radministration of the psychedelic. A method of\\rtreating anxiety, by administering a psychedelic\\r(preferably LSD) to an individual having anxiety not\\rassociated with causes such as a life-threatening\\rserious somatic illness, and inducing positive acute\\rdrug effects and positive long-term therapeutic effects\\rin the individual.\", \"tokenized_text\": [\"effect\", \"lyserg\", \"acid\", \"diethylamid\", \"lsd\", \"lsd\", \"analog\", \"assist\", \"psychotherapi\", \"general\", \"anxieti\", \"anxieti\", \"relat\", \"life-threaten\", \"ill\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 19, \"Title\": \"Multi-substituent psilocybin derivatives and methods of\\rusing\", \"Owner/Assignee\": \"Enveric Biosciences\", \"Patent/Pub. No.\": \"WO2022170438\", \"Priority Date\": \"12/2/2021\", \"Status\": \"Published\", \"general_subject\": \"Disclosed are novel multi-substitute psilocybin\\rderivative compounds and pharmaceutical and\\rrecreational drug formulations containing the same.\\rThe compounds may be produced by reacting a\\rreactant psilocybin derivative with a substitute\\rcontaining compound.\", \"tokenized_text\": [\"multi-substitu\", \"psilocybin\", \"deriv\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 20, \"Title\": \"Pharmaceutically acceptable salts of psilocin and uses\\rthereof\", \"Owner/Assignee\": \"Eleusis Therapeutics\", \"Patent/Pub. No.\": \"WO2022173888\", \"Priority Date\": \"10/2/2021\", \"Status\": \"Published\", \"general_subject\": \"The present invention features pharmaceutically\\racceptable salts of psilocin and compositions thereof.\\rThe pharmaceutically acceptable salts of psilocin may\\rbe used to treat a disease or condition, such as a\\rneurological injury, an inflammatory condition, chronic\\rpain, or a psychological condition, in a subject in need\\rthereof.\", \"tokenized_text\": [\"pharmaceut\", \"accept\", \"salt\", \"psilocin\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 2, \"#\": 21, \"Title\": \"Methods of use and formulations of allosteric\\rmodulators of the serotonin, dopamine and other\\rreceptor systems for medical, recreational, religious,\\rresearch and other uses.\", \"Owner/Assignee\": \"David Alan Heldreth,\\rJr.\", \"Patent/Pub. No.\": \"US20220265601\", \"Priority Date\": \"10/2/2021\", \"Status\": \"Published\", \"general_subject\": \"The invention involves the use of formulations of\\rpositive, negative, inverse agonist, or neutral allosteric\\rmodulators of receptors such as, but not limited to:\\r5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht5, 5ht6, 5ht7,\\rdopamine receptors (D1, D2, D3, D4, D5), adrenergic\\rreceptors (.alpha.1A, .alpha.1B, .alpha.2A, .alpha.2B,\\r.alpha.2C, .beta.1, .beta.2), serotonin transporter (SERT),\\rDA transporter (DAT), norepinephrine transporter\\r(NET), imidazoline1 receptor (I1), Sigma receptors\\r(.sigma.1, .sigma.2), delta opioid receptor (DOR), kappa\\ropioid receptor (KOR), mu opioid receptor (MOR),\\rmuscarinic receptors (M1, M2, M3, M4, M5), histamine\\rreceptors (H1, H2), calcium ion channel (Ca+) and N-\\rmethyl D-aspartate (NMDA) glutamate receptor; alone\\ror in combination with items such as, but not limited\\rto: cannabinoids, terpenes, flavonoids, minerals,\\rpsychedelic and psychoactive compounds such as, but\\rnot limited to 5ht2a receptor agonists or other\\rcompounds; for medical, recreational, religious,\\rresearch and other uses.\", \"tokenized_text\": [\"alloster\", \"modul\", \"serotonin\", \"dopamin\", \"medic\", \"recreat\", \"religi\", \"research\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 22, \"Title\": \"Rapid method of producing non-alcoholic and alcoholic\\rbeer\", \"Owner/Assignee\": \"Ceria\", \"Patent/Pub. No.\": \"WO2022165387\", \"Priority Date\": \"31/1/2021\", \"Status\": \"Published\", \"general_subject\": \"A rapid method of brewing malt beverages having\\r0.0% alcohol by volume with the use of yeast in\\raerobic conditions. The yeast is inactivated by boiling\\rafter undergoing fermentative growth, during either\\raerobic or anaerobic conditions. Aspects of the\\rbeverage such as sweetness, aldehyde content, flavor-\\rpositive components, pH, mouthfeel and heat are\\rcontrolled to emulate popular styles of beer. The\\rbeverage may also be fortified with alcohol to create\\ralcoholic products, such as beer, kombucha, hard\\rseltzer, wine spirits in a rapid time frame.\", \"tokenized_text\": [\"rapid\", \"produc\", \"non-alcohol\", \"alcohol\", \"beer\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 23, \"Title\": \"Rapid method of producing non-alcoholic and alcoholic\\rbeer\", \"Owner/Assignee\": \"Ceria\", \"Patent/Pub. No.\": \"US11,521,444\", \"Priority Date\": \"31/1/2021\", \"Status\": \"Granted 2022-12-06\", \"general_subject\": \"A rapid method of brewing malt beverages having\\r0.0% alcohol by volume with the use of yeast in\\raerobic conditions. The yeast is inactivated by boiling\\rafter undergoing fermentative (minimal yeast contact\\rtime) growth, during either aerobic or anaerobic\\rconditions. Aspects of the beverage such as sweetness,\\raldehyde content, flavor-positive components, pH,\\rmouthfeel and heat are controlled to emulate popular\\rstyles of beer. The beverage may also be fortified with\\ralcohol to create alcoholic products, such as beer,\\rkombucha, hard seltzer, wine or spirits in a rapid time\\rframe.\", \"tokenized_text\": [\"rapid\", \"produc\", \"non-alcohol\", \"alcohol\", \"beer\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 2, \"#\": 24, \"Title\": \"Prenylated psilocybin derivatives and methods of using\", \"Owner/Assignee\": \"Enveric Biosciences\", \"Patent/Pub. No.\": \"WO2022155751\", \"Priority Date\": \"22/1/2021\", \"Status\": \"Published\", \"general_subject\": \"Disclosed are novel prenylated psilocybin derivative\\rcompounds and pharmaceutical and recreational drug\\rformulations containing the same. The compounds\\rmay be produced in vitro or in vivo using a\\rbiosynthetic system which comprises cells comprising\\ra prenyl transferase, and, optionally, additional\\renzymes, including a decarboxylase, and an N-acetyl\\rtransferase.\", \"tokenized_text\": [\"prenyl\", \"psilocybin\", \"deriv\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 25, \"Title\": \"Activated cannabis products and methods for\\rpreparation\", \"Owner/Assignee\": \"2655626 Ontario Inc.\", \"Patent/Pub. No.\": \"WO2022155741\", \"Priority Date\": \"20/1/2021\", \"Status\": \"Published\", \"general_subject\": \"The present disclosure describes cannabis products\\rand methods for producing one or more activated\\rcannabinoids, comprising decarboxylating one or\\rmore cannabinoid acids in a cannabis source; and\\rgrinding the cannabis source; to produce the one or\\rmore activated cannabinoids. Embodiments describe\\rone or more activated cannabinoids incorporated into\\ra product, such as a tablet or capsule or other product,\\rfor humans or animals. Embodiments including drying\\rthe cannabis source prior to grinding and\\rdecarboxylation.\", \"tokenized_text\": [\"activ\", \"cannabi\", \"product\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 26, \"Title\": \"Nanoparticle-mediated immune cell manufacture and\\ruses thereof\", \"Owner/Assignee\": \"The George\\rWashington\\rUniversity\", \"Patent/Pub. No.\": \"WO2022150763\", \"Priority Date\": \"11/1/2021\", \"Status\": \"Published\", \"general_subject\": \"The present disclosure generally relates target cancer\\rcell specific immunotherapy compositions, methods of\\rmaking and use thereof. Also provided in the\\rdisclosure are methods of treating a cancer in a\\rsubject in need thereof.\", \"tokenized_text\": [\"nanoparticle-medi\", \"immun\", \"cell\", \"manufactur\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 27, \"Title\": \"Systems and methods for pharmaceutical production of\\rpsilocybin and intermediates or side products\", \"Owner/Assignee\": \"Miami University\", \"Patent/Pub. No.\": \"WO2022150854\", \"Priority Date\": \"11/1/2021\", \"Status\": \"Published\", \"general_subject\": \"Provided are systems and methods for the production\\rof psilocybin or an intermediate or a side product\\rthereof. In certain embodiments, the recombinant host\\rstrain employed is eukaryotic and is selected from the\\rgroup consisting of Saccharomyces cerevisiae,\\rSaccharomyces eubayanus, Saccharomyces\\rpastorianus, Brettanomyces, Aspergillus niger,\\rAspergillus nidulans, Chinese Hamster Ovary (CHO),\\rYarrowia lipolytica, Pichia pastoris, Synechococcus\\relongatus, and Synechocystis sp. PCC6803 In certain\\rembodiments, the recombinant host strain employed\\ris prokaryotic and is selected from the group\\rconsisting of Escherichia coli, Corynebacterium\\rglutamicum, Vibrio natriegens, Bacillus subtilis, Bacillus\\rmegaterium, Escherichia coli Nissle 1917, Clostridium\\racetobutlyicum, Streptomyces coelicolor, Lactococcus\\rlactis, Pseudomonas putida, Streptomyces clavuligerus,\\rand Streptomyces venezuelae. In some embodiments,\\rthe recombinant host strain is grown in an actively\\rgrowing culture.\", \"tokenized_text\": [\"psilocybin\", \"side\", \"product\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 28, \"Title\": \"Treatment of suicidality with psilocin or psilocybin\", \"Owner/Assignee\": \"New York University\", \"Patent/Pub. No.\": \"WO2022150563\", \"Priority Date\": \"8/1/2021\", \"Status\": \"Published\", \"general_subject\": \"The invention relates to a method of preventing or\\rreducing suicidal ideation and/or desire for hastened\\rdeath in a patient suffering from a life-threatening\\rdisease, the method comprising administering a\\rpsychedelic compound which is psilocin or a prodrug\\rof psilocin, or a pharmaceutically acceptable salt\\rthereof, to said patient. Kits useful in the method of\\rthe invention are also described.\", \"tokenized_text\": [\"suicid\", \"psilocin\", \"psilocybin\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 29, \"Title\": \"Psilocybin and norbaeocystin compositions and\\rmethods of treatment\", \"Owner/Assignee\": \"Miami University\", \"Patent/Pub. No.\": \"WO2022150840\", \"Priority Date\": \"8/1/2021\", \"Status\": \"Published\", \"general_subject\": \"Provided is a pharmaceutical composition comprising\\rtwo or more tryptamines that are present in Psilocybe\\rmagic mushrooms. Provided is a pharmaceutical\\rcomposition comprising heterologously produced\\rpsilocybin and heterologously produced\\rnorbaeocystin. Also provided is a method of treating a\\rneurological or psychological disorder or condition in\\ra patient, comprising administering to the patient an\\reffective amount of a pharmaceutical composition\\rcomprising psilocybin and an effective amount of a\\rpharmaceutical composition comprising\\rnorbaeocystin. Also provided is a method of treating a\\rneurological or psychological disorder or condition in\\ra patient, comprising administering to the patient an\\reffective amount of a pharmaceutical composition\\rcomprisingpsilocybin and an effective amount of a\\rpharmaceutical composition comprising\\rnorbaeocystin. In some embodiments, the psilocybin is\\rheterologously produced. In some embodiments, the\\rnorbaeocystin is heterologously produced.\", \"tokenized_text\": [\"psilocybin\", \"norbaeocystin\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 1, \"#\": 30, \"Title\": \"Protected alkyl tryptamines and their therapeutic uses\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"WO2022150530\", \"Priority Date\": \"8/1/2021\", \"Status\": \"Published\", \"general_subject\": \"The disclosure relates to protected alkyl tryptamine\\rcompounds of formula (I). The disclosure relates to\\rcompositions comprising, consisting essentially of, or\\rconsisting of a compound of formula (I) and an\\rexcipient. The disclosure also relates to pharmaceutical\\rcompositions comprising a therapeutically effective\\ramount of a compound of formula (I) where the\\rexcipient is a pharmaceutically acceptable carrier. The\\rdisclosure further relates to therapeutic uses of\\rcompounds of formula (I).\", \"tokenized_text\": [\"protect\", \"alkyl\", \"tryptamin\", \"therapeut\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 31, \"Title\": \"Composition for treating opioid withdrawal and method\\rof manufacture\", \"Owner/Assignee\": \"Mai Nguyen\", \"Patent/Pub. No.\": \"US20220218649\", \"Priority Date\": \"7/1/2021\", \"Status\": \"Published\", \"general_subject\": \"A composition for treating opioid withdrawal and\\rmethod of manufacture and administration of the\\rcomposition creates a synergistic combination of\\rcannabinoids, terpenoids, herbs, and medicinal\\rmushrooms that help to eliminate the symptoms of\\ropioid withdrawal by creating a medicinal entourage.\\rThe composition combines: between about 2.5 to 100\\rmilligrams of a cannabinoid, between about 0.084 to\\r33.6 milligrams of a terpenoid, between about 0.5 to\\r3000 milligrams of an herb, and between about 25 to\\r2500 milligrams of a medicinal mushroom. The\\rcomposition is orally administered in a lipid-enclosed\\rcapsule form. The terpenoid has a lipophilic nature\\rthat enhances the bioavailability of the cannabinoid.\\rThe herb works with the body's endocannabinoid\\rsystem to enhance pain relief capacity of the\\rcannabinoid, so as to help inhibit symptoms of opioid\\rwithdrawal. The medicinal mushroom comprises a\\rpsychedelic drug that creates a therapeutic effect with\\rthe cannabinoid to inhibit symptoms of opioid\\rwithdrawal.\", \"tokenized_text\": [\"opioid\", \"withdraw\", \"manufactur\"], \"year\": \"2021\"}, {\"Unnamed: 0\": 0, \"#\": 32, \"Title\": \"Vaporizable psychoactive alkaloid composition and\\rpreparation thereof\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"WO2022140846\", \"Priority Date\": \"28/12/2020\", \"Status\": \"Published\", \"general_subject\": \"This liquid composition includes a psychoactive\\ralkaloid extract or synthetic psychoactive alkaloid. The\\ralkaloids in the extract are efficiently\\rdephosphorylated rather than phosphorylated. The\\rvaporizble psychoactive alkaloid composition includes\\ran alcohol or polyol carrier, fatty acid, fatty alcohol,\\roptional antioxidant, optional flavorant, and optional\\rfurther excipients. A process for obtaining a vaporizble\\rpsychoactive alkaloid composition includes\\rdephosphorylating the alkaloid during extraction,\\rpurifying the extracted alkaloid, and standardizing it to\\ra specific concentration by adding measured\\rquantities of excipients.\", \"tokenized_text\": [\"vaporiz\", \"psychoact\", \"alkaloid\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 33, \"Title\": \"Transmucosal psychoactive alkaloid composition and\\rpreparation thereof\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"WO2022140841\", \"Priority Date\": \"28/12/2020\", \"Status\": \"Published\", \"general_subject\": \"A transmucosal psychoactive alkaloid composition\\rincluding a psychoactive alkaloid extract or synthetic\\rpsychoactive alkaloid. The alkaloids in the extract are\\rpredominantly dephosphorylated rather than\\rphosphorylated. The transmucosal psychoactive\\ralkaloid composition also includes a mucoadhesive\\rpolymer, a carrier, and optional further excipients. The\\rnon-ingestive composition may be taken orally\\rthrough the mucosa. A process for obtaining an oral\\rtransmucosal psychoactive alkaloid composition\\rincludes dephosphorylating the alkaloid during\\rextraction, purifying the extracted alkaloid and\\rstandardizing to a specific concentration by adding\\rmeasured quantities of excipients.\", \"tokenized_text\": [\"transmucos\", \"psychoact\", \"alkaloid\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 34, \"Title\": \"Vaporizable psychoactive alkaloid composition and\\rpreparation thereof\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"US20220313713\", \"Priority Date\": \"28/12/2020\", \"Status\": \"Published\", \"general_subject\": \"This liquid composition includes a psychoactive\\ralkaloid extract or synthetic psychoactive alkaloid. The\\ralkaloids in the extract are predominantly\\rdephosphorylated rather than phosphorylated. The\\rvaporizble psychoactive alkaloid composition includes\\ran alcohol or polyol carrier, fatty acid, fatty alcohol,\\roptional antioxidant, optional flavorant, and optional\\rfurther excipients. A process for obtaining a vaporizble\\rpsychoactive alkaloid composition includes\\rdephosphorylating the alkaloid during extraction,\\rpurifying the extracted alkaloid, and standardizing it to\\ra specific concentration by adding measured\\rquantities of excipients.\", \"tokenized_text\": [\"vaporiz\", \"psychoact\", \"alkaloid\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 35, \"Title\": \"Transmucosal psychoactive alkaloid composition and\\rpreparation thereof\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"US20220313762\", \"Priority Date\": \"28/12/2020\", \"Status\": \"Published\", \"general_subject\": \"A transmucosal psychoactive alkaloid composition\\rincluding a psychoactive alkaloid extract or synthetic\\rpsychoactive alkaloid. The alkaloids in the extract are\\rpredominantly dephosphorylated rather than\\rphosphorylated. The transmucosal psychoactive\\ralkaloid composition also includes a mucoadhesive\\rpolymer, a carrier, and optional further excipients. The\\rnon-ingestive composition may be taken orally\\rthrough the mucosa. A process for obtaining an oral\\rtransmucosal psychoactive alkaloid composition\\rincludes dephosphorylating the alkaloid during\\rextraction, purifying the extracted alkaloid and\\rstandardizing to a specific concentration by adding\\rmeasured quantities of excipients.\", \"tokenized_text\": [\"transmucos\", \"psychoact\", \"alkaloid\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 36, \"Title\": \"Compositions and methods for anxiety disorder\\rtreatment\", \"Owner/Assignee\": \"Psilobrain\\rTherapeutics\", \"Patent/Pub. No.\": \"WO2022137107\", \"Priority Date\": \"21/12/2020\", \"Status\": \"Published\", \"general_subject\": \"Composition consisting of psilocybin and crocin to\\rtreat anxiety disorder\", \"tokenized_text\": [\"anxieti\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 37, \"Title\": \"Use of psilocybin in cancer treatment\", \"Owner/Assignee\": \"Silo Pharma\", \"Patent/Pub. No.\": \"WO2022125949\", \"Priority Date\": \"13/12/2020\", \"Status\": \"Published\", \"general_subject\": \"Methods of treating and/or alleviating proliferating\\rdisease and one or more of their symptoms, and\\rdelaying the onset of symptoms. Comprises\\radministering to the subject a therapeutically effective\\ramount of a pharmaceutical composition, where the\\rpharmaceutical composition comprises a targeting\\rpeptide comprising an amino acid sequence of any\\rone of SEQ ID NOs: 1-22 associated with psilocybin, or\\ra pharmaceutically acceptable salt, co-crystal,\\rpolymorph, hydrate, solvate, stereoisomer, or pro-drug\\rof psilocybin, and where the targeting peptide is\\rcapable of delivering the psilocybin, or the\\rpharmaceutically acceptable salt, co-crystal,\\rpolymorph, hydrate, solvate, stereoisomer, or pro-drug\\rof psilocybin, to a target environment of the subject.\", \"tokenized_text\": [\"psilocybin\", \"cancer\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 38, \"Title\": \"Dialkyl trytamines and their therapeutic uses\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"WO2022125616\", \"Priority Date\": \"9/12/2020\", \"Status\": \"Published\", \"general_subject\": \"The disclosure relates to a composition comprising,\\rconsisting essentially of, or consisting of as a first\\ractive component: a compound of formula (I) or\\rformula (la) of the disclosure; and as a second active\\rcomponent selected from (a) a serotonergic drug, (b) a\\rpurified psilocybin derivative, (c) one or two purified\\rcannabinoids and (d) a purified terpene, (e) an\\radrenergic drug, (f) a dopaminergic drug, (g) a\\rmonoamine oxidase inhibitor, (h) a purified erinacine,\\rand (i) a purified hericenone; and a pharmaceutically\\racceptable excipient.\", \"tokenized_text\": [\"dialkyl\", \"trytamin\", \"therapeut\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 39, \"Title\": \"Pharmaceutical composition comprising psilocybin or its\\rpolymorphs\", \"Owner/Assignee\": \"Beckley Psytech\", \"Patent/Pub. No.\": \"WO2022123232\", \"Priority Date\": \"7/12/2020\", \"Status\": \"Published\", \"general_subject\": \"A composition for use in a method of treatment of\\rshort-lasting unilateral neuralgiform headache with\\rconjunctival injection and tearing (SUNCT) or short-\\rlasting neuralgiform headaches with cranial autonomic\\rsymptoms (SUNA), wherein the composition comprises\\ra pharmaceutically effective amount of psilocybin,\\rpsilocin or a prodrug thereof, wherein the psilocybin,\\rpsilocin or a prodrug thereof, has been synthesised, or\\rhas been isolated from a naturally occurring substance\\ror product.\", \"tokenized_text\": [\"psilocybin\", \"polymorph\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 40, \"Title\": \"Aldehyde and ketone derivatives of psilocybin and\\rmethods of using\", \"Owner/Assignee\": \"Enveric Biosciences\", \"Patent/Pub. No.\": \"WO2022115960\", \"Priority Date\": \"4/12/2020\", \"Status\": \"Published\", \"general_subject\": \"A chemical compound having the psilocybin molecular\\rstructure, wherein at least one component is either an\\rAldehyde or Ketone derivative.\", \"tokenized_text\": [\"aldehyd\", \"keton\", \"deriv\", \"psilocybin\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 41, \"Title\": \"Novel psilocin analog compositions and methods of\\rsynthesizing the same\", \"Owner/Assignee\": \"Mydecine\\rInnovations\", \"Patent/Pub. No.\": \"WO2022120181\", \"Priority Date\": \"3/12/2020\", \"Status\": \"Published\", \"general_subject\": \"Novel psilosin analogs exhibiting enhanced resistance\\rto oxidation; may show modified pharmacokinetics,\\rstability, delivery, and bioavailability, and metabolism\\rdue to differences in glucuronidation and/or\\rdemethylation of the dimethyl amine functionality\\ramong other considerations.\", \"tokenized_text\": [\"novel\", \"psilocin\", \"analog\", \"synthes\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 42, \"Title\": \"Carboxylated psilocybin derivatives and methods of\\rusing\", \"Owner/Assignee\": \"Enveric Biosciences\", \"Patent/Pub. No.\": \"WO2022115944\", \"Priority Date\": \"1/12/2020\", \"Status\": \"Published\", \"general_subject\": \"A chemical compound having the psilocybin molecular\\rstructure, wherein atleast one component is a carboxyl\\rgroup or carboxylic acid derivative.\", \"tokenized_text\": [\"carboxyl\", \"psilocybin\", \"deriv\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 43, \"Title\": \"Compositions and methods for treating migraine\", \"Owner/Assignee\": \"Wesana Health\", \"Patent/Pub. No.\": \"WO2022115798\", \"Priority Date\": \"30/11/2020\", \"Status\": \"Published\", \"general_subject\": \"Disclosure features compositions containing\\rcannabidiol (CBD) and/or psilocybin, optionally in\\rcombination with a mushroom blend. Also featured\\rare methods for treating or preventing migraine, or\\rsymptoms thereof, with a cannabidiol and/or\\rpsilocybin, optionally in combination with a mushroom\\rblend.\", \"tokenized_text\": [\"migrain\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 44, \"Title\": \"Compositions and methods for treating neurological\\rconditions\", \"Owner/Assignee\": \"Wesana Health\", \"Patent/Pub. No.\": \"WO2022115796\", \"Priority Date\": \"30/11/2020\", \"Status\": \"Published\", \"general_subject\": \"Disclosure features compositions containing a\\rcannabidiol (CBD) and/or psilocybin, optionally in\\rcombination with a mushroom blend. The present\\rdisclosure also features methods for treating\\rneurological conditions (e.g., traumatic brain injury or\\rTBI), or symptoms thereof (e.g., anxiety or depression),\\rwith a cannabidiol and/or psilocybin, optionally in\\rcombination with a mushroom blend. The present\\rdisclosure also features compositions and methods of\\rusing psilocybin in combination with a\\rneurotransmitter activity modulator for the treatment\\rof neurological conditions (e.g., TBI), or symptoms\\rthereof (e.g., anxiety or depression).\", \"tokenized_text\": [\"neurolog\", \"condit\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 45, \"Title\": \"Treatment of anxiety and depression\", \"Owner/Assignee\": \"New York University\", \"Patent/Pub. No.\": \"US20220151993\", \"Priority Date\": \"16/11/2020\", \"Status\": \"Published\", \"general_subject\": \"Method of alleviating depression and/or anxiety in a\\rcancer patient, comprising administering a single dose\\rof psilocin or a prodrug of psilocin, or a\\rpharmaceutically acceptable salt thereof, to said\\rcancer patient optionally in conjunction with a\\rpsychotherapy treatment.\", \"tokenized_text\": [\"anxieti\", \"depress\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 46, \"Title\": \"Engineered microorganisms for producing substituted\\rtryptamines\", \"Owner/Assignee\": \"Algae-C\", \"Patent/Pub. No.\": \"WO2022099424\", \"Priority Date\": \"16/11/2020\", \"Status\": \"Published\", \"general_subject\": \"Presented herein are microorganisms for producing\\rsubstituted tryptamines and cell cultures thereof, the\\rmicroorganisms comprising at least one exogenous\\rnucleic acid molecule that encodes at least one\\rsubstituted tryptamine biosynthetic pathway enzyme.\", \"tokenized_text\": [\"engin\", \"microorgan\", \"produc\", \"substitut\", \"tryptamin\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 47, \"Title\": \"Compositions and methods for extracting, stabilizing,\\rand manufacturing stable dosage forms of psilocin,\\rpsychedelic drugs, entheogens, and medicinal\\rmushrooms as nano-dimensional drug delivery\\rstructures\", \"Owner/Assignee\": \"Richard C Kaufman\", \"Patent/Pub. No.\": \"US20220054402\", \"Priority Date\": \"5/11/2020\", \"Status\": \"Published\", \"general_subject\": \"Invention discloses nano-dimensional compositions of\\rpsychedelics/entheogens/medicinal mushrooms\\rdelivery in dosage forms of by intraoral,\\rgastrointestinal, transdermal, and intranasal, routes of\\radministration.\", \"tokenized_text\": [\"extract\", \"stabil\", \"manufactur\", \"stabl\", \"dosag\", \"psilocin\", \"psychedel\", \"drug\", \"entheogen\", \"medicin\", \"mushroom\", \"nano-dimension\", \"drug\", \"structur\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 48, \"Title\": \"Thc beverage preparation apparatus and method of use\\rthereof\", \"Owner/Assignee\": \"Cave; Mason; et al.\", \"Patent/Pub. No.\": \"US20220125091\", \"Priority Date\": \"24/10/2020\", \"Status\": \"Published\", \"general_subject\": \"A method for preparing and packaging a THC\\rbeverage containing psilocybin.\", \"tokenized_text\": [\"thc\", \"beverag\", \"apparatus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 49, \"Title\": \"Cannabis time release apparatus and method of\\rmanufacture thereof\", \"Owner/Assignee\": \"Hazen; Kevin; et al.\", \"Patent/Pub. No.\": \"US20220125755\", \"Priority Date\": \"24/10/2020\", \"Status\": \"Published\", \"general_subject\": \"A method for forming a Cannabis product, comprising\\rthe steps of preparing a tetrahydrocannabinol\\remulsion comprising particles, said particles\\rcomprising: a first peak concentration of said particles\\rless than nine hundred nanometers in diameter; and a\\rsecond peak concentration of said particles greater\\rthan nine hundred nanometers in diameter; and\\radding said tetrahydrocannabinol emulsion to at least\\rone of an edible; a beverage; an additive in a vape\\rcartridge; and a pre-roll. Further, adding into at least\\rone of said tetrahydrocannabinol emulsion and said\\rbeverage at least one of: Psilocybe; psilocin;\\rbaeocystin; Cubensis; and Panaeolus (Copelandia).\", \"tokenized_text\": [\"cannabi\", \"time\", \"releas\", \"apparatus\", \"manufactur\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 50, \"Title\": \"Food / beverage nootropic amendment apparatus and\\rmethod of use thereof\", \"Owner/Assignee\": \"Roth; Michael; et al.\", \"Patent/Pub. No.\": \"US20220127058\", \"Priority Date\": \"24/10/2020\", \"Status\": \"Published\", \"general_subject\": \"The invention comprises a method and apparatus for\\ramending a food product, comprising the steps of: (1)\\rforming a nootropic emulsion comprising a nootropic,\\ran emulsifier, and water, the nootropic including at\\rleast one of: Psilocybe, Cubensis; and Panaeolus\\r(Copelandia); (2) subjecting the nootropic emulsion to\\rshear forces exceeding 50,000 sec.sup.-1 in a high\\rpressure emulsifier; and (3) amending the food\\rproduct with the nootropic emulsion to form a\\rnootropic amended food product with the optional\\rstep of receiving the food product from a first state of\\rthe United States of America where at least one\\rnootropic component and/or tetrahydrocannabinol\\r(THC) in the nootropic emulsion is illegal in food, the\\rstep of amending adding the nootropic and/or the\\rTHC to the food product being legal in a second state\\rwhere the at least one nootropic component and/or\\rthe THC is added to the food product.\", \"tokenized_text\": [\"food\", \"beverag\", \"nootrop\", \"amend\", \"apparatus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 51, \"Title\": \"Thc food / beverage product method of manufacture\", \"Owner/Assignee\": \"Reich; Alton J.; et al.\", \"Patent/Pub. No.\": \"US20220125088\", \"Priority Date\": \"24/10/2020\", \"Status\": \"Published\", \"general_subject\": \"A method for amending an original food product,\\rcomprising the steps of: receiving the original food\\rproduct into a THC licensed manufacturing facility\\rfrom a legal zone where THC in the original food\\rproduct is illegal; exposing THC, water, and an\\remulsifier to shear forces exceeding 50,000 sec.sup.-1\\rto generate a THC emulsion; adding, in the THC\\rlicensed manufacturing facility, said THC emulsion to\\rthe original food product to form a THC amended\\rproduct. Adding at least one of Psilocybe, Cubensis;\\rand Panaeolus (Copelandia) to said THC emulsion.\", \"tokenized_text\": [\"thc\", \"food\", \"beverag\", \"product\", \"manufactur\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 52, \"Title\": \"Thc container apparatus and method of use thereof\", \"Owner/Assignee\": \"Cave; Mason; et al.\", \"Patent/Pub. No.\": \"US20220125810\", \"Priority Date\": \"24/10/2020\", \"Status\": \"Published\", \"general_subject\": \"method of preparing and packaging a THC infused\\rsoda that is at least 3% alcohol and containing at least\\rone of: Psilocybe; psilocin; and baeocystin.\", \"tokenized_text\": [\"thc\", \"contain\", \"apparatus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 53, \"Title\": \"Method for forming a beverage with a dissolvable thc\\rtablet\", \"Owner/Assignee\": \"Michael Roth et al.\", \"Patent/Pub. No.\": \"US20220241238\", \"Priority Date\": \"24/10/2020\", \"Status\": \"Published\", \"general_subject\": \"The invention comprises a method and apparatus for\\rforming a beverage, comprising the steps of:\\rdissolving a tablet in the beverage, the tablet\\rcontaining tetrahydrocannabinol; forming gas bubbles,\\rsuch as carbon dioxide, within the beverage through a\\rchemical reaction; and mixing the\\rtetrahydrocannabinol in the beverage through motion\\rof the gas bubbles, such as where the\\rtetrahydrocannabinol is maintained, after the step of\\rmixing, in suspension in the beverage for a period of\\rat least five minutes through at least movement of the\\rgas bubbles.\", \"tokenized_text\": [\"form\", \"beverag\", \"dissolv\", \"thc\", \"tablet\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 54, \"Title\": \"Process for obtaining a purified psychoactive alkaloid\\rsolution\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"WO2022082320\", \"Priority Date\": \"23/10/2020\", \"Status\": \"Published\", \"general_subject\": \"A psychoactive alkaloid source is used to obtain a\\rpsychoactive alkaloid extract. The source may be\\rpsychedelic mushrooms, animals or plants or a prior\\rextract therefrom. Psychoactive alkaloids in the extract\\rare adsorbed onto an adsorbent material, from which\\rthey are then eluted to provide a purified psychoactive\\ralkaloid solution.\", \"tokenized_text\": [\"process\", \"obtain\", \"purifi\", \"psychoact\", \"alkaloid\", \"solut\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 55, \"Title\": \"Use of benzodiazepines to increase sensitivity to\\rpsilocybin following a chronic ssri regimen\", \"Owner/Assignee\": \"Compass Pathfinder\", \"Patent/Pub. No.\": \"WO2022084480\", \"Priority Date\": \"21/10/2020\", \"Status\": \"Published\", \"general_subject\": \"A method of administering psilocybin to a subject in\\rneed thereof, wherein prior to administration of\\rpsilocybin the subject was on a selective serotonin\\rreuptake inhibitor (SSRI) therapy regimen comprising\\ra) ceasing SSRI therapy 1 to 35 days prior to\\radministration of psilocybin; b) administering one or\\rmore benzodiazepines at least once daily to the\\rsubject starting at least 1 to 35 days prior to\\radministration of psilocybin; and c) administering\\rpsilocybin to the subject.\", \"tokenized_text\": [\"benzodiazepin\", \"increas\", \"sensit\", \"psilocybin\", \"follow\", \"chronic\", \"ssri\", \"regimen\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 56, \"Title\": \"Compositions for reducing inflammation to improve or\\rmaintain mental or physical health\", \"Owner/Assignee\": \"Goodcap\\rPharmaceuticals\", \"Patent/Pub. No.\": \"WO2022079574\", \"Priority Date\": \"12/10/2020\", \"Status\": \"Published\", \"general_subject\": \"A composition comprising a therapeutic combination\\rof a 5HT2A agonist compound and at least one TRP\\ragonist compound, wherein the therapeutically\\reffective amount of the 5HT2A agonist is between\\rabout 1 pg and about 300 mg; and the therapeutically\\reffective amount of the at least one TRP receptor\\ragonist is between about 0.01 mg and about 300 mg.\", \"tokenized_text\": [\"reduc\", \"inflamm\", \"improv\", \"maintain\", \"mental\", \"physic\", \"health\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 57, \"Title\": \"Deuterated derivatives of psilocybin and uses thereof\", \"Owner/Assignee\": \"Lennham\\rPharmaceuticals\", \"Patent/Pub. No.\": \"US11,324.762\", \"Priority Date\": \"8/10/2020\", \"Status\": \"Granted 2022-05-10\\r(expires 2040-12-10)\", \"general_subject\": \"Compositions comprising deuterated derivatives of\\rpsilocybin. The provided compositions may be useful\\rfor treating and/or preventing various diseases and\\rconditions, such as mood or psychiatric disorders.\", \"tokenized_text\": [\"deuter\", \"deriv\", \"psilocybin\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 58, \"Title\": \"Deuterated derivatives of psilocybin and uses thereof\", \"Owner/Assignee\": \"Lennham\\rPharmaceuticals\", \"Patent/Pub. No.\": \"US11,000,534B1\", \"Priority Date\": \"8/10/2020\", \"Status\": \"Granted 2021-05-11\\r(expires 2040-12-10)\", \"general_subject\": \"Pharmaceutical compositions of deuterated psilocybin.\", \"tokenized_text\": [\"deuter\", \"deriv\", \"psilocybin\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 59, \"Title\": \"Deuterated derivatives of psilocybin and uses thereof\", \"Owner/Assignee\": \"Lennham\\rPharmaceuticals\", \"Patent/Pub. No.\": \"US20220110955\", \"Priority Date\": \"8/10/2020\", \"Status\": \"Published\", \"general_subject\": \"Compositions comprising deuterated derivatives of\\rpsilocybin. The provided compositions may be useful\\rfor treating and/or preventing various diseases and\\rconditions, such as mood or psychiatric disorders.\", \"tokenized_text\": [\"deuter\", \"deriv\", \"psilocybin\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 60, \"Title\": \"Novel psychedelic compositions, delivery systems, and\\rtherapeutic uses thereof\", \"Owner/Assignee\": \"Mydecine\\rInnovations\", \"Patent/Pub. No.\": \"WO2022072808A1\", \"Priority Date\": \"1/10/2020\", \"Status\": \"Pending\", \"general_subject\": \"Combinations of at least one psychedelic compound,\\rwhich is preferably includes a serotonin receptor\\ragonist, and at least one secondary agent that\\rmodulates the activity of the serotonin receptor\\ragonist, or the physiological response to the serotonin\\rreceptor agonist in a subject, such as a UGI inhibitor or\\ra MAO inhibitor. In this manner, the serotonin receptor\\ragonist remains in its active form and in the body for a\\rlonger period of time, which in turn allows for lower\\rdosages of the serotonin receptor agonist to produce\\rthe same or better therapeutic response.\", \"tokenized_text\": [\"novel\", \"psychedel\", \"therapeut\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 61, \"Title\": \"Novel formulations of psilocybin and psilocin\\rcompounds as serotonin agonists in combination with\\r3,4 methylenedioxymethamphetamine (mdma)\", \"Owner/Assignee\": \"Mydecine\\rInnovations\", \"Patent/Pub. No.\": \"WO2022061196\", \"Priority Date\": \"18/9/2020\", \"Status\": \"Published\", \"general_subject\": \"Use of novel formulated psilocybin and/or psilocin\\rcompounds in combination with 3,4-\\rmethylenedioxymethamphetamine (MDMA) or other\\rentactogens, to modulate activity of serotonin\\rreceptors, and preferably the 5-HT2A serotonin\\rreceptor in humans.\", \"tokenized_text\": [\"novel\", \"psilocybin\", \"psilocin\", \"serotonin\", \"agonist\", \"3,4\", \"methylenedioxymethamphetamin\", \"mdma\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 62, \"Title\": \"Methods of quantifying psilocybin's main metabolites,\\rpsilocin and 4-hydroxyindole-3-acetic acid, in human\\rplasma\", \"Owner/Assignee\": \"Universitatsspital\\rBasel\", \"Patent/Pub. No.\": \"US20220082578A1\", \"Priority Date\": \"12/9/2020\", \"Status\": \"Published\", \"general_subject\": \"A method of measuring and identifying metabolites of\\ra tryptamine compound, by obtaining a sample from\\ran individual, and measuring and identifying\\rmetabolites of the tryptamine compound in the\\rsample by performing a LC-MS/MS analysis. A method\\rof adjusting dosing in patients with tryptamine\\rcompound-assisted psychotherapy in therapeutic drug\\rmonitoring (TDM), by obtaining a sample from an\\rindividual, measuring and identifying metabolites of\\rthe tryptamine compounds in the sample by\\rperforming a LC-MS/MS analysis, and adjusting a dose\\rof the tryptamine compounds based on the measured\\rmetabolites.\", \"tokenized_text\": [\"quantifi\", \"psilocybin\", \"'s\", \"main\", \"metabolit\", \"psilocin\", \"4-hydroxyindole-3-acet\", \"acid\", \"human\", \"plasma\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 63, \"Title\": \"Psilocybin in patients with obsessive-compulsive\\rdisorder\", \"Owner/Assignee\": \"Yale University\", \"Patent/Pub. No.\": \"US20220062310\", \"Priority Date\": \"3/9/2020\", \"Status\": \"Published\", \"general_subject\": \"Psilocybin to treat OCD\", \"tokenized_text\": [\"psilocybin\", \"patient\", \"obsessive-compuls\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 64, \"Title\": \"Nitrated psilocybin derivatives and use thereof for\\rmodulating 5-HT2A receptor and for treating a\\rpsychiatric disorder\", \"Owner/Assignee\": \"Enveric Biosciences\", \"Patent/Pub. No.\": \"WO2022047583\", \"Priority Date\": \"2/9/2020\", \"Status\": \"Published\", \"general_subject\": \"Nitrated psilocybin compounds\", \"tokenized_text\": [\"nitrat\", \"psilocybin\", \"deriv\", \"modul\", \"5-ht2a\", \"psychiatr\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 65, \"Title\": \"Cellular composition for treatment of diseases, disorders\\ror conditions and methods of use\", \"Owner/Assignee\": \"YZTherapeutic\\rPerformance\", \"Patent/Pub. No.\": \"WO2022049574\", \"Priority Date\": \"2/9/2020\", \"Status\": \"Published\", \"general_subject\": \"A composition comprising a serotonin (5-HT)\\rreceptor-expressing cells for use in the treatment of a\\rdisease, disorder or condition, wherein said cells have\\rbeen exposed to (i) a serotonin receptor agonist; or (ii)\\ra prodrug of said serotonin receptor agonist in the\\rpresence of an enzyme capable of converting said\\rprodrug to said serotonin receptor agonist.\", \"tokenized_text\": [\"cellular\", \"diseas\", \"condit\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 66, \"Title\": \"Halogenated psilocybin derivatives and methods of\\rusing\", \"Owner/Assignee\": \"Enveric Biosciences\", \"Patent/Pub. No.\": \"WO2022047579\", \"Priority Date\": \"1/9/2020\", \"Status\": \"Published\", \"general_subject\": \"Halogenated psilocybin derivative compounds\\rproduced using a biosynthetic system which comprises\\rcells comprising a psilocybin biosynthetic enzyme\\rcomplement.\", \"tokenized_text\": [\"halogen\", \"psilocybin\", \"deriv\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 5, \"#\": 67, \"Title\": \"Hydroxylated psilocybin derivatives and methods of\\rusing\", \"Owner/Assignee\": \"Enveric Biosciences\", \"Patent/Pub. No.\": \"WO2022047580\", \"Priority Date\": \"1/9/2020\", \"Status\": \"Published\", \"general_subject\": \"Hydroxylated psilocybin derivative compounds\\rproduced synthetically or biosynthetically.\", \"tokenized_text\": [\"hydroxyl\", \"psilocybin\", \"deriv\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 68, \"Title\": \"Glycosylated psilocybin derivatives and methods of\\rusing\", \"Owner/Assignee\": \"Enveric Biosciences\", \"Patent/Pub. No.\": \"WO2022040802\", \"Priority Date\": \"26/8/2020\", \"Status\": \"Published\", \"general_subject\": \"Novel glycosylated psilocybin derivative compounds\\rthat activate the 5-HT2A cell surface receptor and\\rincrease intracellular calcium concentration with a\\rprofile different from that of psilocin\", \"tokenized_text\": [\"glycosyl\", \"psilocybin\", \"deriv\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 69, \"Title\": \"Biosynthesis and method of production of psilocin and\\rpsilocybin in microorganisims\", \"Owner/Assignee\": \"Synbionik Gmbh\", \"Patent/Pub. No.\": \"EP 3957726A1\", \"Priority Date\": \"21/8/2020\", \"Status\": \"Published\", \"general_subject\": \"Biosynthetic methods of production of psilocin and\\rpsilocybin using DMT as starting material\", \"tokenized_text\": [\"biosynthesi\", \"psilocin\", \"psilocybin\", \"microorganisim\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 70, \"Title\": \"Novel psilocin derivatives having prodrug properties\", \"Owner/Assignee\": \"Compass Pathfinder\", \"Patent/Pub. No.\": \"WO2022038299\", \"Priority Date\": \"21/8/2020\", \"Status\": \"Published\", \"general_subject\": \"Novel Psilocin derivatives that exhibit improved\\rpharmacokinetic properties during uptake aswell as\\rreduced side effects from metabolites.\", \"tokenized_text\": [\"novel\", \"psilocin\", \"deriv\", \"prodrug\", \"properti\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 71, \"Title\": \"Tailored hypoimmune nanovesicular delivery systems for\\rcancer tumors, hereditary and infectious diseases\", \"Owner/Assignee\": \"Thomas Malcolm;\\rSafia Rizvi; Surya\\rSankuratri\", \"Patent/Pub. No.\": \"US20220040106A1\", \"Priority Date\": \"5/8/2020\", \"Status\": \"Published\", \"general_subject\": \"Compositions of biomimetic nanovesicles (Hypo-\\rBioNVs) containing therapeutic compounds such as\\ribogaine to treat patients suffering from a variety of\\rdisorders.\", \"tokenized_text\": [\"tailor\", \"hypoimmun\", \"nanovesicular\", \"cancer\", \"tumor\", \"hereditari\", \"infecti\", \"diseas\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 72, \"Title\": \"Central nervous system delivery of nonsteroidal anti-\\rinflammatory drugs and psilocybin\", \"Owner/Assignee\": \"Silo Pharma\", \"Patent/Pub. No.\": \"WO2022031552A1\", \"Priority Date\": \"3/8/2020\", \"Status\": \"Published\", \"general_subject\": \"Treating a disease using a central nervous system\\rhoming or targeting peptide associated with a\\rnonsteroidal anti-inflammatory drug (NSAID) and\\rpsilocybin or an analogue thereof.\", \"tokenized_text\": [\"central\", \"nervous\", \"system\", \"nonsteroid\", \"anti-\", \"inflammatori\", \"drug\", \"psilocybin\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 5, \"#\": 73, \"Title\": \"Central nervous system delivery of psilocybin\", \"Owner/Assignee\": \"Silo Pharma\", \"Patent/Pub. No.\": \"WO2022031551A1\", \"Priority Date\": \"3/8/2020\", \"Status\": \"Published\", \"general_subject\": \"Treating a disease using a central nervous system\\rhoming or targeting peptide associated with\\rpsilocybin or an analog thereof.\", \"tokenized_text\": [\"central\", \"nervous\", \"system\", \"psilocybin\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 6, \"#\": 74, \"Title\": \"Extended release 5-ht receptor agonists for neurological\\rconditions\", \"Owner/Assignee\": \"Diamond\\rTherapeutics\", \"Patent/Pub. No.\": \"WO2022023812A1\", \"Priority Date\": \"29/7/2020\", \"Status\": \"Pending\", \"general_subject\": \"Methods and compositions for treating or managing a\\rmental, behavioral, or neuropsychiatric\\rcondition,wherein the composition comprises one or\\rmore 5-HT receptor agonists. In certain embodiments,\\rsuch methods involve the administration of one or\\rmore 5-HT agonist in microdose amounts.\", \"tokenized_text\": [\"extend\", \"releas\", \"5-ht\", \"agonist\", \"neurolog\", \"condit\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 75, \"Title\": \"Compositions and methods for treatment of psychoses\\rand psychotic disorders\", \"Owner/Assignee\": \"Stephen Barnhill; Ai\\rPharmaceuticals\\rJamaica\", \"Patent/Pub. No.\": \"WO2022018709\", \"Priority Date\": \"21/7/2020\", \"Status\": \"Published\", \"general_subject\": \"Compositions of at least one serotonergic psychedelic,\\rat least one cannabinoid, at least one terpene, and at\\rleast one edible or medicinal mushroom or extract\\rthereof, including methods for optimizing the\\rcompositions using AI algorithms.\", \"tokenized_text\": [\"psychos\", \"psychot\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 76, \"Title\": \"Method of treatment for psilocybin or psilocin infusion\", \"Owner/Assignee\": \"Eleusis\", \"Patent/Pub. No.\": \"WO2022011350A1\", \"Priority Date\": \"10/7/2020\", \"Status\": \"Published\", \"general_subject\": \"Iv administration of psilocybin or psilocin that may\\rinclude an additional compound such as a\\rbenzodiazepine, preferably lorazepam\", \"tokenized_text\": [\"psilocybin\", \"psilocin\", \"infus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 77, \"Title\": \"Methods and systems for providing a personalized\\rtreatment regemin using canabinoid or psychedelic\\rcompounds\", \"Owner/Assignee\": \"Greenway DNA\", \"Patent/Pub. No.\": \"US20210407643\", \"Priority Date\": \"25/6/2020\", \"Status\": \"Published\", \"general_subject\": \"Methods and systems for providing a personalized\\rcannabinoid or psychedelic (including LSD) experience\\rby using genetic information from a patient to a\\rprovide personally tailored treatment.\", \"tokenized_text\": [\"provid\", \"person\", \"regemin\", \"canabinoid\", \"psychedel\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 78, \"Title\": \"Compositions comprising psychoactive compounds from\\rpsychoactive organisms\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"WO2021253116A1\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Published\", \"general_subject\": \"A method for generating a psychoactive alkaloid\\rextract from a psychoactive organism\", \"tokenized_text\": [\"psychoact\", \"psychoact\", \"organ\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 79, \"Title\": \"Extraction of psychoactive compounds from psilocybin\\rfungus\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"WO2021253123A1\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Published\", \"general_subject\": \"The solvent used for extraction is a lower aliphatic\\ralcohol, water, a hydro-alcohol mixture, an acidic\\rhydro-alcohol mixture, or an alkaline hydro-alcohol\\rmixture.\", \"tokenized_text\": [\"extract\", \"psychoact\", \"psilocybin\", \"fungus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 5, \"#\": 80, \"Title\": \"Methanol-based extraction of psychoactive compounds\\rfrom fungus\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"WO2021253124A1\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Published\", \"general_subject\": \"The solvent used for extraction is methanol or a hydro-\\rmethanol mixture, an acidic hydro-methanol mixture,\\ror an alkaline hydro-methanol mixture.\", \"tokenized_text\": [\"methanol-bas\", \"extract\", \"psychoact\", \"fungus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 6, \"#\": 81, \"Title\": \"Methods and compositions comprising psychoactive\\rcompounds from psychoactive organisms\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"US20210393716A1\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Published\", \"general_subject\": \"A method for generating a psychoactive alkaloid\\rextract from a psychoactive organism\", \"tokenized_text\": [\"psychoact\", \"psychoact\", \"organ\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 82, \"Title\": \"Aqueous extraction of psychoactive compounds from\\rpsilocybin fungus\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"US20220202886\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Published\", \"general_subject\": \"This invention relates to the extraction of psychoactive\\rcompounds from psilocybin fungus for use in\\rmedicine. Raw psilocybin fungus is dried and ground.\\rThe solvent used for extraction is a lower aliphatic\\ralcohol, water, a hydro-alcohol mixture, an acidic\\rhydro-alcohol mixture, or an alkaline hydro-alcohol\\rmixture. The extraction slurry is filtered and pH-\\radjusted if necessary. The solvent is then partially\\revaporated, or completely evaporated with water\\radded back, to form a concentrated slurry. The\\rconcentrated slurry is then standardized to provide a\\rknown concentration of the psychoactive alkaloids\\rthat have been extracted. The standardized slurry may\\rthen be dried to result in a powdered psilocybin\\rmushroom extract with a precisely defined purity.\", \"tokenized_text\": [\"aqueous\", \"extract\", \"psychoact\", \"psilocybin\", \"fungus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 83, \"Title\": \"Extraction of psychoactive compounds from psilocybin\\rfungus\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"CA3088384C\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Granted 2021-08-03\\r(expires 2040-07-29)\", \"general_subject\": \"This invention relates to the extraction of psychoactive\\rcompounds from organisms for use in medicine.\\rExtraction is carried out with a strong acid or strong\\rbase to either promote or inhibit dephosphorylation.\\rThe extract in the slurry form is standardized with\\radded excipient so that when it is dried the powdered\\rcomposition has a specified total psychoactive alkaloid\\rconcentration, with a known ratio of phosphorylated\\rto dephosphorylated psychoactive alkaloids.\", \"tokenized_text\": [\"extract\", \"psychoact\", \"psilocybin\", \"fungus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 84, \"Title\": \"Methods and compositions comprising psychoactive\\rcompounds from psychoactive organisms\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"US20210393717A1\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Published\", \"general_subject\": \"A method for generating a psychoactive alkaloid\\rextract from a psychoactive organism\", \"tokenized_text\": [\"psychoact\", \"psychoact\", \"organ\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 85, \"Title\": \"Methods and compositions comprising psychoactive\\rcompounds from psychoactive organisms\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"US20220152136\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Published\", \"general_subject\": \"This invention relates to the extraction of psychoactive\\rcompounds from organisms for use in medicine.\\rExtraction is carried out with a strong acid or strong\\rbase to either promote or inhibit dephosphorylation\", \"tokenized_text\": [\"psychoact\", \"psychoact\", \"organ\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 86, \"Title\": \"Psychoactive alkaloid extraction and composition with\\rcontrolled dephosphorylation\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"WO20220040246\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Published\", \"general_subject\": \"This invention relates to the extraction of psychoactive\\rcompounds from organisms for use in medicine.\\rExtraction is carried out with a strong acid or strong\\rbase to either promote or inhibit dephosphorylation.\\rThe extract in the slurry form is standardized with\\radded excipient so that when it is dried the powdered\\rcomposition has a specified total psychoactive alkaloid\\rconcentration, with a known ratio of phosphorylated\\rto dephosphorylated psychoactive alkaloids.\", \"tokenized_text\": [\"psychoact\", \"alkaloid\", \"extract\", \"control\", \"dephosphoryl\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 87, \"Title\": \"Methanol-based extraction of psychoactive alkaloids\\rfrom fungus\", \"Owner/Assignee\": \"Psilo Scientific\", \"Patent/Pub. No.\": \"US20220305402\", \"Priority Date\": \"17/6/2020\", \"Status\": \"Published\", \"general_subject\": \"This invention relates to the extraction of psychoactive\\rcompounds from fungus for use in medicine. Raw\\rfungus is dried and ground. The solvent used for\\rextraction is methanol or a hydro-methanol mixture,\\ran acidic hydro-methanol mixture, or an alkaline\\rhydro-methanol mixture. The extraction slurry is\\rfiltered and pH-adjusted if necessary. The methanol in\\rthe solvent is then completely evaporated and water\\radded back, where necessary, to form a concentrated\\rslurry. The concentrated slurry is then standardized to\\rprovide a known concentration of the psychoactive\\ralkaloids that have been extracted. The standardized\\rslurry may then be dried to result in a powdered\\rextract with a precisely defined purity of psychoactive\\rcompounds.\", \"tokenized_text\": [\"methanol-bas\", \"extract\", \"psychoact\", \"alkaloid\", \"fungus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 88, \"Title\": \"Enzymes and regulatory proteins in tryptamine\\rmetabolism\", \"Owner/Assignee\": \"CB Therapeutics\", \"Patent/Pub. No.\": \"WO2021248087\", \"Priority Date\": \"6/6/2020\", \"Status\": \"Published\", \"general_subject\": \"Non-naturally occurring nucleic acids comprising a\\rsequence encoding an enzyme or regulatory protein in\\rtryptamine metabolism. Also provided are a\\rrecombinant microorganisms expressing the enzyme\\ror regulatory protein. Methods of expressing the\\renzyme or regulatory protein are additionally\\rprovided.\", \"tokenized_text\": [\"enzym\", \"regulatori\", \"protein\", \"tryptamin\", \"metabol\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 89, \"Title\": \"Method for weight loss with therapy\", \"Owner/Assignee\": \"Neonmind\\rBiosciences\", \"Patent/Pub. No.\": \"WO2021243460A1\", \"Priority Date\": \"3/6/2020\", \"Status\": \"Published\", \"general_subject\": \"Disclosed is a method of aiding in weight loss, treating\\rcompulsive eating disorder, treating obesity or a\\rcomplication thereof, and/or altering the diet of an\\rindividual comprising administering psilocin,\\rpsilocybin, and/or an analog thereof combined with a\\rpsychotherapy.\", \"tokenized_text\": [\"weight\", \"loss\", \"therapi\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 90, \"Title\": \"Crystalline 4-hydroxy-n,n-di-n-propyltryptammonium\\r(4-ho-dpt) salts\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"WO2021236759A1\", \"Priority Date\": \"20/5/2020\", \"Status\": \"Published\", \"general_subject\": \"4-Hydroxy-N,N-di-n-propyltryptamine, or 4-HO-DPT,\\ris a derivative of psilocin, which is the primary active\\rpsychedelic in \\\"magic\\\" mushrooms.\", \"tokenized_text\": [\"crystallin\", \"4-hydroxy-n\", \"n-di-n-propyltryptammonium\", \"4-ho-dpt\", \"salt\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 91, \"Title\": \"Deuterated tryptamine derivatives and methods of use\", \"Owner/Assignee\": \"Cybin IRL\", \"Patent/Pub. No.\": \"US20220119346\", \"Priority Date\": \"19/5/2020\", \"Status\": \"Published\", \"general_subject\": \"The present disclosure is based at least in part on the\\ridentification of compounds that modulate serotonin\\r5-HT.sub.2 receptors and methods of using the same\\rto treat diseases associated with a serotonin 5-\\rHT.sub.2 receptor. More specifically, the present\\rdisclosure provides novel compounds that permit, for\\rexample, once-daily dosing to selectively engage 5-\\rHT.sub.2ARs without producing psychedelic effects,\\rand to treat neuropsychiatric and other disorders\\rassociated with inflammation.\", \"tokenized_text\": [\"deuter\", \"tryptamin\", \"deriv\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 92, \"Title\": \"Novel compositions of matter and pharmaceutical\\rcompositions\", \"Owner/Assignee\": \"Psilera\", \"Patent/Pub. No.\": \"WO2021226416A1\", \"Priority Date\": \"8/5/2020\", \"Status\": \"Published\", \"general_subject\": \"Pharmaceutical formulations of indole compounds and\\r\\\"psilocybin analogs\\\" (including LSD) that can be\\rprovided in oral, transdermal, or nasal pharmaceutical\\rcompositions and used to treat neurological, mood or\\rabuse diseases and disorders\", \"tokenized_text\": [\"novel\", \"matter\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 93, \"Title\": \"Transdermal drug delivery devices having psilocybin,\\rlysergic acid diethylamide or\\rmethylenedioxymethamphetamine coated\\rmicroprotrusions\", \"Owner/Assignee\": \"Zosano Pharma\", \"Patent/Pub. No.\": \"WO2021222885A1\", \"Priority Date\": \"1/5/2020\", \"Status\": \"Published\", \"general_subject\": \"Compositions, devices, and methods using psilocybin,\\rLSD, or MDMA to treat health conditions, including\\rdepression, anxiety, PTSD, migraines and cluster\\rheadaches; methods and apparatuses for drug delivery\\rby intracutaneous administration via microneedle\\radministration\", \"tokenized_text\": [\"transderm\", \"drug\", \"devic\", \"psilocybin\", \"lyserg\", \"acid\", \"diethylamid\", \"methylenedioxymethamphetamin\", \"coat\", \"microprotrus\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 94, \"Title\": \"Use of psilocybin in the treatment of neurological brain\\rinjury and migraines\", \"Owner/Assignee\": \"Revive Therapeutics\", \"Patent/Pub. No.\": \"WO2021207824A1\", \"Priority Date\": \"17/4/2020\", \"Status\": \"Published\", \"general_subject\": \"Methods for the treatment of a brain injury or a\\rmigraine in a mammal including administering a\\rtherapeutically effective amount of psilocybin or a\\rpharmaceutically acceptable salt or solvate thereof\", \"tokenized_text\": [\"psilocybin\", \"neurolog\", \"brain\", \"injuri\", \"migrain\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 95, \"Title\": \"LSD dose identification\", \"Owner/Assignee\": \"Matthias\\rLiechti/Universit\\u00e4tss\\rpital Basel\", \"Patent/Pub. No.\": \"WO2021211358A1\", \"Priority Date\": \"13/4/2020\", \"Status\": \"Published\", \"general_subject\": \"Methods of dosing psychedelics at \\\"microdose,\\rminidose, psychedelic dose, good effect dose, ego-\\rdissolution dose, or cardiovascular safe dose,\\\" and\\r\\\"producing maximum positive subjective acute effects\\\"\\r\\\"associated with more positive long-term outcomes\\rand minimizing negative acute effects.\\\"\", \"tokenized_text\": [\"lsd\", \"dose\", \"identif\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 96, \"Title\": \"LSD dose identification\", \"Owner/Assignee\": \"Matthias\\rLiechti/Universit\\u00e4tss\\rpital Basel\", \"Patent/Pub. No.\": \"US20210315884A1\", \"Priority Date\": \"13/4/2020\", \"Status\": \"Published\", \"general_subject\": \"A method of dosing and treating patients with a\\rpsychedelic, by administering a psychedelic at a dose\\rof a microdose, minidose, psychedelic dose, good\\reffect dose, ego-dissolution dose, or cardiovascular\\rsafe dose, and producing maximum positive subjective\\racute effects that are known to be associated with\\rmore positive long-term outcomes and minimizing\\rnegative acute effects\", \"tokenized_text\": [\"lsd\", \"dose\", \"identif\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 97, \"Title\": \"Medicinal food products and methods for producing\\rsaid products\", \"Owner/Assignee\": \"Daniel Lilly\", \"Patent/Pub. No.\": \"US20210392933\", \"Priority Date\": \"10/4/2020\", \"Status\": \"Published\", \"general_subject\": \"A method for producing medicinal cannabinoids\\rand/or psilocybin food products which allows for\\rprolonged storage of products\", \"tokenized_text\": [\"medicin\", \"food\", \"product\", \"produc\", \"said\", \"product\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 98, \"Title\": \"Molecularly-initiated, experimentally-delivered\\rtreatments and systems for practicing same\", \"Owner/Assignee\": \"The Regents of the\\rUniversity of\\rCalifornia\", \"Patent/Pub. No.\": \"WO2021202730\", \"Priority Date\": \"1/4/2020\", \"Status\": \"Published\", \"general_subject\": \"Methods of providing a sensory environment to an\\rindividual who has been administered a psychoactive\\ror psychedelic agent (including LSD) and adjusting\\rthat sensory environment in response to neural and\\rphysiological feedback from the individual\", \"tokenized_text\": [\"molecularly-initi\", \"experimentally-deliv\", \"treatment\", \"practic\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 99, \"Title\": \"Crystalline forms of psilacetin\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US11,358,934\", \"Priority Date\": \"23/3/2020\", \"Status\": \"Granted 2022-06-14\\r(expires 2040-12-23)\", \"general_subject\": \"Crystalline forms of 4-acetoxy-N,N-\\rdimethyltryptamine (psilacetin) and methods of use,\\rincluding crystaline 4-acetoxy-N,N-\\rdimethyltryptammonium hydrofumerate, the fumerate\\rsalt of psilacetin, and or crystalline bis(4-acetoxy-N,N-\\rdimethyltryptammonium) fumerate\", \"tokenized_text\": [\"crystallin\", \"psilacetin\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 100, \"Title\": \"Psilocybin and psilocin containing compositions and\\rmethods of using and making the same\", \"Owner/Assignee\": \"Orthogonal Thinker\", \"Patent/Pub. No.\": \"WO2021188870A1\", \"Priority Date\": \"20/3/2020\", \"Status\": \"Published\", \"general_subject\": \"Compositions of psilocybin and/or psilocin and\\rsupplements, e.g., amino acids, vitamins, GABA,\\rcaffeine, resveratrol, herbs, ginsing, etc., and methods\\rof using and making them.\", \"tokenized_text\": [\"psilocybin\", \"psilocin\", \"contain\", \"make\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 101, \"Title\": \"Crystalline norpsilocin compounds\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"WO2021188812A1\", \"Priority Date\": \"19/3/2020\", \"Status\": \"Published\", \"general_subject\": \"Norpsilocin compounds (crystalline 4-HO-NMT\\rfreebase and fumarate, 4-HO-NMT fumarate),\\rpharmaceutical compositions thereof, methods of their\\ruse\", \"tokenized_text\": [\"crystallin\", \"norpsilocin\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 102, \"Title\": \"Crystalline psilacetin derivatives\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"WO2021188782A1\", \"Priority Date\": \"19/3/2020\", \"Status\": \"Published\", \"general_subject\": \"Crystalline 4-acetoxy-substituted versions of psilocin\\ranalogs (4-AcO-MET and 4-AcO-MALT hydrofumarate,\\r4-AcO-DALT fumarate fumaric acid) and their use\", \"tokenized_text\": [\"crystallin\", \"psilacetin\", \"deriv\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 103, \"Title\": \"3-(2-(aminoethyl)-indol-4-ol derivatives, methods of\\rpreparation thereof, and the use as 5-HT2 receptor\\rmodulators\", \"Owner/Assignee\": \"Bright Minds\\rBiosciences\", \"Patent/Pub. No.\": \"WO2021179091A1\", \"Priority Date\": \"12/3/2020\", \"Status\": \"Published\", \"general_subject\": \"Psilocin analogs that possess 5-HT2A and/or 5-HT2c\\rselective receptor activity, but lack at least some of the\\rundesirable characteristics of 5-HT2B-agonist related\\ractivities.\", \"tokenized_text\": [\"3-\", \"2-\", \"aminoethyl\", \"-indol-4-ol\", \"deriv\", \"5-ht2\", \"modul\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 5, \"#\": 104, \"Title\": \"Methods and systems for enhancing clinical safety of\\rpsychoactive therapies\", \"Owner/Assignee\": \"Eleusis Health\\rSolutions\", \"Patent/Pub. No.\": \"WO2021183490A2\", \"Priority Date\": \"9/3/2020\", \"Status\": \"Published\", \"general_subject\": \"Methods of enhancing the safety of a psychoactive\\rtherapy session by monitoring the session using \\\"an\\raccess module capable of relaying session data.\\\"\", \"tokenized_text\": [\"clinic\", \"safeti\", \"psychoact\", \"therapi\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 6, \"#\": 105, \"Title\": \"Method for obtaining an extract of a plant biomass\", \"Owner/Assignee\": \"Cure Pharmaceutical\", \"Patent/Pub. No.\": \"US20210275618A1\", \"Priority Date\": \"5/3/2020\", \"Status\": \"Pending in US\", \"general_subject\": \"Methods for obtaining an extract using a supercritical\\rfluid solvent system, where the extract is from plant\\rbiomass comprising both psilocybin mushrooms and\\rcannabis\", \"tokenized_text\": [\"obtain\", \"extract\", \"plant\", \"biomass\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 106, \"Title\": \"Cannabis treatment of insomnia, pain, and skin\\rconditions\", \"Owner/Assignee\": \"Alte Verde\", \"Patent/Pub. No.\": \"US20220071946\", \"Priority Date\": \"3/3/2020\", \"Status\": \"Published\", \"general_subject\": \"A pharmaceutical composition for treating one or\\rmore symptoms of insomnia is disclosed herein. The\\rpharmaceutical composition includes an amount of\\rcannabidiol (CBD) and an amount of delta-9-\\rtetrahydrocannabinol (THC), wherein the amount of\\rCBD and the amount of THC are effective in treating\\rinsomnia. The pharmaceutical composition may\\rinclude an amount of a selected herb and an amount\\rof another cannabinoid. A pharmaceutical composition\\rfor treating one or more symptoms of chronic and\\racute pain using an amount of CBD and/or THC is also\\rdisclosed herein. The pharmaceutical composition may\\rinclude an amount of another cannabinoid. A\\rpharmaceutical composition for treating one or more\\rsymptoms of skin diseases and conditions using CBD\\rand/or THC is also disclosed herein. The\\rpharmaceutical composition may include an amount\\rof another cannabinoid, an essential oil, a permeation\\renhancer, and/or an anti-bacterial/anti-viral agent.\", \"tokenized_text\": [\"cannabi\", \"insomnia\", \"pain\", \"skin\", \"condit\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 107, \"Title\": \"Controlling effects after 5ht2a agonists administration\", \"Owner/Assignee\": \"Universit\\u00e4tsspital\\rBasel\", \"Patent/Pub. No.\": \"WO2021173273A1\", \"Priority Date\": \"28/2/2020\", \"Status\": \"Published\", \"general_subject\": \"Methods of psychotherapy and drug combinations\\rinvolving administration of a psychedelic like LSD in\\rconjunction with a \\\"duration shortening agent\\\" that\\rreduces the acute effects and duration of the\\rpsychedelic trip\", \"tokenized_text\": [\"control\", \"effect\", \"5ht2a\", \"agonist\", \"administr\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 108, \"Title\": \"Crystalline bis-miprocin fumarate\", \"Owner/Assignee\": \"Caamtech\", \"Patent/Pub. No.\": \"WO2021173989A1\", \"Priority Date\": \"27/2/2020\", \"Status\": \"Published\", \"general_subject\": \"Compositions of crystalline forms of bis(4-hydroxy-N-\\rmethyl-N-isopropyltryptammonium) fumarate\\r(\\\"crystalline bis-miprocin fumarate\\\"), and serotonergic\\rdrugs such as ibogaine.\", \"tokenized_text\": [\"crystallin\", \"bis-miprocin\", \"fumar\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 109, \"Title\": \"Method for producing an extract of mushrooom and\\rmushroom extract made therefrom\", \"Owner/Assignee\": \"Neonmind\\rBiosciences\", \"Patent/Pub. No.\": \"WO2021159213A1\", \"Priority Date\": \"12/2/2020\", \"Status\": \"Published\", \"general_subject\": \"Methods of manufacturing a mushroom extract,\\rincluding from Psilocybe mushroms, the mushroom\\rextract itself, and pharmaceutical formulations\", \"tokenized_text\": [\"produc\", \"extract\", \"mushrooom\", \"mushroom\", \"extract\", \"made\", \"therefrom\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 110, \"Title\": \"Psychedelic treatment for headache disorders\", \"Owner/Assignee\": \"Yale University, U.S.\\rDep't of Veterans\\rAffairs\", \"Patent/Pub. No.\": \"US20210236523A1\", \"Priority Date\": \"5/2/2020\", \"Status\": \"Pending in US\", \"general_subject\": \"Treating a headache disorder by administering\\rpsilocybin, LSD, mescaline, DMT, DOI, DOB, and\\ranalogs thereof.\", \"tokenized_text\": [\"psychedel\", \"headach\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 111, \"Title\": \"Psilocin derivatives as serotonergic psychedelic agents\\rfor the treatment of CNS disorders\", \"Owner/Assignee\": \"Mindset Pharma\", \"Patent/Pub. No.\": \"WO2021155470\", \"Priority Date\": \"4/2/2020\", \"Status\": \"Published\", \"general_subject\": \"Prodrugs and deuterated derivatives of psilocybin, and\\rmethods of treating CNS disease, disorder or\\rcondition and/or a neurological disease, disorder or\\rcondition.\", \"tokenized_text\": [\"psilocin\", \"deriv\", \"serotonerg\", \"psychedel\", \"cns\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 2, \"#\": 112, \"Title\": \"3-pyrrolidine-indole derivatives as serotonergic\\rpsychedelic agents for the treatment of CNS disorders\", \"Owner/Assignee\": \"Mindset Pharma\", \"Patent/Pub. No.\": \"WO2021155467\", \"Priority Date\": \"4/2/2020\", \"Status\": \"Published\", \"general_subject\": \"3-pyrrolidine-indole derivatives of psilocybin, and\\rmethods of treating CNS disease, disorder or\\rcondition and/or a neurological disease, disorder or\\rcondition.\", \"tokenized_text\": [\"3-pyrrolidine-indol\", \"deriv\", \"serotonerg\", \"psychedel\", \"cns\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 3, \"#\": 113, \"Title\": \"Psilocin derivatives as serotonergic psychedelic agents\\rfor the treatment of CNS disorders\", \"Owner/Assignee\": \"Mindset Pharma\", \"Patent/Pub. No.\": \"US20220024956A1\", \"Priority Date\": \"4/2/2020\", \"Status\": \"Published\", \"general_subject\": \"Psilocin derivatives to processes for their preparation,\\rto compositions comprising them and to their use in\\ractivation of a serotonin receptor in a cell, as well as to\\rtreating diseases, disorders or conditions by activation\\rof a serotonin receptor in a cell\", \"tokenized_text\": [\"psilocin\", \"deriv\", \"serotonerg\", \"psychedel\", \"cns\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 4, \"#\": 114, \"Title\": \"Psilocin derivatives as serotonergic psychedelic agents\\rfor the treatment of CNS disorders\", \"Owner/Assignee\": \"Mindset Pharma\", \"Patent/Pub. No.\": \"WO2021155468\", \"Priority Date\": \"4/2/2020\", \"Status\": \"Published\", \"general_subject\": \"Prodrugs and deuterated derivatives of psilocybin, and\\rmethods of treating CNS disease, disorder or\\rcondition and/or a neurological disease, disorder or\\rcondition.\", \"tokenized_text\": [\"psilocin\", \"deriv\", \"serotonerg\", \"psychedel\", \"cns\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 5, \"#\": 115, \"Title\": \"Psilocin derivatives as serotonergic psychedelic agents\\rfor the treatment of CNS disorders\", \"Owner/Assignee\": \"Mindset Pharma\", \"Patent/Pub. No.\": \"US11,427,604\", \"Priority Date\": \"4/2/2020\", \"Status\": \"Granted 2022-08-30\\r(expires 2041-02-04)\", \"general_subject\": \"The present application relates to psilocin derivatives\\rof Formula (I), to processes for their preparation, to\\rcompositions comprising them and to their use in\\ractivation of a serotonin receptor in a cell, as well as to\\rtreating diseases, disorders or conditions by activation\\rof a serotonin receptor in a cell.\", \"tokenized_text\": [\"psilocin\", \"deriv\", \"serotonerg\", \"psychedel\", \"cns\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 0, \"#\": 116, \"Title\": \"3-pyrrolidine-indole derivatives as serotonergic\\rpsychedelic agents for the treatment of CNS disorders\", \"Owner/Assignee\": \"Mindset Pharma\", \"Patent/Pub. No.\": \"US11,453,689\", \"Priority Date\": \"4/2/2020\", \"Status\": \"Granted 2022-09-27\", \"general_subject\": \"The present application relates to 3-cyclic amine-\\rindole derivatives of general Formula (I), to processes\\rfor their preparation, to compositions comprising\\rthem and to their use in activation of a serotonin\\rreceptor in a cell, as well as to treating diseases,\\rdisorders or conditions by activation of a serotonin\\rreceptor in a cell. The diseases, disorders or conditions\\rinclude, for example, psychosis, mental illnesses, and\\rother neurological diseases, disorders and conditions.\", \"tokenized_text\": [\"3-pyrrolidine-indol\", \"deriv\", \"serotonerg\", \"psychedel\", \"cns\"], \"year\": \"2020\"}, {\"Unnamed: 0\": 1, \"#\": 117, \"Title\": \"Complexes comprising a carbohydrate polymer and an\\ractive ingredient and processes for their preparation\", \"Owner/Assignee\": \"Folium Labs\", \"Patent/Pub. No.\": \"WO2021113986A1\", \"Priority Date\": \"13/12/2019\", \"Status\": \"Published\", \"general_subject\": \"\\\"Stabilized molecular complexes\\\" and compositions\\rcontaining carbohydrate polymers complexed with a\\rbiologically active compound, which may be a\\r\\\"psychedelic therapy drug\\\" such as LSD.\", \"tokenized_text\": [\"complex\", \"carbohydr\", \"polym\", \"activ\", \"ingredi\", \"process\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 2, \"#\": 118, \"Title\": \"Use of psilocin, psilocybin or analogs thereof in weight\\rloss, treatment of obesity and compulsive eating\\rdisorder\", \"Owner/Assignee\": \"Neonmind\\rBiosciences\", \"Patent/Pub. No.\": \"WO2021108911A1\", \"Priority Date\": \"4/12/2019\", \"Status\": \"Pending in US\", \"general_subject\": \"Methods of aiding weight loss, treating compulsive\\reating disorder and obesity, and altering the diet by\\radministering psilocybin, psilocin, and analogs\", \"tokenized_text\": [\"psilocin\", \"psilocybin\", \"analog\", \"weight\", \"loss\", \"obes\", \"compuls\", \"eat\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 3, \"#\": 119, \"Title\": \"Tryptamine compositions for enhancing neurite\\routgrowth\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"US20220160737\", \"Priority Date\": \"19/11/2019\", \"Status\": \"Published\", \"general_subject\": \"Nootropic or neurotrophic compositions for use in\\rpreventing serotonin receptor disorders\", \"tokenized_text\": [\"tryptamin\", \"neurit\", \"outgrowth\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 4, \"#\": 120, \"Title\": \"Tryptamine compositions for enhancing neurite\\routgrowth\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"US20220125809\", \"Priority Date\": \"19/11/2019\", \"Status\": \"Published\", \"general_subject\": \"Nootropic or neurotrophic compositions for use in\\rpreventing serotonin receptor disorders\", \"tokenized_text\": [\"tryptamin\", \"neurit\", \"outgrowth\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 5, \"#\": 121, \"Title\": \"Tryptamine compositions for enhancing neurite\\routgrowth\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"US20210145851A1\", \"Priority Date\": \"19/11/2019\", \"Status\": \"Pending in US\", \"general_subject\": \"Neurotrophic and nootropic compositions comprising\\rtryptamines and other mushroom extracts,\\rcannabinoids, as well as phenethylamines and\\ramphetamines\", \"tokenized_text\": [\"tryptamin\", \"neurit\", \"outgrowth\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 6, \"#\": 122, \"Title\": \"Tryptamine compositions for enhancing neurite\\routgrowth\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"WO2021101926A1\", \"Priority Date\": \"19/11/2019\", \"Status\": \"Published\", \"general_subject\": \"Neurotrophic and nootropic compositions and\\rmethods of their use in treatment, including with\\rtryptamines (such as LSD), phenethylamines or\\ramphetamines, erinacines or hericenones,\\rcannabinoids, \\\"adversive compounds\\\" (such as niacin),\\rand excipients\", \"tokenized_text\": [\"tryptamin\", \"neurit\", \"outgrowth\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 0, \"#\": 123, \"Title\": \"Biosynthetic production of psilocybin and related\\rintermediates in recombinant organisms\", \"Owner/Assignee\": \"CB Therapeutics\", \"Patent/Pub. No.\": \"US11,441,164\", \"Priority Date\": \"15/11/2019\", \"Status\": \"Granted 2022-09-13\\r(expires 2040-11-16)\", \"general_subject\": \"The systems and methods herein include engineering\\ra host to produce psilocybin using engineered\\renzymes, genetic changes, and exogenous psilocybin\\rprecursor addition (e.g., addition of L-tryptophan to a\\rgrowing culture of a psilocybin producing\\rrecombinant host strain). The process occurs in\\rgenetically engineered host cell(s) that can produce\\rpsilocybin.\", \"tokenized_text\": [\"biosynthet\", \"psilocybin\", \"relat\", \"recombin\", \"organ\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 1, \"#\": 124, \"Title\": \"Methods for the production of psilocybin and\\rintermediates or side products\", \"Owner/Assignee\": \"Miami University\", \"Patent/Pub. No.\": \"WO2021086513A1\", \"Priority Date\": \"28/10/2019\", \"Status\": \"Published\", \"general_subject\": \"Biosynthetic methods, prokaryotic (bacterial) host cells,\\rexpression vectors, and kits for the production of\\rpsilocybin and its intermediates and side products\", \"tokenized_text\": [\"psilocybin\", \"side\", \"product\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 2, \"#\": 125, \"Title\": \"Compositions comprising superfine compounds and\\rproduction thereof\", \"Owner/Assignee\": \"Esolate\", \"Patent/Pub. No.\": \"WO2021081138A1\", \"Priority Date\": \"21/10/2019\", \"Status\": \"Published\", \"general_subject\": \"Stable edible, inhalable, soluble, and drinkable\\rpharmaceutical grade APIs, and methods for making\\rthem, including where the API is a psychedelic such as\\rpsilocybin or psilocin\", \"tokenized_text\": [\"superfin\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 3, \"#\": 126, \"Title\": \"Stimulation of neuronal plasticity\", \"Owner/Assignee\": \"Institute Of Science\\rAnd Technology\\rAustria\", \"Patent/Pub. No.\": \"WO2021074448A1\", \"Priority Date\": \"18/10/2019\", \"Status\": \"Published\", \"general_subject\": \"Inducing synchronized gamma oscillations by applying\\ra visual stimulus comprising a flashing light, together\\rin some embodiments with a psychedelic including\\rpsilocybin.\", \"tokenized_text\": [\"stimul\", \"neuron\", \"plastic\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 4, \"#\": 127, \"Title\": \"Controlled release formulations of psilocybe-derived\\ragents and method for their use, and methods and\\rcompositions for threating mild traumatic brain injury\\rwith post traumatic stress disorder\", \"Owner/Assignee\": \"Tassili Life Sciences\\r(Champignon\\rBrands)\", \"Patent/Pub. No.\": \"WO2021072530A1\", \"Priority Date\": \"15/10/2019\", \"Status\": \"Published\", \"general_subject\": \"Controlled release formulations of psilocybin and\\rpsilocybe-derived agents, for alleviating symptoms of\\rmTBI and PTSD\", \"tokenized_text\": [\"control\", \"releas\", \"psilocybe-deriv\", \"threat\", \"mild\", \"traumat\", \"brain\", \"injuri\", \"post\", \"traumat\", \"stress\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 5, \"#\": 128, \"Title\": \"Flavored bioactive extracts and methods of flavor\\rintroduction\", \"Owner/Assignee\": \"Pure Laboratories\", \"Patent/Pub. No.\": \"US20210100741A1\", \"Priority Date\": \"4/10/2019\", \"Status\": \"Pending in US\", \"general_subject\": \"Methods of formulating a homogeneous flavored\\rbioactive product by melting an extract, combining a\\rflavoring and carrier, and cooling; the extracts include\\rpsilocybin.\", \"tokenized_text\": [\"flavor\", \"bioactiv\", \"extract\", \"flavor\", \"introduct\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 0, \"#\": 129, \"Title\": \"Genetic engineering of fungi to modulate tryptamine\\rexpression\", \"Owner/Assignee\": \"Empyrean\\rNeuroscience\", \"Patent/Pub. No.\": \"WO2021067626A1\", \"Priority Date\": \"1/10/2019\", \"Status\": \"Published\", \"general_subject\": \"Methods for modulating the psilocybin biosynthesis\\rpathway and genetically modified organisms with\\rinduced and/or increased expression of psilocybin and\\rpsilocin.\", \"tokenized_text\": [\"genet\", \"engin\", \"fungi\", \"modul\", \"tryptamin\", \"express\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 1, \"#\": 130, \"Title\": \"Genetic engineering of fungi to modulate tryptamine\\rexpression\", \"Owner/Assignee\": \"Empyrean\\rNeuroscience\", \"Patent/Pub. No.\": \"US20220306997\", \"Priority Date\": \"1/10/2019\", \"Status\": \"Published\", \"general_subject\": \"Provided herein are methods for modulating the\\rpsilocybin biosynthesis pathway in fungi or other\\rorganisms. Also provided are genetically modified\\rfungi and organisms with induced and/or increased\\rexpression of psilocybin and psilocin and psilocybin\\rand/or psilocin compositions generated by the\\rprovided methods.\", \"tokenized_text\": [\"genet\", \"engin\", \"fungi\", \"modul\", \"tryptamin\", \"express\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 2, \"#\": 131, \"Title\": \"Yeast cells and methods for production of tryptophan\\rderivatives\", \"Owner/Assignee\": \"Danmarks Tekniske\\rUniversitet\", \"Patent/Pub. No.\": \"WO2021052989A1\", \"Priority Date\": \"16/9/2019\", \"Status\": \"Published\", \"general_subject\": \"Transformed cells capable of producing compounds\\rincluding norbaeocystin, baeocystin, psilocybin,\\rpsilocin, aeruginascin, and methods of their use in\\rproduction.\", \"tokenized_text\": [\"yeast\", \"cell\", \"tryptophan\", \"deriv\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 3, \"#\": 132, \"Title\": \"Alkyl quaternary ammonium tryptamines and their\\rtherapeutic uses\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US20220112162\", \"Priority Date\": \"25/8/2019\", \"Status\": \"Published\", \"general_subject\": \"This disclosure relates to alkyl quaternary ammonium\\rtryptamines, compositions and pharmaceutical\\rcompositions containing them as well as their use in\\rtreating various diseases.\", \"tokenized_text\": [\"alkyl\", \"quaternari\", \"ammonium\", \"tryptamin\", \"therapeut\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 4, \"#\": 133, \"Title\": \"Methods of treating psychological and brain disorders\", \"Owner/Assignee\": \"University of\\rMaryland\", \"Patent/Pub. No.\": \"WO2021030571A1\", \"Priority Date\": \"13/8/2019\", \"Status\": \"Published\", \"general_subject\": \"Methods of treating a psychological disorder by\\radministering a 5-HT agonist in combination with a 5-\\rHT2A antagonist, the 5-HT agonists including\\rpsilocybin\", \"tokenized_text\": [\"psycholog\", \"brain\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 5, \"#\": 134, \"Title\": \"Methods of treating psychological and brain disorders\", \"Owner/Assignee\": \"University of\\rMaryland\", \"Patent/Pub. No.\": \"US20220273680\", \"Priority Date\": \"13/8/2019\", \"Status\": \"Published\", \"general_subject\": \"Provided herein are methods for preventing or\\rtreating a psychological disorder. A serotonin agonist\\ror an agonist of serotonin receptors is administered\\rseparately, sequentially or simultaneously in\\rcombination with a serotonin receptor 2A antagonist.\", \"tokenized_text\": [\"psycholog\", \"brain\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 0, \"#\": 135, \"Title\": \"Controlled release formulations of multiple active\\rpharmaceutical agents, and psilocybe-derived agents in\\rcombination with cannabis-derived agents and methods\\rfor their use\", \"Owner/Assignee\": \"Tassili Life Sciences\\r(Champignon\\rBrands)\", \"Patent/Pub. No.\": \"WO2021016710\", \"Priority Date\": \"30/7/2019\", \"Status\": \"Published\", \"general_subject\": \"Psilocybe and cannabis derived compounds\\rformulated in multiple layers to release the ingredients\\rat different times, dosages and/or locations in body.\", \"tokenized_text\": [\"control\", \"releas\", \"multipl\", \"activ\", \"psilocybe-deriv\", \"cannabis-deriv\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 1, \"#\": 136, \"Title\": \"Compositions containing toad secretion compounds\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US20220273620\", \"Priority Date\": \"23/7/2019\", \"Status\": \"Published\", \"general_subject\": \"Disclosed are compositions containing two purified\\rtoad secretion tryptamines chosen from the following\\r5-MeO-DMT, 5-MeO-NMT, 5-Methoxytryptamine,\\rbufobutanoic Acid, bufobutarginine, bufoserotonin A,\\rbufoserotonin B, bufoserotonin C, bufotenidine,\\rbufotenin, bufotenin Oxide, bufotenine-O-Sulphate,\\rbufoviridine, dET, dMT, n-Acetylserotonin, n'-\\rFormylserotonin, n-Methylserotonin, o-\\rMethylbufoviridine, serotonin, tryptamine, and\\rbufopyramide or the salts of these toad secretion\\rtryptamines. The disclosure also relates to\\rformulations, including pharmaceutical formulations,\\rof such a composition and an excipient.\\rPharmaceutical formulation further containing a\\rtherapeutically effective amount of a serotonergic\\rdrug, a purified psilocybin derivative, a purified\\rcannabinoid, or a purified terpene a disclosed. Also\\rdisclosed are methods of regulating the activity of a\\rneurotransmitter receptor and methods of treating a\\rpsychological disorder, a compulsive disorder, or a\\rdepressive disorder.\", \"tokenized_text\": [\"contain\", \"toad\", \"secret\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 2, \"#\": 137, \"Title\": \"Oral soft gel capsule containing psychedelic compound\", \"Owner/Assignee\": \"Concept Matrix\\rSolutions\", \"Patent/Pub. No.\": \"US20210015833A1\", \"Priority Date\": \"18/7/2019\", \"Status\": \"Pending in US\", \"general_subject\": \"Softgels containing \\u201cpsilocybin, psilocin, baeocystin,\\rmescaline, LSD, ketamine, salvinorin A, ibotenic acid,\\rmuscimol, DMT, MDMA, MDEA, MDA, &\\rcombinations\\\"\", \"tokenized_text\": [\"oral\", \"soft\", \"gel\", \"capsul\", \"contain\", \"psychedel\", \"compound\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 0, \"#\": 138, \"Title\": \"Oral dissolvable film containing psychedelic compound\", \"Owner/Assignee\": \"Concept Matrix\\rSolutions\", \"Patent/Pub. No.\": \"US20210015738A1\", \"Priority Date\": \"17/7/2019\", \"Status\": \"Pending in US\", \"general_subject\": \"Films containing \\u201cpsilocybin, psilocin, baeocystin,\\rmescaline, LSD, ketamine, salvinorin A, ibotenic acid,\\rmuscimol, DMT, MDMA, MDEA, MDA, &\\rcombinations\\\"\", \"tokenized_text\": [\"oral\", \"dissolv\", \"film\", \"contain\", \"psychedel\", \"compound\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 1, \"#\": 139, \"Title\": \"Cannabinoid derivatives\", \"Owner/Assignee\": \"Canopy Growth Corp\", \"Patent/Pub. No.\": \"US20220259221\", \"Priority Date\": \"12/7/2019\", \"Status\": \"Published\", \"general_subject\": \"This disclosure relates to a cannabinoid derivative of\\rformula (I), pharmaceutical composition thereof, and\\rmethod of treating or preventing diseases associated\\rwith cannabinoid receptor in a subject in need thereof,\\rwherein the cannabinoid receptor is one or more of\\rCB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119,\\rTRPV1, TRPV2, PPAR.gamma. or a .mu.-opioid\\rreceptor.\", \"tokenized_text\": [\"cannabinoid\", \"deriv\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 2, \"#\": 140, \"Title\": \"Metered dosing compositions and methods of use of\\rpsychedelic compounds\", \"Owner/Assignee\": \"SW Holdings\", \"Patent/Pub. No.\": \"WO2021003467A1\", \"Priority Date\": \"4/7/2019\", \"Status\": \"Published\", \"general_subject\": \"Compositions of psychedelic compounds for use in\\rmetered-dosing administration modalities, such as a\\rnasal spray or pressurized metered-dose inhaler.\", \"tokenized_text\": [\"meter\", \"dose\", \"psychedel\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 3, \"#\": 141, \"Title\": \"Cannabinoid derivatives\", \"Owner/Assignee\": \"Canopy Growth Corp\", \"Patent/Pub. No.\": \"US20220267239\", \"Priority Date\": \"4/7/2019\", \"Status\": \"Published\", \"general_subject\": \"The present invention provides cannabinoid\\rderivatives, a pharmaceutical composition comprising\\rsaid derivative and a method of using said derivatives\\rin treating or preventing a disease associated with\\rcannabinoid receptors. The claimed cannabinoid\\rderivatives are described by formula (I) or an\\renantiomer, diastereomer, racemate, tautomer, or\\rmetabolite thereof, or a pharmaceutically acceptable\\rsalt, solvate or hydrate of the compound.\", \"tokenized_text\": [\"cannabinoid\", \"deriv\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 4, \"#\": 142, \"Title\": \"Ibogaine formulations\", \"Owner/Assignee\": \"CaamTech\", \"Patent/Pub. No.\": \"WO2020263941A1\", \"Priority Date\": \"24/6/2019\", \"Status\": \"Published\", \"general_subject\": \"New compositions and methods comprising a\\rcombination of active ingredients that includes at least\\rone ibogaine derivative. Several selected examples of\\rnon-naturally occurring ibogaine derivative\\rformulations are also disclosed.\", \"tokenized_text\": [\"ibogain\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 0, \"#\": 143, \"Title\": \"Process for making aqueous therapeutic particle having\\rstable exterior water clustering with nanosized thickness\", \"Owner/Assignee\": \"Karl Dresdner,\\rMichael Cary, Chase\\rHudson\", \"Patent/Pub. No.\": \"US20200345585A1\", \"Priority Date\": \"30/4/2019\", \"Status\": \"Pending in US\", \"general_subject\": \"Processes for making aqueous therapeutic\\rnanoparticles, including with cannabinoids, psilocybin\\rand related tryptamines, LSD, MDMA and MDA,\\rayahuasca, and ketamine\", \"tokenized_text\": [\"process\", \"make\", \"aqueous\", \"therapeut\", \"particl\", \"stabl\", \"exterior\", \"water\", \"cluster\", \"nanos\", \"thick\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 1, \"#\": 144, \"Title\": \"Methods of treating neurocognitive disorders, chronic\\rpain and reducing inflammation\", \"Owner/Assignee\": \"Compass Pathfinder\\rLtd\", \"Patent/Pub. No.\": \"US20220169668\", \"Priority Date\": \"17/4/2019\", \"Status\": \"Published\", \"general_subject\": \"The disclosure provides methods for treating a subject\\rin need thereof comprising administering to the\\rsubject a therapeutically-effective dose of psilocybin.\\rThe methods described herein may be used to treat a\\rvariety of diseases, disorders, and conditions. For\\rexample, the methods may be used to treat\\rneurocognitive disorders (e.g., Alzheimer's disease,\\rParkinson's disease), ADHD, Epilepsy, Autism, Sleep-\\rwake disorders, Chronic pain, Inflammatory Disorders,\\rIBD, Stroke, ALS, and/or Multiple Sclerosis.\", \"tokenized_text\": [\"neurocognit\", \"chronic\", \"pain\", \"reduc\", \"inflamm\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 2, \"#\": 145, \"Title\": \"Treatment of depression and other various disorders\\rwith psilocybin\", \"Owner/Assignee\": \"Compass Pathfinder\\rLtd\", \"Patent/Pub. No.\": \"WO2020212952A1\", \"Priority Date\": \"17/4/2019\", \"Status\": \"Published\", \"general_subject\": \"Treating depression, bipolar disorder, neurocognitive\\rdisorders, autism spectrum disorder, ADHD, and other\\rdisorders with psilocybin.\", \"tokenized_text\": [\"depress\", \"various\", \"psilocybin\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 3, \"#\": 146, \"Title\": \"Method for treating anxiety disorders, headache\\rdisorders, and eating disorders with psilocybin\", \"Owner/Assignee\": \"Compass Pathfinder\\rLtd\", \"Patent/Pub. No.\": \"US20220088041A1\", \"Priority Date\": \"17/4/2019\", \"Status\": \"Published\", \"general_subject\": \"The disclosure provides methods for treating a subject\\rin need thereof comprising administering to the\\rsubject a therapeutically-effective dose of psilocybin.\\rThe methods described herein may be used to treat a\\rvariety of diseases, disorders, and conditions. For\\rexample, the methods may be used to treat anxiety\\rdisorders, eating disorders, and headache disorders.\", \"tokenized_text\": [\"anxieti\", \"headach\", \"eat\", \"psilocybin\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 4, \"#\": 147, \"Title\": \"Methods of treating neurocognitive disorders, chronic\\rpain and reducing inflammation\", \"Owner/Assignee\": \"Compass Pathfinder\\rLtd\", \"Patent/Pub. No.\": \"WO2020212948A1\", \"Priority Date\": \"17/4/2019\", \"Status\": \"Published\", \"general_subject\": \"Treating neurocognitive disorders, Parkinsonian\\rsyndrome, epilepsy, sleep-wake disorders, chronic pain\\rand reducing inflammation with psilocybin.\", \"tokenized_text\": [\"neurocognit\", \"chronic\", \"pain\", \"reduc\", \"inflamm\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 5, \"#\": 148, \"Title\": \"Methods for treating anxiety disorders, headache\\rdisorders, and eating disorders with psilocybin\", \"Owner/Assignee\": \"Compass Pathfinder\\rLtd\", \"Patent/Pub. No.\": \"WO2020212951A1\", \"Priority Date\": \"17/4/2019\", \"Status\": \"Published\", \"general_subject\": \"Treating anxiety disorders, OCD, headache disorders,\\reating disorders, and their comorbidities with\\rpsilocybin.\", \"tokenized_text\": [\"anxieti\", \"headach\", \"eat\", \"psilocybin\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 0, \"#\": 149, \"Title\": \"Compositions and methods for modulating lipid and\\rsteroid metabolism\", \"Owner/Assignee\": \"The Regents Of The\\rUniversity Of\\rCalifornia\", \"Patent/Pub. No.\": \"WO2020185581A2\", \"Priority Date\": \"8/3/2019\", \"Status\": \"Published\", \"general_subject\": \"Promoting colonization of spore-forming bacteria in a\\rpatient\\u2019 s gut, by administering a serotonin receptor\\ragonist, including psilocybin, psilocin, DMT, and 5-\\rMeO-DMT.\", \"tokenized_text\": [\"modul\", \"lipid\", \"steroid\", \"metabol\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 1, \"#\": 150, \"Title\": \"Compositions and methods of use comprising\\rsubstances with neural plasticity actions administered at\\rnon-psychedelic/psychotomimetic dosages and\\rformulations\", \"Owner/Assignee\": \"Abormentis\", \"Patent/Pub. No.\": \"WO2020181194A1\", \"Priority Date\": \"7/3/2019\", \"Status\": \"Published\", \"general_subject\": \"Structural analogs of psilocin, norpsilocin, psilocybin,\\rbaeocystin, norbaeocystin, DOI, DMT, LSD, and\\ribogaine, and their use as neuroplastogens and for\\rmicrodosing.\", \"tokenized_text\": [\"substanc\", \"neural\", \"plastic\", \"action\", \"administ\", \"non-psychedelic/psychotomimet\", \"dosag\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 2, \"#\": 151, \"Title\": \"Compositions and methods of use comprising\\rsubstances with neural plasticity actions administered at\\rnon-psychedelic/psychotomimetic dosages and\\rformulations\", \"Owner/Assignee\": \"Abormentis\", \"Patent/Pub. No.\": \"US20220143051\", \"Priority Date\": \"7/3/2019\", \"Status\": \"Published\", \"general_subject\": \"Structural analogs of psilocin, norpsilocin, psilocybin,\\rbaeocystin, norbaeocystin, DOI, DMT, LSD, and\\ribogaine, and their use as neuroplastogens and for\\rmicrodosing.\", \"tokenized_text\": [\"substanc\", \"neural\", \"plastic\", \"action\", \"administ\", \"non-psychedelic/psychotomimet\", \"dosag\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 3, \"#\": 152, \"Title\": \"Methods and compositions comprising a 5ht receptor\\ragonist for the treatment of psychological, cognitive,\\rbehavioral, and/or mood disorders\", \"Owner/Assignee\": \"Diamond\\rTherapeutics\", \"Patent/Pub. No.\": \"US20220096504\", \"Priority Date\": \"30/1/2019\", \"Status\": \"Published\", \"general_subject\": \"Provided herein are methods and compositions for the\\rtreatment of psychological, cognitive, behavioral,\\rand/or mood disorders, the composition comprising a\\r5HT agonist (e.g. psilocybin). In certain embodiments,\\rsuch compositions are administered in amounts or\\rlevels high enough to provide a therapeutic effect, but\\rinsufficient to provide an adverse effect.\", \"tokenized_text\": [\"5ht\", \"agonist\", \"psycholog\", \"cognit\", \"behavior\", \"and/or\", \"mood\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 4, \"#\": 153, \"Title\": \"Methods and compositions comprising a 5ht receptor\\ragonist for the treatment of psychological, cognitive,\\rbehavioral, and/or mood disorders\", \"Owner/Assignee\": \"Diamond\\rTherapeutics\", \"Patent/Pub. No.\": \"WO2020157569A1\", \"Priority Date\": \"30/1/2019\", \"Status\": \"Published\", \"general_subject\": \"Treating a neurological condition by administration of\\ra serotonin receptor agonist, including psilocybin, in\\ran amount insufficient to cause a hallucinogenic effect.\", \"tokenized_text\": [\"5ht\", \"agonist\", \"psycholog\", \"cognit\", \"behavior\", \"and/or\", \"mood\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 5, \"#\": 154, \"Title\": \"Systems and methods of mitigating negative effects of\\rtherapies with transcutaneous vibration\", \"Owner/Assignee\": \"Apollo Neuroscience\", \"Patent/Pub. No.\": \"US10,974,020\", \"Priority Date\": \"4/1/2019\", \"Status\": \"Granted 2021-04-13\\r(expires 2039-12-20)\", \"general_subject\": \"Transcutaneous vibratory simulation during psilocybin-\\rassisted psychotherapy\", \"tokenized_text\": [\"mitig\", \"negat\", \"effect\", \"therapi\", \"transcutan\", \"vibrat\"], \"year\": \"2019\"}, {\"Unnamed: 0\": 6, \"#\": 155, \"Title\": \"Methods of treating food allergy conditions\", \"Owner/Assignee\": \"Palo Alto Investors\", \"Patent/Pub. No.\": \"US11,045,454B2\", \"Priority Date\": \"6/12/2018\", \"Status\": \"Granted 2021-6-9\", \"general_subject\": \"Methods for treating a subject for a food allergy\\rcondition are provided. Aspects of the methods\\rinclude administering to a subject in need thereof a\\rpsychedelic agent in a manner effective to treat the\\rsubject for a food allergy condition. Doses may include\\rmicrodoses.\", \"tokenized_text\": [\"food\", \"allergi\", \"condit\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 0, \"#\": 156, \"Title\": \"Combination therapy for treating or preventing\\rdepression or other mood diseases\", \"Owner/Assignee\": \"Yale University, U.S.\\rDep't of Veterans\\rAffairs\", \"Patent/Pub. No.\": \"US20210251969A1\", \"Priority Date\": \"20/8/2018\", \"Status\": \"Pending in US\", \"general_subject\": \"Treating depression and mood disorders, with\\rcombination of a TOR inhibitor or immunosuppressant\\rtogether with ketamine, psilocybin, LSD, ayahuasca,\\rand DMT.\", \"tokenized_text\": [\"therapi\", \"prevent\", \"depress\", \"mood\", \"diseas\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 1, \"#\": 157, \"Title\": \"Methods for inhibiting microbe growth\", \"Owner/Assignee\": \"Mcmaster University\", \"Patent/Pub. No.\": \"US11,400,106\", \"Priority Date\": \"1/8/2018\", \"Status\": \"Granted 2022-08-02\\r(expires 2039-08-01)\", \"general_subject\": \"Provided herein are methods and compositions useful\\rfor inhibiting microbe growth. The methods can\\rcomprise contacting the microbe with an antimicrobial\\ragent and bicarbonate. In some embodiments,\\rprovided herein are methods for treating or\\rpreventing a microbial infection, comprising\\radministering to a subject in need an effective amount\\rof (i) bicarbonate and (ii) an antimicrobial agent.\", \"tokenized_text\": [\"inhibit\", \"microb\", \"growth\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 2, \"#\": 158, \"Title\": \"Taar receptor agonists for the treatment of alopecia\", \"Owner/Assignee\": \"Applied Biology\", \"Patent/Pub. No.\": \"WO2020023084A1\", \"Priority Date\": \"26/7/2018\", \"Status\": \"Published\", \"general_subject\": \"Methods for treating hair shedding by applying a\\rcomposition of a pilomotor effective amount of a Taar\\rreceptor agonist topically, including tryptamines and\\rpsilocin\", \"tokenized_text\": [\"taar\", \"agonist\", \"alopecia\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 3, \"#\": 159, \"Title\": \"Method of inducing dendritic and synaptic genesis in\\rneurodegenerative chronic diseases\", \"Owner/Assignee\": \"Robert Petcavich\", \"Patent/Pub. No.\": \"WO2019246532A1\", \"Priority Date\": \"21/6/2018\", \"Status\": \"Published\", \"general_subject\": \"Treating neurodegenerative disease by administration\\rof a psychedelic, including psilocybin.\", \"tokenized_text\": [\"induc\", \"dendrit\", \"synapt\", \"genesi\", \"neurodegen\", \"chronic\", \"diseas\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 4, \"#\": 160, \"Title\": \"Method of inducing dendritic and synaptic genesis in\\rneurodegenerative chronic diseases\", \"Owner/Assignee\": \"Robert John\\rPetcavich\", \"Patent/Pub. No.\": \"WO2019246532A1\", \"Priority Date\": \"21/6/2018\", \"Status\": \"Published\", \"general_subject\": \"Methods to recover and restore dendritic and synaptic\\rneuron connections that have been degraded or\\rdestroyed by neurodegenerative diseases, including by\\rLSD microdosing\", \"tokenized_text\": [\"induc\", \"dendrit\", \"synapt\", \"genesi\", \"neurodegen\", \"chronic\", \"diseas\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 5, \"#\": 161, \"Title\": \"Heterologous production of psilocybin\", \"Owner/Assignee\": \"VTT Technical\\rResearch Centre of\\rFinland\", \"Patent/Pub. No.\": \"US20210010015A1\", \"Priority Date\": \"19/3/2018\", \"Status\": \"Pending in US\", \"general_subject\": \"Biosynthetic production of psilocybin from host cell\", \"tokenized_text\": [\"heterolog\", \"psilocybin\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 6, \"#\": 162, \"Title\": \"Processes for the production of tryptamines\", \"Owner/Assignee\": \"New Atlas\\rBiotechnologies\", \"Patent/Pub. No.\": \"US20210277433\", \"Priority Date\": \"8/3/2018\", \"Status\": \"Pending in US\", \"general_subject\": \"Tryptamine and ibogamine compounds,\\rpharmaceutical compositions comprising them, and\\rmethods of using them to improve perception and\\rmood.\", \"tokenized_text\": [\"process\", \"tryptamin\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 0, \"#\": 163, \"Title\": \"Processes for the production of tryptamines\", \"Owner/Assignee\": \"New Atlas\\rBiotechnologies\", \"Patent/Pub. No.\": \"US20210108238A1\", \"Priority Date\": \"8/3/2018\", \"Status\": \"Pending in US\", \"general_subject\": \"Prokaryotic and eukaryotic microbes, including E. coli\\rand S. cerevisiae, genetically altered to biosynthesize\\rtryptamine and tryptamine derivatives, including\\rpsilocybin\", \"tokenized_text\": [\"process\", \"tryptamin\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 1, \"#\": 164, \"Title\": \"Cognitive platform including computerized elements\\rcoupled with a therapy for mood disorder\", \"Owner/Assignee\": \"Akili Interactive\", \"Patent/Pub. No.\": \"WO2019161050\", \"Priority Date\": \"18/2/2018\", \"Status\": \"Published\", \"general_subject\": \"Computer systems for mood and cognitive assessment\\rduring psychedelic-assisted psychotherapy, including\\rwith psilocybin\", \"tokenized_text\": [\"cognit\", \"platform\", \"includ\", \"computer\", \"element\", \"coupl\", \"therapi\", \"mood\"], \"year\": \"2018\"}, {\"Unnamed: 0\": 2, \"#\": 165, \"Title\": \"Compositions comprising a psilocybin derivative and a\\rcannabinoid\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US20190142851A1\", \"Priority Date\": \"16/11/2017\", \"Status\": \"Pending in US\", \"general_subject\": \"Purified psilocybin derivatives combined with a\\rcannabinoid\", \"tokenized_text\": [\"psilocybin\", \"cannabinoid\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 3, \"#\": 166, \"Title\": \"Combination product for the treatment of neurological\\rand/or psychiatric disorders\", \"Owner/Assignee\": \"Consejo Superior De\\rInvestigaciones\\rCient\\u00edficas (CSIC)\", \"Patent/Pub. No.\": \"WO2019081764A1\", \"Priority Date\": \"26/10/2017\", \"Status\": \"Published\", \"general_subject\": \"Combination product comprising (1) psychedelic,\\rincluding psilocybin and psilocin, and (2) a 5-HT2A\\rreceptor antagonist to prevent hallucinations\", \"tokenized_text\": [\"product\", \"neurolog\", \"and/or\", \"psychiatr\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 4, \"#\": 167, \"Title\": \"Methods and systems for enhancing safety of\\rpsychedelic drug therapies\", \"Owner/Assignee\": \"Eleusis Benefit Corp\", \"Patent/Pub. No.\": \"WO2019079742A1\", \"Priority Date\": \"19/10/2017\", \"Status\": \"Published\", \"general_subject\": \"Screening a candidate for treatment with a psychedelic\\ragent, including psilocybin.\", \"tokenized_text\": [\"safeti\", \"psychedel\", \"drug\", \"therapi\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 5, \"#\": 168, \"Title\": \"Preparation of psilocybin, different polymorphic forms,\\rintermediates, formulations and their use\", \"Owner/Assignee\": \"Compass Pathways\", \"Patent/Pub. No.\": \"US10,947,257\", \"Priority Date\": \"9/10/2017\", \"Status\": \"Granted 2021-03-23\\r(expires 2038-10-09)\", \"general_subject\": \"Oral dosage forms of crystalline psilocybin in the form\\rPolymorph A and methods of treating MDD\", \"tokenized_text\": [\"psilocybin\", \"differ\", \"polymorph\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 6, \"#\": 169, \"Title\": \"Preparation of psilocybin, different polymorphic forms,\\rintermediates, formulations and their use\", \"Owner/Assignee\": \"Compass Pathways\", \"Patent/Pub. No.\": \"US10,947,257\", \"Priority Date\": \"9/10/2017\", \"Status\": \"Granted 2021-03-16\\r(expires 2038-10-09)\", \"general_subject\": \"Pharmaceutical compositions of crystalline psilocybin\\rin the form Polymorph A, and methods of treating\\rMDD\", \"tokenized_text\": [\"psilocybin\", \"differ\", \"polymorph\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 7, \"#\": 170, \"Title\": \"Preparation of psilocybin, different polymorphic forms,\\rintermediates, formulations and their use\", \"Owner/Assignee\": \"Compass Pathfinder\\rLtd\", \"Patent/Pub. No.\": \"US11,149,044B2\", \"Priority Date\": \"9/10/2017\", \"Status\": \"Granted 2021-10-19\\r(expires 2038-12-11)\", \"general_subject\": \"The large-scale production of psilocybin for use in\\rmedicine. More particularly, it relates to a method of\\robtaining high purity crystalline psilocybin,\\rparticularly, in the form of Polymorph A. It further\\rrelates to a method for the manufacture of psilocybin\\rand intermediates in the production thereof and\\rformulations containing psilocybin.\", \"tokenized_text\": [\"psilocybin\", \"differ\", \"polymorph\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 0, \"#\": 171, \"Title\": \"Preparation of psilocybin, different polymorphic forms,\\rintermediates, formulations and their use\", \"Owner/Assignee\": \"Compass Pathfinder\", \"Patent/Pub. No.\": \"US11,180,517B2\", \"Priority Date\": \"9/10/2017\", \"Status\": \"Granted 2021-11-23\\r(expires 2038-10-09)\", \"general_subject\": \"The large-scale production of psilocybin for use in\\rmedicine. A method of obtaining high purity\\rcrystalline psilocybin, particularly, in the form of\\rPolymorph A.\", \"tokenized_text\": [\"psilocybin\", \"differ\", \"polymorph\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 1, \"#\": 172, \"Title\": \"Preparation of psilocybin, different polymorphic forms,\\rintermediates, formulations and their use\", \"Owner/Assignee\": \"Compass Pathways\", \"Patent/Pub. No.\": \"US11,505,564B2\", \"Priority Date\": \"9/10/2017\", \"Status\": \"Granted 2022-11-22\", \"general_subject\": \"Methods for manufacturing psilocybin from psilocin at\\rgreater than 100g scale\", \"tokenized_text\": [\"psilocybin\", \"differ\", \"polymorph\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 2, \"#\": 173, \"Title\": \"Preparation of psilocybin, different polymorphic forms,\\rintermediates, formulations and their use\", \"Owner/Assignee\": \"Compass Pathways\", \"Patent/Pub. No.\": \"US10,519,175B2\", \"Priority Date\": \"9/10/2017\", \"Status\": \"Granted 2019-12-31\\r(expires 2038-10-09)\", \"general_subject\": \"Treating drug resistant depression with crystalline\\rpsilocybin in the form Polymorph A.\", \"tokenized_text\": [\"psilocybin\", \"differ\", \"polymorph\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 3, \"#\": 174, \"Title\": \"Preparation of psilocybin, different polymorphic forms,\\rintermediates, formulations and their use\", \"Owner/Assignee\": \"Compass Pathfinder\\rLimited\", \"Patent/Pub. No.\": \"US11,447,510B2\", \"Priority Date\": \"9/10/2017\", \"Status\": \"Granted 2022-09-20\\r(expires 2038-12-11)\", \"general_subject\": \"This invention relates to the large-scale production of\\rpsilocybin for use in medicine. Move particularly, it\\rrelates to a method of obtaining high purity crystalline\\rpsilocybin, particularly, in the form of Polymorph A. It\\rfurther relates to a method for the manufacture of\\rpsilocybin and intermediates in the production thereof\\rand formulations containing psilocybin.\", \"tokenized_text\": [\"psilocybin\", \"differ\", \"polymorph\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 4, \"#\": 175, \"Title\": \"Use of cannabidiol in combination with 5-ht2b receptor\\ragonists or amphetamins in the treatment of epilepsy\", \"Owner/Assignee\": \"GW Research\", \"Patent/Pub. No.\": \"US20200237683\", \"Priority Date\": \"29/9/2017\", \"Status\": \"Pending in US\", \"general_subject\": \"CBD in combination with a 5-HT2B receptor agonist to\\rtreat epilepsy, including N,N-DMT and 5-MeO-DMT.\", \"tokenized_text\": [\"cannabidiol\", \"5-ht2b\", \"agonist\", \"amphetamin\", \"epilepsi\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 5, \"#\": 176, \"Title\": \"Use of cannabidiol in combination with 5-ht2b receptor\\ragonists or amphetamines in the treatment of epilepsy\", \"Owner/Assignee\": \"GW Research\", \"Patent/Pub. No.\": \"US20200237683\", \"Priority Date\": \"29/9/2017\", \"Status\": \"Published\", \"general_subject\": \"Treatments for epilepsy using CBD in combination with\\ra 5-HT2B receptor agonist, amphetamine, or an\\ramphetamine derivative, including MDMA.\", \"tokenized_text\": [\"cannabidiol\", \"5-ht2b\", \"agonist\", \"amphetamin\", \"epilepsi\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 6, \"#\": 177, \"Title\": \"Use of cannibidiol in combination with 5-ht2b receptor\\ragonists or amphetamines in the treatment of epilepsy\", \"Owner/Assignee\": \"GW Research\", \"Patent/Pub. No.\": \"WO2019064031A1\", \"Priority Date\": \"29/9/2017\", \"Status\": \"Published\", \"general_subject\": \"Methods of treating epileptic seizures using a\\rcombination of CBD and an amphetamine or a 5-HT2b\\rreceptor agonist such as LSD\", \"tokenized_text\": [\"cannibidiol\", \"5-ht2b\", \"agonist\", \"amphetamin\", \"epilepsi\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 0, \"#\": 178, \"Title\": \"Use of cannabidiol in combination with 5-HT2B receptor\\ragonists or amphetamines in the treatment of epilepsy\", \"Owner/Assignee\": \"GW Research\\rLimited\", \"Patent/Pub. No.\": \"US11,419,829\", \"Priority Date\": \"29/9/2017\", \"Status\": \"Published\", \"general_subject\": \"The present invention relates to the use of cannabidiol\\r(CBD) in combination with an agonist of 5-HT2B\\rreceptors. Such a combination provides protection\\ragainst the adverse effects caused by agonists of 5-\\rHT2B receptors. The invention further relates to the\\ruse of CBD in combination5 with an amphetamine or\\ramphetamine derivative in the treatment of epilepsy.\\rIn one embodiment the CBD is used in combination\\rwith the amphetamine derivative fenfluramine to\\rproduce a significant reduction in seizures. Preferably\\rthe CBD used is in the form of a highly purified extract\\rof cannabis such that the CBD is present at greater\\rthan 98% of the total extract (w/w) and the other\\rcomponents of the extract are characterised. In\\rparticular the cannabinoid10 tetrahydrocannabinol\\r(THC) has been substantially removed, to a level of not\\rmore than 0.15% (w/w) and the propyl analogue of\\rCBD, cannabidivarin, (CBDV) is present in amounts of\\rup to 1%. Alternatively, the CBD may be a synthetically\\rproduced CBD. In use the CBD in combination with an\\ragonist of 5-HT2B receptors, amphetamine or\\ramphetamine derivative may be formulated for\\radministration separately, sequentially or\\rsimultaneously with the15 amphetamine or\\ramphetamine derivative or the combination may be\\rprovided in a single dosage form. Where the CBD is\\rformulated for administration separately, sequentially\\ror simultaneously it may be provided as a kit or\\rtogether with instructions to administer the one or\\rmore components in the manner indicated.\", \"tokenized_text\": [\"cannabidiol\", \"5-ht2b\", \"agonist\", \"amphetamin\", \"epilepsi\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 0, \"#\": 179, \"Title\": \"Liquid dispensing system creating and maintaining a\\rpersonalised bubble with a defined radius and\\rconcentration\", \"Owner/Assignee\": \"Sensory Design &\\rTechnology\", \"Patent/Pub. No.\": \"US20200211703A1\", \"Priority Date\": \"29/7/2017\", \"Status\": \"Pending in US\", \"general_subject\": \"Wearable devices that dispense controllable volumes\\rof liquids such as perfume, but that also can be used\\rfor microdosing psychedelic medicines such as LSD\\rand psilocybin.\", \"tokenized_text\": [\"liquid\", \"dispens\", \"system\", \"creat\", \"maintain\", \"personalis\", \"bubbl\", \"defin\", \"radius\", \"concentr\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 1, \"#\": 180, \"Title\": \"Liquid dispensing system creating and maintaining a\\rpersonalised bubble with a defined radius and\\rconcentration\", \"Owner/Assignee\": \"Sensory Design &\\rTechnology\", \"Patent/Pub. No.\": \"WO2019025763\", \"Priority Date\": \"29/7/2017\", \"Status\": \"Published\", \"general_subject\": \"Methods and devices for \\\"creating and maintaining a\\rpersonalized bubble of scent,\\\" with a wearable device\\rhaving a perfume reservoir, a perfume dispenser, and\\ra controller to dispense perfume at intervals or to\\rdispense \\\"psychotherapeutic compounds\\\" such as\\rLSD.\", \"tokenized_text\": [\"liquid\", \"dispens\", \"system\", \"creat\", \"maintain\", \"personalis\", \"bubbl\", \"defin\", \"radius\", \"concentr\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 2, \"#\": 181, \"Title\": \"Compositions and methods for treating ocular\\rpathologies\", \"Owner/Assignee\": \"Timothy Foster and\\rCharles Nichols\", \"Patent/Pub. No.\": \"US20200330405A1\", \"Priority Date\": \"1/5/2017\", \"Status\": \"Pending in US\", \"general_subject\": \"Methods of treating an eye condition using a\\rserotonin 2A receptor agonist, including a psychedelic\", \"tokenized_text\": [\"ocular\", \"patholog\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 3, \"#\": 182, \"Title\": \"Assessing and treating psychedelic-responsive subjects\", \"Owner/Assignee\": \"Eleusis PBC\", \"Patent/Pub. No.\": \"US20200147038\", \"Priority Date\": \"20/4/2017\", \"Status\": \"Pending in US\", \"general_subject\": \"Improving mental or physical well-being by\\radministration of a psychedelic, including psilocybin.\", \"tokenized_text\": [\"assess\", \"psychedelic-respons\", \"subject\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 4, \"#\": 183, \"Title\": \"Assessing and treating psychedelic-responsive subjects\", \"Owner/Assignee\": \"Eleusis PBC\", \"Patent/Pub. No.\": \"WO2018195455\", \"Priority Date\": \"20/4/2017\", \"Status\": \"Published\", \"general_subject\": \"Methods of identifying a subject as being likely to\\rhave a positive therapeutic response to a psychedelic\\ragent, including LSD, and identifying a course of\\rtherapy for the subject, e.g., based on personality state\\ror trait predictors\", \"tokenized_text\": [\"assess\", \"psychedelic-respons\", \"subject\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 0, \"#\": 184, \"Title\": \"Compositions comprising a serotonergic tryptamine\\rcompound\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US20210346346A1\", \"Priority Date\": \"9/2/2017\", \"Status\": \"Published\", \"general_subject\": \"Compositions comprising a serotonergic tryptamine\\rcompound, combinations thereof, and methods of\\rusing them for treating and preventing a variety of\\rhuman conditions. In one embodiment, disclosed\\rherein are new compositions and methods which\\rcomprise a therapeutically effective amount of a first\\rpurified psilocybin derivative and a therapeutically\\reffective amount of a second compound. The second\\rcompound is selected from the group consisting of a\\rsecond purified psilocybin derivative, a purified\\rterpene, a serotonergic drug, an adrenergic drug, a\\rdopaminergic drug, a purified erinacine, and a purified\\rhericenone.\", \"tokenized_text\": [\"serotonerg\", \"tryptamin\", \"compound\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 1, \"#\": 185, \"Title\": \"Compositions and methods comprising a psilocybin\\rderivative\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US10,933,073B2\", \"Priority Date\": \"9/2/2017\", \"Status\": \"Granted 2021-03-02\\r(expires 2038-09-11)\", \"general_subject\": \"Dosage formulations comprising certain psilocybin\\rderivatives and cannabinoids\", \"tokenized_text\": [\"psilocybin\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 2, \"#\": 186, \"Title\": \"Compositions and methods comprising a combination\\rof serotonergic drugs\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US20210085671A1\", \"Priority Date\": \"9/2/2017\", \"Status\": \"Pending in US\", \"general_subject\": \"Combinations of two serotonergic drugs, including\\rpsilocybin derivatives, tryptamines, cannabinoids,\\rSSRIs, LSD, and MDMA, and use to treat psychological\\rdisorders.\", \"tokenized_text\": [\"serotonerg\", \"drug\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 3, \"#\": 187, \"Title\": \"Compositions comprising a serotonergic tryptamine\\rcompound\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US20210361679A1\", \"Priority Date\": \"9/2/2017\", \"Status\": \"Published\", \"general_subject\": \"A serotonergic tryptamine compound, combinations\\rthereof, and methods of using them for treating and\\rpreventing a variety of human conditions. In one\\rembodiment, disclosed herein are new compositions\\rand methods which comprise a therapeutically\\reffective amount of a first purified psilocybin\\rderivative and a therapeutically effective amount of a\\rsecond compound.\", \"tokenized_text\": [\"serotonerg\", \"tryptamin\", \"compound\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 4, \"#\": 188, \"Title\": \"Compositions and methods comprising a psilocybin\\rderivative\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"WO2018148605A1\", \"Priority Date\": \"9/2/2017\", \"Status\": \"Published\", \"general_subject\": \"Methods of modulating activity at a neurotransmitter\\rreceptor comprising administering a psilocybin\\rderivative and in some embodiments a serotonergic\\rdrug including MDMA\", \"tokenized_text\": [\"psilocybin\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 0, \"#\": 189, \"Title\": \"Compositions and methods comprising a combination\\rof serotonergic drugs\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US202117388252\", \"Priority Date\": \"9/2/2017\", \"Status\": \"Published\", \"general_subject\": \"Compositions and methods of a first serotonergic\\rdrug and a second serotonergic drug, including a\\rpurified psilocybin derivative, a purified cannabinoid, a\\rpurified terpene, a purified tryptamine, purified LSD,\\rand/or purified MDMA.\", \"tokenized_text\": [\"serotonerg\", \"drug\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 1, \"#\": 190, \"Title\": \"Compositions and methods comprising a combination\\rof serotonergic drugs\", \"Owner/Assignee\": \"CaaMTech\", \"Patent/Pub. No.\": \"US202017095430\", \"Priority Date\": \"9/2/2017\", \"Status\": \"Pending in US\", \"general_subject\": \"Compositions and methods of a first serotonergic\\rdrug and a second serotonergic drug, including of a\\rpurified psilocybin derivative, a purified cannabinoid, a\\rpurified terpene, a purified tryptamine, purified LSD,\\rand/or purified MDMA.\", \"tokenized_text\": [\"serotonerg\", \"drug\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 2, \"#\": 191, \"Title\": \"Psilocybin and/or psilocin in combination with\\rcannabinoids and/or terpenes\", \"Owner/Assignee\": \"Procare Beheer\", \"Patent/Pub. No.\": \"US10,729,706B2\", \"Priority Date\": \"18/1/2017\", \"Status\": \"Granted 2020-08-04\\r(expires 2038-01-18)\", \"general_subject\": \"Treating a psychological disorder by administration of\\rpsilocybin together with a cannabinoid and/or a\\rterpene.\", \"tokenized_text\": [\"psilocybin\", \"and/or\", \"psilocin\", \"cannabinoid\", \"and/or\", \"terpen\"], \"year\": \"2017\"}, {\"Unnamed: 0\": 3, \"#\": 192, \"Title\": \"Method for treatment of depression using synaptic\\rpathway training\", \"Owner/Assignee\": \"Joseph Rustick\", \"Patent/Pub. No.\": \"US10,596,378B2\", \"Priority Date\": \"18/10/2016\", \"Status\": \"Granted 2020-03-24\\r(expires 2038-06-07)\", \"general_subject\": \"Treating a neurologic condition by synaptic pathway\\rtraining, including by administration of psilocybin.\", \"tokenized_text\": [\"depress\", \"synapt\", \"pathway\", \"train\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 4, \"#\": 193, \"Title\": \"Biosynthetic cannabinoid production methods\", \"Owner/Assignee\": \"Insectergy\", \"Patent/Pub. No.\": \"US11,180,781B2\", \"Priority Date\": \"21/8/2016\", \"Status\": \"Granted 2021-11-23\\r(expires 2036-08-21)\", \"general_subject\": \"Distilled compositions comprising a mixture of\\rbiosynthetic and non-biosynthetic cannabinoids, some\\rfurther comprising psilocybin.\", \"tokenized_text\": [\"biosynthet\", \"cannabinoid\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 5, \"#\": 194, \"Title\": \"Cannabis nanoemulsion methods\", \"Owner/Assignee\": \"Insectergy\", \"Patent/Pub. No.\": \"US10,738,268B2\", \"Priority Date\": \"21/8/2016\", \"Status\": \"Granted 2020-08-11\\r(expires 2036-11-01)\", \"general_subject\": \"Methods to produce cannabis oil nanoemulsions with\\rvarious compounds including psilocybin\", \"tokenized_text\": [\"cannabi\", \"nanoemuls\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 6, \"#\": 195, \"Title\": \"Compositions and methods for treating depression\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"US20220016104A1\", \"Priority Date\": \"23/7/2016\", \"Status\": \"Published\", \"general_subject\": \"Methods and compositions for enhancing\\rneurogenesis, resolving neuropathy and improving\\rneurological health and functioning using fungal\\rextracts and their active ingredients, including species\\rof mushrooms and mycelia containing psilocybin and\\rpsilocin, combined with erinacines and hericenones or\\rfungal extracts containing those active ingredients,\\rwith the addition of nicotinic acid. The compositions\\rmay optionally be combined with nervine plants.\", \"tokenized_text\": [\"depress\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 0, \"#\": 196, \"Title\": \"Compositions and methods for enhancing\\rneuroregeneration and cognition by combining\\rmushroom extracts containing [] psilocin or psilocybin\\rwith erinacines or hericenones enhanced with niacin\", \"Owner/Assignee\": \"Paul Stamets\", \"Patent/Pub. No.\": \"US20180021326A1\", \"Priority Date\": \"23/7/2016\", \"Status\": \"Abandoned\", \"general_subject\": \"Compositions of psilocybin, niacin, and mushroom or\\rcannabis extracts, and their use to improve\\rneurological health.\", \"tokenized_text\": [\"neuroregener\", \"cognit\", \"combin\", \"mushroom\", \"extract\", \"contain\", \"psilocin\", \"psilocybin\", \"erinacin\", \"hericenon\", \"enhanc\", \"niacin\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 1, \"#\": 197, \"Title\": \"Psilocybin compositions\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"US20190105313A1\", \"Priority Date\": \"23/7/2016\", \"Status\": \"Pending in US\", \"general_subject\": \"Compositions of psilocybin, niacin, and mushroom or\\rcannabis extracts, and their use to treat neurological\\ror mental health disorders\", \"tokenized_text\": [\"psilocybin\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 2, \"#\": 198, \"Title\": \"Compositions of psilocybin and analogs\", \"Owner/Assignee\": \"Paul Stamets\", \"Patent/Pub. No.\": \"US20200375967\", \"Priority Date\": \"23/7/2016\", \"Status\": \"Pending in US\", \"general_subject\": \"Compositions of psilocybin, niacin, and mushroom or\\rcannabis extracts, and their use to treat neurological\\ror mental health disorders\", \"tokenized_text\": [\"psilocybin\", \"analog\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 3, \"#\": 199, \"Title\": \"Tryptamine compositions for enhancing neurite\\routgrowth\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"US20210251976A1\", \"Priority Date\": \"23/7/2016\", \"Status\": \"Pending in US\", \"general_subject\": \"Methods of treating or improving a mental health\\rdisorder by administering up to 10 mg psilocybin or\\rup to 0.3 g psilocybin containing mushrooms.\", \"tokenized_text\": [\"tryptamin\", \"neurit\", \"outgrowth\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 4, \"#\": 200, \"Title\": \"Psilocybin compositions\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"US20190192498A1\", \"Priority Date\": \"23/7/2016\", \"Status\": \"Pending in US\", \"general_subject\": \"Compositions of psilocybin, niacin, and mushroom or\\rcannabis extracts, and their use to treat neurological\\ror mental health disorders\", \"tokenized_text\": [\"psilocybin\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 5, \"#\": 201, \"Title\": \"Tryptamine compositions for enhancing neurite\\routgrowth\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"US20210069170A1\", \"Priority Date\": \"23/7/2016\", \"Status\": \"Pending in US\", \"general_subject\": \"Neurotrophic and nootropic compositions comprising\\rpsilocybin and other mushroom extracts,\\rcannabinoids, as well as phenethylamines and\\ramphetamines.\", \"tokenized_text\": [\"tryptamin\", \"neurit\", \"outgrowth\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 6, \"#\": 202, \"Title\": \"Psilocybin Compositions\", \"Owner/Assignee\": \"Turtle Bear Holdings\", \"Patent/Pub. No.\": \"US20220313674A1\", \"Priority Date\": \"23/7/2016\", \"Status\": \"Published\", \"general_subject\": \"Methods and compositions are disclosed for\\renhancing neurogenesis, resolving neuropathy and\\rimproving neurological health and functioning using\\rfungal extracts and their active ingredients, including\\rspecies of mushrooms and mycelia containing\\rpsilocybin and psilocin, combined with erinacines and\\rhericenones or fungal extracts containing those active\\ringredients, with the addition of nicotinic acid. The\\rcompositions may optionally be combined with\\rnervine plants.\", \"tokenized_text\": [\"psilocybin\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 0, \"#\": 203, \"Title\": \"Orally administrable composition\", \"Owner/Assignee\": \"CTT Pharma\", \"Patent/Pub. No.\": \"US20220079881\", \"Priority Date\": \"3/3/2016\", \"Status\": \"Published\", \"general_subject\": \"An orally administrable micellar composition is\\rprovided. The composition comprises: i) at least one\\rphysiologically acceptable film forming agent in an\\ramount ranging from about 30 to 80% by wt in a\\rpharmaceutically acceptable aqueous solvent\\rcombined with ii) a micellar composition comprising a\\rdrug encapsulated in micelles of 50-1000 nm in size\\rformed by micelle-forming compounds, in a\\rpharmaceutically acceptable aqueous solvent.\", \"tokenized_text\": [\"oral\", \"administr\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 1, \"#\": 204, \"Title\": \"Personal vaporizing device with slidable cart\", \"Owner/Assignee\": \"Syqe Medical\", \"Patent/Pub. No.\": \"US11,229,758\", \"Priority Date\": \"11/1/2016\", \"Status\": \"Granted 2022-01-25\", \"general_subject\": \"A device for delivering an active substance through\\rinhalation and, more particularly, but not exclusively,\\rto delivery of at least one active substance through a\\rplurality of delivery events in which a controlled\\rportion of source material is heated independently of\\rother portions of the source material.\", \"tokenized_text\": [\"person\", \"vapor\", \"devic\", \"slidabl\", \"cart\"], \"year\": \"2016\"}, {\"Unnamed: 0\": 2, \"#\": 205, \"Title\": \"Flow regulating inhaler device\", \"Owner/Assignee\": \"Syqe Medical\", \"Patent/Pub. No.\": \"US10,166,349\", \"Priority Date\": \"30/6/2014\", \"Status\": \"Granted 2019-01-01\", \"general_subject\": \"An inhaler device for pulmonary delivery of at least\\rone substance from a drug dose cartridge to an\\rinhaling user.\", \"tokenized_text\": [\"flow\", \"regul\", \"inhal\", \"devic\"], \"year\": \"2014\"}, {\"Unnamed: 0\": 3, \"#\": 206, \"Title\": \"Drug dose cartridge for an inhaler device\", \"Owner/Assignee\": \"Syqe Medical\", \"Patent/Pub. No.\": \"US11,160,937\", \"Priority Date\": \"30/6/2014\", \"Status\": \"Granted 2021-11-02\", \"general_subject\": \"Devices and methods are described for preparing,\\rmanaging, and/or administering metered doses of\\rsubstances for vaporized administration.\", \"tokenized_text\": [\"drug\", \"dose\", \"cartridg\", \"inhal\", \"devic\"], \"year\": \"2014\"}, {\"Unnamed: 0\": 4, \"#\": 207, \"Title\": \"Pharmaceutical compositions\", \"Owner/Assignee\": \"Charleston\\rLaboratories\", \"Patent/Pub. No.\": \"WO2015157738A1\", \"Priority Date\": \"10/4/2014\", \"Status\": \"Published\", \"general_subject\": \"Compositions of substances, including ibogaine, and\\rmethods of using the same for pain treatment.\", \"tokenized_text\": [], \"year\": \"2014\"}, {\"Unnamed: 0\": 5, \"#\": 208, \"Title\": \"Integrative fungal solutions for protecting bees\", \"Owner/Assignee\": \"Paul Stamets\", \"Patent/Pub. No.\": \"US20200376055A1\", \"Priority Date\": \"10/3/2014\", \"Status\": \"Pending in US\", \"general_subject\": \"Compositions for improving bee health and for\\rpreventing and treating colony collapse disorder\\rcomprising mycelium extracts, including from\\rpsilocybe spp.\", \"tokenized_text\": [\"integr\", \"fungal\", \"solut\", \"protect\", \"bee\"], \"year\": \"2014\"}, {\"Unnamed: 0\": 6, \"#\": 209, \"Title\": \"Methods, apparatuses and systems for transcranial\\rstimulation\", \"Owner/Assignee\": \"The University of\\rNorth Carolina at\\rChapel Hill\", \"Patent/Pub. No.\": \"US10,188,342B2\", \"Priority Date\": \"5/11/2013\", \"Status\": \"Granted 2019-01-29\", \"general_subject\": \"Methods of transcranial stimulation, including\\radministering a drug, such as ibogaine, in\\rconnjunction with transcranial stimulation.\", \"tokenized_text\": [\"apparatus\", \"transcrani\", \"stimul\"], \"year\": \"2013\"}, {\"Unnamed: 0\": 0, \"#\": 210, \"Title\": \"Method and system for drug delivery\", \"Owner/Assignee\": \"Syqe Medical\", \"Patent/Pub. No.\": \"US11,071,712B2\", \"Priority Date\": \"22/12/2010\", \"Status\": \"Granted 2021-07-27\\r(expires 2032-07-23)\", \"general_subject\": \"Drug dose structure for use with an inhaler device\\rhaving source material from which at least one active\\rsubstance is released for delivery by vaporization,\\rincluding psilocybin.\", \"tokenized_text\": [\"system\", \"drug\"], \"year\": \"2010\"}, {\"Unnamed: 0\": 1, \"#\": 211, \"Title\": \"Method and system for drug delivery\", \"Owner/Assignee\": \"Syqe Medical\", \"Patent/Pub. No.\": \"US9,775,379B2\", \"Priority Date\": \"22/12/2010\", \"Status\": \"Granted 2017-10-03\\r(expires 2034-09-26)\", \"general_subject\": \"Inhaler device for controlled extraction of at least one\\ractive substance from at least one type of plant matter\\rby application of heat, including psilocybin\", \"tokenized_text\": [\"system\", \"drug\"], \"year\": \"2010\"}, {\"Unnamed: 0\": 2, \"#\": 212, \"Title\": \"Methods of improving behavioral therapies\", \"Owner/Assignee\": \"Emory University\", \"Patent/Pub. No.\": \"US20120108510A1\", \"Priority Date\": \"20/5/2010\", \"Status\": \"Abandoned\", \"general_subject\": \"Psychedelic-assisted psychotherapy using an oxytocin-\\rreleasing agent, including psilocybin.\", \"tokenized_text\": [\"improv\", \"behavior\", \"therapi\"], \"year\": \"2010\"}, {\"Unnamed: 0\": 3, \"#\": 213, \"Title\": \"Pharmaceutical compositions for treating or preventing\\rpain\", \"Owner/Assignee\": \"Locl Pharma;\\rCharleston\\rLaboratories\", \"Patent/Pub. No.\": \"US10,532,030\", \"Priority Date\": \"8/7/2009\", \"Status\": \"Granted 2020-01-14\", \"general_subject\": \"Methods and compositions are provided which\\rcomprise effective amounts of one or more analgesics.\", \"tokenized_text\": [\"prevent\", \"pain\"], \"year\": \"2009\"}, {\"Unnamed: 0\": 4, \"#\": 214, \"Title\": \"Compositions and methods for evaluating cognitive\\rdefects\", \"Owner/Assignee\": \"Galenea Corp\", \"Patent/Pub. No.\": \"US20120159656A1\", \"Priority Date\": \"24/4/2009\", \"Status\": \"Abandoned\", \"general_subject\": \"Using psilocybin to identify a candidate therapeutic\\ragent for treatment of a cognitive deficit.\", \"tokenized_text\": [\"evalu\", \"cognit\", \"defect\"], \"year\": \"2009\"}, {\"Unnamed: 0\": 5, \"#\": 215, \"Title\": \"Composition for transdermal delivery of cationic active\\ragents\", \"Owner/Assignee\": \"LTS Lohmann\\rTherapie Systeme\\rGmbH\", \"Patent/Pub. No.\": \"US10,881,607B2\", \"Priority Date\": \"19/6/2008\", \"Status\": \"Granted 2021-01-05\\r(expires 2029-06-16)\", \"general_subject\": \"Transdermal patch with composition for transdermal\\rdelivery of at least one cationic active agent, including\\rindole compounds such as N,N-DMT\", \"tokenized_text\": [\"transderm\", \"cation\", \"activ\"], \"year\": \"2008\"}, {\"Unnamed: 0\": 6, \"#\": 216, \"Title\": \"Salts of physiologically active and psychoactive alkaloids\\rand amines simultaneously exhibiting bioavailability and\\rabuse resistance\", \"Owner/Assignee\": \"Pisgah Labs\", \"Patent/Pub. No.\": \"US20080293695A1\", \"Priority Date\": \"22/5/2007\", \"Status\": \"Abandoned\", \"general_subject\": \"Drug substances that can be administered\\rtherapeutically but having anti-abuse properties when\\rused non-therapeutically, the substances including\\rpsilocybin and psilocin\", \"tokenized_text\": [\"salt\", \"physiolog\", \"activ\", \"psychoact\", \"alkaloid\", \"amin\", \"simultan\", \"exhibit\", \"bioavail\", \"abus\", \"resist\"], \"year\": \"2007\"}, {\"Unnamed: 0\": 7, \"#\": 217, \"Title\": \"Opioid and attention deficit hyperactivity disorder\\rmedications possessing abuse deterrent and anti-dose\\rdumping safety features\", \"Owner/Assignee\": \"Pisgah Labs\", \"Patent/Pub. No.\": \"US10,183,001\", \"Priority Date\": \"22/5/2007\", \"Status\": \"Granted 2019-01-22\\r(expires 2027-10-13)\", \"general_subject\": \"Drug products with improved safety and anti-abuse\\rproperties, comprising a matrix of BNDO and an active\\rcompound, including MDMA and Ibogaine.\", \"tokenized_text\": [\"opioid\", \"attent\", \"deficit\", \"hyperact\", \"medic\", \"possess\", \"abus\", \"deterr\", \"anti-dos\", \"dump\", \"safeti\", \"featur\"], \"year\": \"2007\"}, {\"Unnamed: 0\": 8, \"#\": 218, \"Title\": \"Safety of pseudoephedrine drug products\", \"Owner/Assignee\": \"Pisgah Labs\", \"Patent/Pub. No.\": \"US9,421,266\", \"Priority Date\": \"22/5/2007\", \"Status\": \"Expired\", \"general_subject\": \"Drug products with improved safety and anti-abuse\\rproperties, by the inclusion of alditol acetals to reduce\\rbioavailability in the mucosal membranes, the active\\rcompounds including MDMA.\", \"tokenized_text\": [\"safeti\", \"pseudoephedrin\", \"drug\", \"product\"], \"year\": \"2007\"}, {\"Unnamed: 0\": 0, \"#\": 219, \"Title\": \"Abuse deterrent and anti-dose dumping pharmaceutical\\rsalts useful for the treatment of attention\\rdeficit/hyperactivity disorder\", \"Owner/Assignee\": \"Pisgah Laboratories\", \"Patent/Pub. No.\": \"US9,226,925B1\", \"Priority Date\": \"10/11/2006\", \"Status\": \"Granted 2016-01-05\", \"general_subject\": \"Pharmaceutical compositions which are particularly\\rsuitable for treating Attention Deficit/Hyperactivity\\rDisorder.\", \"tokenized_text\": [\"abus\", \"deterr\", \"anti-dos\", \"dump\", \"salt\", \"use\", \"attent\", \"deficit/hyperact\"], \"year\": \"2006\"}, {\"Unnamed: 0\": 1, \"#\": 220, \"Title\": \"Cannabinoid candy foodstuff compositions\", \"Owner/Assignee\": \"Insectergy\", \"Patent/Pub. No.\": \"US20220151980\", \"Priority Date\": \"3/7/2002\", \"Status\": \"Published\", \"general_subject\": \"Cannabinoid candy foodstuff compositions are\\rdescribed comprising a binding agent, and an\\remulsifier, wherein the composition includes a\\rcannabinoid microemulsion and/or a cannabinoid\\rnanoemulsion to enhance bioavailability of said\\rcannabinoid when introduced into a human and/or an\\ranimal to have an active effect. The composition\\rincludes a biosynthetic cannabinoid derived from a\\rgenetically modified microorganism or a non-\\rbiosynthetic cannabinoid derived from cannabis\\rplants, and may include an acid, an extrudate, a sugar\\rcoating, an insect lipid, a flavoring, a terpene, a\\rmedium chain triglyceride, glycerin, a microorganism,\\ra sweetener, an oil, a drug such as psilocybin or\\rMDMA, melatonin, a fiber-starch material, a density\\rimproving textural supplement, or a moisture\\rimproving textural supplement.\", \"tokenized_text\": [\"cannabinoid\", \"candi\", \"foodstuff\"], \"year\": \"2002\"}, {\"Unnamed: 0\": 2, \"#\": 221, \"Title\": \"Modulation of secondary metabolite production by zinc\\rbinuclear cluster proteins\", \"Owner/Assignee\": \"Koninklijke DSM\\r(formerly Microbia\\rInc)\", \"Patent/Pub. No.\": \"US7,229,784B2\", \"Priority Date\": \"19/9/2000\", \"Status\": \"Granted 2007-06-12\\r(expires 2023-06-05)\", \"general_subject\": \"Improving yield of fungal metabolites in\\rbioengineered cells, including psilocybin.\", \"tokenized_text\": [\"modul\", \"secondari\", \"metabolit\", \"zinc\", \"binuclear\", \"cluster\", \"protein\"], \"year\": \"2000\"}, {\"Unnamed: 0\": 3, \"#\": 222, \"Title\": \"Method of inducing therapeutic tranquilization with\\rpsilocybin and psilocin\", \"Owner/Assignee\": \"Sandoz\", \"Patent/Pub. No.\": \"US3,192,111A\", \"Priority Date\": \"16/2/1959\", \"Status\": \"Granted 1965-06-29\\r(expired 1982-06-29)\", \"general_subject\": \"Using psilocybin and psilocin to induce tranquilization.\", \"tokenized_text\": [\"induc\", \"therapeut\", \"tranquil\", \"psilocybin\", \"psilocin\"], \"year\": \"1959\"}, {\"Unnamed: 0\": 4, \"#\": 223, \"Title\": \"Esters of indoles\", \"Owner/Assignee\": \"Sandoz\", \"Patent/Pub. No.\": \"US3,075,992A\", \"Priority Date\": \"12/9/1958\", \"Status\": \"Granted 1963-01-29\\r(expired 1980-01-29)\", \"general_subject\": \"Discloses, with coinventor Franz Troxler, the first\\rlaboratory synthesis of psilocybin and various\\ranalogues; claims novel analogues.\", \"tokenized_text\": [\"ester\", \"indol\"], \"year\": \"1958\"}, {\"Unnamed: 0\": 5, \"#\": 224, \"Title\": \"Obtaining psilocybin and psilocin from fungal material\", \"Owner/Assignee\": \"Sandoz\", \"Patent/Pub. No.\": \"US3,183,172A\", \"Priority Date\": \"21/2/1958\", \"Status\": \"Granted 1965-05-11\\r(expired 1982-05-11)\", \"general_subject\": \"Extracting psilocybin and psilocin from fungal material.\", \"tokenized_text\": [\"obtain\", \"psilocybin\", \"psilocin\", \"fungal\", \"materi\"], \"year\": \"1958\"}]}}, {\"mode\": \"vega-lite\"});\n",
       "</script>"
      ],
      "text/plain": [
       "alt.Chart(...)"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "alt.Chart(data_p).mark_point().encode(\n",
    "    x='year',\n",
    "    y='count(yield):Q',\n",
    "    size='count(yield):Q',\n",
    "    tooltip = 'count(yield):Q'\n",
    ")"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "INICIA NLTK"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import gensim"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "tokens_solos = data_p['tokenized_text'].tolist()\n",
    "dictionary = gensim.corpora.Dictionary(tokens_solos)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<gensim.corpora.dictionary.Dictionary at 0x1de6cdcaac0>"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dictionary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "dictionary.filter_extremes(no_below=4, no_above=0.8, keep_n=100000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc_term_matrix = [dictionary.doc2bow(rev) for rev in tokens_solos]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "LDA = gensim.models.ldamodel.LdaModel\n",
    "lda_model = LDA(corpus=doc_term_matrix, id2word=dictionary, num_topics=5, random_state=100, chunksize=1000, passes=50, iterations=100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pyLDAvis\n",
    "import pyLDAvis.gensim_models as gensimvis\n",
    "pyLDAvis.enable_notebook()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\cynhe\\anaconda3\\lib\\site-packages\\pyLDAvis\\_prepare.py:243: FutureWarning: In a future version of pandas all arguments of DataFrame.drop except for the argument 'labels' will be keyword-only.\n",
      "  default_term_info = default_term_info.sort_values(\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "<link rel=\"stylesheet\" type=\"text/css\" href=\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.4.0/pyLDAvis/js/ldavis.v1.0.0.css\">\n",
       "\n",
       "\n",
       "<div id=\"ldavis_el2816420548210340161533040011\" style=\"background-color:white;\"></div>\n",
       "<script type=\"text/javascript\">\n",
       "\n",
       "var ldavis_el2816420548210340161533040011_data = {\"mdsDat\": {\"x\": [0.1791666228667974, -0.22390121754724948, 0.05871045852401781, 0.19867987788346161, -0.21265574172702714], \"y\": [-0.0038631224126151917, -0.21663802528406373, 0.0014647961308108986, -0.003209146044918183, 0.22224549761078619], \"topics\": [1, 2, 3, 4, 5], \"cluster\": [1, 1, 1, 1, 1], \"Freq\": [23.092185954423393, 20.846676758928684, 20.11395380368407, 18.761562193377877, 17.185621289585978]}, \"tinfo\": {\"Term\": [\"psilocybin\", \"deriv\", \"tryptamin\", \"psychoact\", \"drug\", \"psilocin\", \"extract\", \"psychedel\", \"modul\", \"polymorph\", \"product\", \"organ\", \"anxieti\", \"alkaloid\", \"differ\", \"system\", \"therapeut\", \"neurit\", \"outgrowth\", \"analog\", \"cannabinoid\", \"crystallin\", \"activ\", \"salt\", \"agonist\", \"apparatus\", \"manufactur\", \"contain\", \"therapi\", \"chronic\", \"deriv\", \"cannabinoid\", \"contain\", \"novel\", \"amphetamin\", \"5-ht2b\", \"epilepsi\", \"deuter\", \"cns\", \"psychedel\", \"serotonerg\", \"psilocin\", \"compound\", \"agonist\", \"and/or\", \"psilocybin\", \"mushroom\", \"thc\", \"beverag\", \"food\", \"safeti\", \"releas\", \"brain\", \"neurolog\", \"control\", \"psycholog\", \"mood\", \"improv\", \"pain\", \"effect\", \"reduc\", \"cognit\", \"analog\", \"dose\", \"crystallin\", \"therapeut\", \"apparatus\", \"salt\", \"modul\", \"extract\", \"tryptamin\", \"psychoact\", \"extract\", \"alkaloid\", \"activ\", \"salt\", \"fungus\", \"cognit\", \"control\", \"psycholog\", \"mood\", \"brain\", \"neurolog\", \"releas\", \"therapi\", \"psychoact\", \"condit\", \"and/or\", \"agonist\", \"diseas\", \"effect\", \"process\", \"safeti\", \"reduc\", \"mushroom\", \"food\", \"thc\", \"beverag\", \"deuter\", \"amphetamin\", \"5-ht2b\", \"epilepsi\", \"improv\", \"depress\", \"devic\", \"produc\", \"cannabi\", \"crystallin\", \"product\", \"manufactur\", \"psilocybin\", \"psilocin\", \"drug\", \"anxieti\", \"system\", \"therapeut\", \"analog\", \"chronic\", \"depress\", \"devic\", \"relat\", \"acid\", \"pain\", \"lsd\", \"process\", \"reduc\", \"effect\", \"diseas\", \"safeti\", \"serotonerg\", \"mushroom\", \"psychedel\", \"dose\", \"psilocybin\", \"therapi\", \"beverag\", \"food\", \"thc\", \"mood\", \"deuter\", \"epilepsi\", \"amphetamin\", \"manufactur\", \"extract\", \"novel\", \"salt\", \"psilocin\", \"organ\", \"tryptamin\", \"polymorph\", \"product\", \"differ\", \"apparatus\", \"manufactur\", \"beverag\", \"food\", \"thc\", \"cannabi\", \"psilocybin\", \"psilocin\", \"condit\", \"safeti\", \"pain\", \"produc\", \"releas\", \"mushroom\", \"neurolog\", \"acid\", \"brain\", \"deuter\", \"amphetamin\", \"5-ht2b\", \"epilepsi\", \"psycholog\", \"mood\", \"control\", \"compound\", \"effect\", \"reduc\", \"relat\", \"contain\", \"activ\", \"analog\", \"fungus\", \"and/or\", \"therapeut\", \"salt\", \"extract\", \"drug\", \"psychedel\", \"tryptamin\", \"modul\", \"organ\", \"neurit\", \"outgrowth\", \"crystallin\", \"improv\", \"produc\", \"dose\", \"mushroom\", \"compound\", \"psychoact\", \"lsd\", \"reduc\", \"cannabi\", \"serotonerg\", \"cns\", \"thc\", \"beverag\", \"food\", \"deuter\", \"safeti\", \"5-ht2b\", \"epilepsi\", \"amphetamin\", \"releas\", \"neurolog\", \"brain\", \"psycholog\", \"control\", \"relat\", \"process\", \"pain\", \"therapeut\", \"salt\", \"extract\", \"therapi\", \"cognit\", \"psychedel\", \"deriv\", \"psilocybin\", \"contain\", \"psilocin\"], \"Freq\": [50.0, 22.0, 16.0, 21.0, 11.0, 19.0, 11.0, 16.0, 8.0, 7.0, 7.0, 7.0, 8.0, 7.0, 6.0, 7.0, 7.0, 6.0, 6.0, 6.0, 7.0, 5.0, 6.0, 6.0, 10.0, 5.0, 5.0, 6.0, 7.0, 5.0, 21.335312275619078, 6.347050674051895, 5.463000515328074, 4.582209425996422, 3.7029201498997386, 3.7029201498997386, 3.7029201498997386, 3.702176845750178, 5.471557418796157, 12.387984284532136, 5.486512559268754, 9.005264878639233, 1.9377052948491629, 4.590071681109656, 1.9385756688197324, 14.249964220167966, 0.18142335318467112, 0.17678925528599576, 0.17633966433916295, 0.17633917560908213, 0.17637251786126143, 0.17636100555269138, 0.1763454612209547, 0.17634342484561802, 0.17634123913608998, 0.17634072325433803, 0.1763387140306725, 0.17724586493982233, 0.17635591461434968, 0.1763462078919115, 0.1763687980823131, 0.1777303457840903, 0.177953844765209, 0.17725388825864885, 0.17708125793344048, 0.17737013813870228, 0.17676795479997406, 0.1770702615066224, 0.17763302061883243, 0.17696340610478886, 0.1768004010470052, 0.17637815183302624, 10.770486744225826, 7.252802457305977, 5.4816967635845355, 5.479111887992158, 4.598422301605307, 4.5974026268154145, 3.714827818615098, 3.7148235046063713, 3.714250525810974, 3.7142301323151763, 3.713635975658758, 3.70919137012266, 5.4362039728334715, 11.671106658746352, 2.832573423608374, 2.830587606955058, 5.478305560542919, 2.5805621719255254, 1.9421165292821865, 1.9478659263667355, 1.0606628731224872, 1.053460537507994, 0.18365236406979935, 0.1769131348409512, 0.17690893113358422, 0.1769077423300431, 0.17691059790968308, 0.17690853895097272, 0.17690853895097272, 0.17690853895097272, 0.17792244130305246, 0.1790439855262816, 0.17698298011291752, 0.1779369888267977, 0.17772213403423026, 0.17771394722221528, 0.17843769572032014, 0.17753657038045906, 0.17926004137809673, 0.17782145428059193, 10.894880549498723, 7.323426061404124, 6.430266532064271, 6.426230537902366, 5.533715042133071, 4.644092021459746, 4.641896555668692, 3.750884435560869, 3.749468469861089, 3.7486269124809954, 2.8622721162194824, 3.761442121020399, 2.8513437898184946, 1.9759774852562761, 1.9685625852375592, 2.216945180947592, 1.4760721571821154, 2.8431457949265293, 1.0634522032240765, 3.8818608843924167, 1.059355286967658, 9.451683051869878, 1.1187293548422652, 0.17863237886559857, 0.17863182309338543, 0.17863194134279248, 0.17921530114259246, 0.17863609189697993, 0.17862936350571879, 0.1786293516807781, 0.18552125822199417, 0.19511694928035014, 0.1809910406633222, 0.18064442800137712, 0.1865827831490824, 0.17999267274453942, 0.18044524870014203, 7.089905797880692, 7.087882654414618, 6.225279506738949, 4.4953425428817155, 4.488684734926281, 3.6313889857675963, 3.6313847502962786, 3.6309432024114114, 3.6325664467939087, 26.674682110164753, 9.66288756173642, 1.8999360761345803, 1.5112929340625236, 1.0332449927254728, 1.0321183573549724, 0.1783967393453746, 0.1759935946870183, 0.17407861015777, 0.17522064323128983, 0.1734973909882787, 0.17293897056673957, 0.17293351077949415, 0.17293351077949415, 0.17293351077949415, 0.17293599250096933, 0.17293525349946337, 0.17293464685643611, 0.1729455333413073, 0.17294241188718518, 0.17296952331556756, 0.17316711246448618, 0.17522036748445927, 0.17497303360730446, 0.17439171516895416, 0.17377857554635523, 0.17371296986042423, 0.17424989305905153, 0.17379946612623975, 0.17426275389122967, 0.17373828341947123, 0.17349966314216267, 15.324532607201002, 8.195583894856261, 6.414418160192351, 5.524748315257652, 5.524748315257652, 4.632045515964363, 3.7405910096865864, 3.7470730160756, 3.7539323231507313, 2.8445804440525335, 1.9622826730208855, 9.093032535427634, 1.9499722277981177, 1.0660517728387697, 1.0672264324084682, 1.954632877361728, 1.0639192318570783, 0.17823153378469986, 0.178230058690972, 0.17822993745039162, 0.17896097773650854, 0.17827511977334362, 0.17822852297695393, 0.17822852297695393, 0.17822850277019053, 0.17823719167845054, 0.17824036414030361, 0.17823939421566065, 0.17823139233735608, 0.17822989703686481, 0.17951316795981323, 0.18268455885442303, 0.17825273067950156, 0.17988707390968078, 0.17931269666016797, 0.18022604236563775, 0.17925694619996022, 0.17873943078264193, 0.1798096213855864, 0.1789894490661326, 0.1788203790768037, 0.17854027292261737, 0.17843129784762626], \"Total\": [50.0, 22.0, 16.0, 21.0, 11.0, 19.0, 11.0, 16.0, 8.0, 7.0, 7.0, 7.0, 8.0, 7.0, 6.0, 7.0, 7.0, 6.0, 6.0, 6.0, 7.0, 5.0, 6.0, 6.0, 10.0, 5.0, 5.0, 6.0, 7.0, 5.0, 22.042824357477006, 7.054593986299699, 6.17288632414245, 5.291302052342109, 4.409620054081174, 4.409620074287937, 4.409620086112878, 4.409623483860089, 7.063965027915174, 16.800308854133565, 10.63417552005617, 19.210987975652955, 4.428496811960587, 10.598218173640642, 5.299752509654713, 50.734409802657495, 4.449101959218099, 4.341504863958484, 4.341498829993373, 4.341498821290089, 4.402675602001731, 4.420823013493073, 4.42094779661543, 4.420933177780893, 4.420964206768983, 4.4209634357924195, 4.420968418494473, 4.44734466444744, 4.427052554192627, 4.4382066435521805, 4.44482811700092, 5.305451674500537, 6.2415449704388335, 5.340416407677722, 5.338443606624526, 7.134660055420655, 5.206137218436107, 6.189938740286565, 8.90283663421177, 11.497055895867833, 16.031634323358706, 21.292409267466024, 11.497055895867833, 7.958947652781479, 6.18990081415179, 6.189938740286565, 5.305438536666932, 5.305451674500537, 4.420964206768983, 4.4209634357924195, 4.420968418494473, 4.42094779661543, 4.420933177780893, 4.420823013493073, 7.083499490214633, 21.292409267466024, 5.26575847603716, 5.299752509654713, 10.598218173640642, 5.325090513349996, 4.4382066435521805, 5.33122710854212, 4.402675602001731, 4.44482811700092, 4.449101959218099, 4.341498821290089, 4.341504863958484, 4.341498829993373, 4.409623483860089, 4.409620054081174, 4.409620074287937, 4.409620086112878, 4.44734466444744, 5.348488912175736, 4.45540786077759, 5.31213382994126, 5.232532083003333, 5.338443606624526, 7.800057982806829, 5.2063500840545345, 50.734409802657495, 19.210987975652955, 11.600247727159443, 8.027846654804925, 7.134734583050264, 7.134660055420655, 6.2415449704388335, 5.348520115518922, 5.348488912175736, 4.45540786077759, 4.455398888871967, 4.4553306553571055, 4.427052554192627, 6.237617183352525, 5.33122710854212, 4.44482811700092, 4.4382066435521805, 5.325090513349996, 4.402675602001731, 10.63417552005617, 4.449101959218099, 16.800308854133565, 5.340416407677722, 50.734409802657495, 7.083499490214633, 4.341498829993373, 4.341498821290089, 4.341504863958484, 4.420968418494473, 4.409623483860089, 4.409620086112878, 4.409620054081174, 5.2063500840545345, 11.497055895867833, 5.291302052342109, 6.189938740286565, 19.210987975652955, 7.120661226217313, 16.031634323358706, 7.800014199406146, 7.800057982806829, 6.9353856073170395, 5.206137218436107, 5.2063500840545345, 4.341498829993373, 4.341498821290089, 4.341504863958484, 5.232532083003333, 50.734409802657495, 19.210987975652955, 5.26575847603716, 4.402675602001731, 4.427052554192627, 5.31213382994126, 4.420823013493073, 4.449101959218099, 4.420933177780893, 4.4553306553571055, 4.42094779661543, 4.409623483860089, 4.409620054081174, 4.409620074287937, 4.409620086112878, 4.4209634357924195, 4.420968418494473, 4.420964206768983, 4.428496811960587, 4.4382066435521805, 4.44482811700092, 4.455398888871967, 6.17288632414245, 6.18990081415179, 6.2415449704388335, 5.305438536666932, 5.299752509654713, 7.134660055420655, 6.189938740286565, 11.497055895867833, 11.600247727159443, 16.800308854133565, 16.031634323358706, 8.90283663421177, 7.120661226217313, 6.22956843398207, 6.229568445807011, 5.338443606624526, 4.44734466444744, 5.31213382994126, 5.340416407677722, 4.449101959218099, 4.428496811960587, 21.292409267466024, 6.237617183352525, 4.44482811700092, 5.232532083003333, 10.63417552005617, 7.063965027915174, 4.341504863958484, 4.341498829993373, 4.341498821290089, 4.409623483860089, 4.402675602001731, 4.409620074287937, 4.409620086112878, 4.409620054081174, 4.420823013493073, 4.420933177780893, 4.42094779661543, 4.4209634357924195, 4.420964206768983, 4.455398888871967, 5.33122710854212, 4.427052554192627, 7.134660055420655, 6.189938740286565, 11.497055895867833, 7.083499490214633, 5.305451674500537, 16.800308854133565, 22.042824357477006, 50.734409802657495, 6.17288632414245, 19.210987975652955], \"Category\": [\"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Default\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic1\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic2\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic3\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic4\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\", \"Topic5\"], \"logprob\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, -1.6985, -2.9109, -3.0609, -3.2367, -3.4498, -3.4498, -3.4498, -3.45, -3.0593, -2.2422, -3.0566, -2.5611, -4.0974, -3.235, -4.0969, -2.1021, -6.4658, -6.4917, -6.4942, -6.4942, -6.494, -6.4941, -6.4942, -6.4942, -6.4942, -6.4942, -6.4942, -6.4891, -6.4941, -6.4942, -6.4941, -6.4864, -6.4851, -6.4891, -6.49, -6.4884, -6.4918, -6.4901, -6.4869, -6.4907, -6.4916, -6.494, -2.2798, -2.6752, -2.9552, -2.9556, -3.1309, -3.1311, -3.3443, -3.3443, -3.3444, -3.3444, -3.3446, -3.3458, -2.9635, -2.1995, -3.6154, -3.6161, -2.9558, -3.7086, -3.9928, -3.9898, -4.5977, -4.6045, -6.3513, -6.3887, -6.3887, -6.3887, -6.3887, -6.3887, -6.3887, -6.3887, -6.383, -6.3767, -6.3883, -6.3829, -6.3841, -6.3842, -6.3801, -6.3852, -6.3755, -6.3836, -2.2325, -2.6297, -2.7598, -2.7604, -2.9099, -3.0852, -3.0857, -3.2988, -3.2992, -3.2994, -3.5692, -3.296, -3.573, -3.9397, -3.9435, -3.8247, -4.2314, -3.5759, -4.5593, -3.2645, -4.5631, -2.3746, -4.5086, -6.3432, -6.3432, -6.3432, -6.34, -6.3432, -6.3432, -6.3432, -6.3054, -6.255, -6.3301, -6.332, -6.2997, -6.3356, -6.3331, -2.5925, -2.5928, -2.7226, -3.0482, -3.0496, -3.2616, -3.2616, -3.2617, -3.2613, -1.2675, -2.2829, -3.9094, -4.1382, -4.5185, -4.5196, -6.2749, -6.2885, -6.2994, -6.2929, -6.3028, -6.306, -6.306, -6.306, -6.306, -6.306, -6.306, -6.306, -6.306, -6.306, -6.3058, -6.3047, -6.2929, -6.2943, -6.2976, -6.3012, -6.3015, -6.2985, -6.3011, -6.2984, -6.3014, -6.3028, -1.734, -2.3599, -2.6049, -2.7542, -2.7542, -2.9305, -3.1442, -3.1425, -3.1407, -3.418, -3.7894, -2.256, -3.7956, -4.3995, -4.3984, -3.7933, -4.4015, -6.1881, -6.1881, -6.1881, -6.184, -6.1879, -6.1882, -6.1882, -6.1882, -6.1881, -6.1881, -6.1881, -6.1881, -6.1881, -6.181, -6.1635, -6.188, -6.1789, -6.1821, -6.177, -6.1824, -6.1853, -6.1793, -6.1839, -6.1848, -6.1864, -6.187], \"loglift\": [30.0, 29.0, 28.0, 27.0, 26.0, 25.0, 24.0, 23.0, 22.0, 21.0, 20.0, 19.0, 18.0, 17.0, 16.0, 15.0, 14.0, 13.0, 12.0, 11.0, 10.0, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, 1.4331, 1.36, 1.3435, 1.3218, 1.291, 1.291, 1.291, 1.2908, 1.2102, 1.161, 0.8039, 0.708, 0.6391, 0.6289, 0.46, 0.1958, -1.7339, -1.7353, -1.7379, -1.7379, -1.7517, -1.7559, -1.756, -1.756, -1.756, -1.756, -1.756, -1.7568, -1.7573, -1.7599, -1.7612, -1.9305, -2.0918, -1.9398, -1.9404, -2.2288, -1.9171, -2.0885, -2.4487, -2.7082, -3.0416, -3.3278, 1.5027, 1.4751, 1.4465, 1.446, 1.425, 1.4247, 1.394, 1.3939, 1.3938, 1.3938, 1.3936, 1.3925, 1.3033, 0.9667, 0.9479, 0.9408, 0.9081, 0.8436, 0.7415, 0.5611, 0.1447, 0.1283, -1.6194, -1.6323, -1.6324, -1.6324, -1.6479, -1.6479, -1.6479, -1.6479, -1.6507, -1.829, -1.6578, -1.8283, -1.8145, -1.8345, -2.2097, -1.8105, -4.0775, -3.1145, 1.541, 1.5119, 1.4998, 1.4992, 1.4834, 1.4625, 1.4621, 1.4316, 1.4313, 1.431, 1.1676, 1.098, 0.978, 0.7931, 0.7908, 0.7275, 0.5109, 0.2846, 0.1726, 0.1387, -0.0139, -0.0767, -0.2418, -1.5869, -1.5869, -1.5869, -1.6018, -1.6024, -1.6025, -1.6025, -1.7307, -2.4725, -1.7716, -1.9304, -3.0306, -2.0741, -2.8831, 1.5779, 1.5776, 1.5653, 1.5266, 1.525, 1.4948, 1.4948, 1.4946, 1.3084, 1.0305, 0.9862, 0.654, 0.6041, 0.2183, 0.035, -1.5367, -1.5567, -1.5612, -1.5625, -1.5646, -1.5652, -1.5653, -1.5653, -1.5653, -1.5678, -1.5678, -1.5678, -1.5695, -1.5717, -1.573, -1.5743, -1.8885, -1.8927, -1.9043, -1.7453, -1.7447, -2.0389, -1.8994, -2.5159, -2.5279, -2.8996, 1.716, 1.6783, 1.6566, 1.641, 1.641, 1.6192, 1.588, 1.4121, 1.4086, 1.3138, 0.9471, 0.9103, 0.5983, 0.3333, 0.1713, 0.0672, -0.1319, -1.4318, -1.4318, -1.4318, -1.4433, -1.4455, -1.4474, -1.4474, -1.4474, -1.4499, -1.4499, -1.4499, -1.4499, -1.4499, -1.4505, -1.6125, -1.4512, -1.9193, -1.7805, -2.3945, -1.9156, -1.6295, -2.7762, -3.0523, -3.8869, -1.782, -2.9179]}, \"token.table\": {\"Topic\": [1, 3, 2, 1, 2, 2, 1, 3, 1, 2, 3, 4, 4, 2, 4, 5, 1, 3, 1, 5, 2, 1, 5, 2, 4, 1, 2, 5, 3, 1, 1, 3, 4, 2, 3, 3, 5, 3, 2, 3, 1, 2, 4, 2, 5, 3, 5, 4, 5, 2, 3, 5, 5, 2, 1, 5, 5, 3, 4, 4, 2, 3, 4, 5, 4, 1, 4, 1, 3, 4, 1, 3, 2, 5, 2, 2, 3, 5, 3, 2, 2, 3, 4, 2, 1, 3, 5, 3, 4, 3, 2, 3, 5], \"Freq\": [0.9071076266464788, 0.8978009286898573, 0.8077673859601506, 0.4717774174941737, 0.4717774174941737, 0.8795132604690085, 0.9071076308032335, 0.9613004517979383, 0.3773761126310223, 0.5660641689465334, 0.8719648370226746, 0.7683239669202526, 0.921340798796462, 0.9047833595914213, 0.7644482511618175, 0.19111206279045437, 0.8505096128355845, 0.9348380284655416, 0.7078177737631973, 0.14156355475263946, 0.9424268293746559, 0.45162051254013635, 0.45162051254013635, 0.5697184961391741, 0.3798123307594494, 0.8099938565926225, 0.9047800011308754, 0.9366025696694541, 0.9348434823558468, 0.9526909827631378, 0.9071069252603142, 0.8977853711695637, 0.865128536424827, 0.5633707056206845, 0.37558047041378967, 0.18725131593902236, 0.7490052637560894, 0.9482556113216363, 0.45063246500827014, 0.45063246500827014, 0.9071076242139576, 0.9567666800640258, 0.9213408006434488, 0.9424291631019781, 0.8994130884382399, 0.641270517638616, 0.320635258819308, 0.7682925534052699, 0.8985900032420729, 0.9047791391738033, 0.224764460146412, 0.6742933804392359, 0.9631485814121917, 0.9047863514661441, 0.9449469999141007, 0.8426183762132666, 0.9631485795839472, 0.6776517701735569, 0.22588392339118565, 0.8974342637136411, 0.37514815243857075, 0.562722228657856, 0.18824826934208805, 0.7529930773683522, 0.8974292262223761, 0.4684818923111164, 0.5205354359012404, 0.2759468387324508, 0.1773943963280041, 0.5321831889840123, 0.7142725829738248, 0.23809086099127494, 0.5635811264597255, 0.4226858448447941, 0.9047801589164319, 0.22498057825343643, 0.44996115650687285, 0.22498057825343643, 0.8977871790538453, 0.9048088982054581, 0.2271346086787175, 0.2271346086787175, 0.454269217357435, 0.8077624367197733, 0.47018219612512, 0.282109317675072, 0.188072878450048, 0.8409563004984077, 0.9213395182869593, 0.8409650850065965, 0.7058657951351808, 0.14117315902703617, 0.9356500839184203], \"Term\": [\"5-ht2b\", \"acid\", \"activ\", \"agonist\", \"agonist\", \"alkaloid\", \"amphetamin\", \"analog\", \"and/or\", \"and/or\", \"anxieti\", \"apparatus\", \"beverag\", \"brain\", \"cannabi\", \"cannabi\", \"cannabinoid\", \"chronic\", \"cns\", \"cns\", \"cognit\", \"compound\", \"compound\", \"condit\", \"condit\", \"contain\", \"control\", \"crystallin\", \"depress\", \"deriv\", \"deuter\", \"devic\", \"differ\", \"diseas\", \"diseas\", \"dose\", \"dose\", \"drug\", \"effect\", \"effect\", \"epilepsi\", \"extract\", \"food\", \"fungus\", \"improv\", \"lsd\", \"lsd\", \"manufactur\", \"modul\", \"mood\", \"mushroom\", \"mushroom\", \"neurit\", \"neurolog\", \"novel\", \"organ\", \"outgrowth\", \"pain\", \"pain\", \"polymorph\", \"process\", \"process\", \"produc\", \"produc\", \"product\", \"psilocin\", \"psilocin\", \"psilocybin\", \"psilocybin\", \"psilocybin\", \"psychedel\", \"psychedel\", \"psychoact\", \"psychoact\", \"psycholog\", \"reduc\", \"reduc\", \"reduc\", \"relat\", \"releas\", \"safeti\", \"safeti\", \"safeti\", \"salt\", \"serotonerg\", \"serotonerg\", \"serotonerg\", \"system\", \"thc\", \"therapeut\", \"therapi\", \"therapi\", \"tryptamin\"]}, \"R\": 30, \"lambda.step\": 0.01, \"plot.opts\": {\"xlab\": \"PC1\", \"ylab\": \"PC2\"}, \"topic.order\": [1, 2, 3, 4, 5]};\n",
       "\n",
       "function LDAvis_load_lib(url, callback){\n",
       "  var s = document.createElement('script');\n",
       "  s.src = url;\n",
       "  s.async = true;\n",
       "  s.onreadystatechange = s.onload = callback;\n",
       "  s.onerror = function(){console.warn(\"failed to load library \" + url);};\n",
       "  document.getElementsByTagName(\"head\")[0].appendChild(s);\n",
       "}\n",
       "\n",
       "if(typeof(LDAvis) !== \"undefined\"){\n",
       "   // already loaded: just create the visualization\n",
       "   !function(LDAvis){\n",
       "       new LDAvis(\"#\" + \"ldavis_el2816420548210340161533040011\", ldavis_el2816420548210340161533040011_data);\n",
       "   }(LDAvis);\n",
       "}else if(typeof define === \"function\" && define.amd){\n",
       "   // require.js is available: use it to load d3/LDAvis\n",
       "   require.config({paths: {d3: \"https://d3js.org/d3.v5\"}});\n",
       "   require([\"d3\"], function(d3){\n",
       "      window.d3 = d3;\n",
       "      LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.4.0/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
       "        new LDAvis(\"#\" + \"ldavis_el2816420548210340161533040011\", ldavis_el2816420548210340161533040011_data);\n",
       "      });\n",
       "    });\n",
       "}else{\n",
       "    // require.js not available: dynamically load d3 & LDAvis\n",
       "    LDAvis_load_lib(\"https://d3js.org/d3.v5.js\", function(){\n",
       "         LDAvis_load_lib(\"https://cdn.jsdelivr.net/gh/bmabey/pyLDAvis@3.4.0/pyLDAvis/js/ldavis.v3.0.0.js\", function(){\n",
       "                 new LDAvis(\"#\" + \"ldavis_el2816420548210340161533040011\", ldavis_el2816420548210340161533040011_data);\n",
       "            })\n",
       "         });\n",
       "}\n",
       "</script>"
      ],
      "text/plain": [
       "PreparedData(topic_coordinates=              x         y  topics  cluster       Freq\n",
       "topic                                                \n",
       "0      0.179167 -0.003863       1        1  23.092186\n",
       "1     -0.223901 -0.216638       2        1  20.846677\n",
       "2      0.058710  0.001465       3        1  20.113954\n",
       "3      0.198680 -0.003209       4        1  18.761562\n",
       "4     -0.212656  0.222245       5        1  17.185621, topic_info=          Term       Freq      Total Category  logprob  loglift\n",
       "9   psilocybin  50.000000  50.000000  Default  30.0000  30.0000\n",
       "24       deriv  22.000000  22.000000  Default  29.0000  29.0000\n",
       "28   tryptamin  16.000000  16.000000  Default  28.0000  28.0000\n",
       "3    psychoact  21.000000  21.000000  Default  27.0000  27.0000\n",
       "35        drug  11.000000  11.000000  Default  26.0000  26.0000\n",
       "..         ...        ...        ...      ...      ...      ...\n",
       "5    psychedel   0.179810  16.800309   Topic5  -6.1793  -2.7762\n",
       "24       deriv   0.178989  22.042824   Topic5  -6.1839  -3.0523\n",
       "9   psilocybin   0.178820  50.734410   Topic5  -6.1848  -3.8869\n",
       "42     contain   0.178540   6.172886   Topic5  -6.1864  -1.7820\n",
       "18    psilocin   0.178431  19.210988   Topic5  -6.1870  -2.9179\n",
       "\n",
       "[233 rows x 6 columns], token_table=      Topic      Freq       Term\n",
       "term                            \n",
       "64        1  0.907108     5-ht2b\n",
       "20        3  0.897801       acid\n",
       "0         2  0.807767      activ\n",
       "17        1  0.471777    agonist\n",
       "17        2  0.471777    agonist\n",
       "...     ...       ...        ...\n",
       "39        4  0.921340        thc\n",
       "8         3  0.840965  therapeut\n",
       "49        2  0.705866    therapi\n",
       "49        3  0.141173    therapi\n",
       "28        5  0.935650  tryptamin\n",
       "\n",
       "[93 rows x 3 columns], R=30, lambda_step=0.01, plot_opts={'xlab': 'PC1', 'ylab': 'PC2'}, topic_order=[1, 2, 3, 4, 5])"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "vis = pyLDAvis.gensim_models.prepare(lda_model, doc_term_matrix, dictionary)\n",
    "vis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
